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1. Introduction 
 
Kidneys are two bean-like shaped organs located in the abdominal cavity behind the 
peritoneum, on the left and right side of the spine. A physiological renal function is essential 
for maintenance of homeostasis, ions regulation in blood or water, hormone production and 
secretion and, last but not least, formation of urine (figure 1.1).  
A transversal cut of the kidney reveals, in the parenchyma, three major structures: cortex, 
medulla and papilla layers, respectively form the outer to the inner part (figure 1.2). 
 
 
Figure 1.1 The renal system is responsible for maintaining crucial physiological processes such as ions regulation, fluid 
homeostasis, hormonal balance and excretion of waste products of metabolisms.  
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Figure 1.2 Hematoxylin and eosin (H&E) staining of Sprague Dawley (SD) rat kidney. A) cortex layer, B) medulla and C) 
papillary region. Image acquired with Axio Scan.Z1 microscope (ZEISS), 20x objective. 
 
The nephron is the functional and structural unit of the kidney and it spread between the 
cortex and the medullary region. Each nephron is composed of a renal corpuscle, consisting of 
a glomerulus surrounded by Bowman's capsule, and the renal tubule. The nephron is 
responsible for three essential processes: filtration, reabsorption and secretion (figure 1.3). 
 
 
Figure 1.3 Nephron structure and function1. 
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Due to the important and fundamental roles, especially in maintaining homeostasis and pH, 
kidneys are often exposed to a multitude of insults that may compromise their functionality. 
 
1.1 Cystic Kidney Disease  
In the last decades, the uprising of chronic kidney diseases (CKD) has become one of the 
worse and alarming public health problems. An early diagnosis of renal diseases might be 
beneficial for the quality of life for the patients but often, early stages of the disease are 
asymptomatic and first evidences appear when the progression of the pathology leads to 
chronic or end-stage renal disease (ESRD)
2, 3
. 
Cystic kidney disease is the fourth common cause of ESRD, just after diabetes, hypertension 
and glomerulonephritis. Cystic disease is a heterogeneous group of chronic disorders with a 
wide range of manifestations and may be hereditary, or might develop sporadically, as 
consequence of aging and lifestyle. Genetic cystic kidney disease, such as autosomal 
dominant polycystic kidney disease (ADPKD), autosomal recessive (AR) PKD and 
nephronophthisis (NPHP), are the most clinically significant types of cystic renal disease
4
. 
 
1.1.1 ADPKD 
ADPKD is the most common form of cystic kidney disease with an incidence of 1:1000 
individuals
5
. ADPKD is a monogenic disorder with a penetrance of 100%
6
. It is caused by the 
mutation of two different genes: polycystin 1 (PKD1) and polycystin 2 (PKD2), both of which 
are found on the primary cilia of renal tubules. It is known from literature that the interaction 
of these two genes promotes the normal development and function of the kidney
7, 8
. 
Phenotypically, both kidneys appear enlarged due to the development of multiple cysts of 
different size. Patients with a mutation on the PKD1 gene present a larger kidney and faster 
progression to ESRD in comparison to patients with a PKD2 mutation. They present with a 
milder disorder. Since, usually, the early stage of the disease is asymptomatic, in the past 
decades ADPKD was identify as a disease of the adult life but, recently the first symptoms 
have also been detect in childhood
9
. Early clinical manifestations are the disruption of the 
inner renal medullary region, polyuria, enlargement of both of the kidneys and hypertension
10
. 
ADPKD, as a kidney disorder, is affecting primarily the kidney but also other organs might be 
involved. Extrarenal manifestations of the disease have an impact on liver, consisting of the 
development of cysts and dilatation of bile ducts, cardiovascular abnormalities and 
intracranial aneurysm
11-14
. Based on the severe decline of the glomerular filtration rate (GFR), 
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which describes the efficiency of the renal function, patients with ADPKD are classify into 
categories. Classification is helpful to identify patients who may benefit most from therapy 
and patients with a slower progression or late stage of the disease who might not benefit from 
it
15, 16
. Dialysis and kidney transplantation are usually the therapeutic gold standard, and the 
only possibility, for the treatment of cystic kidney disease
17, 18
. Clinical trials led to the 
development of the first FDA approved drug: Tolvaptan, a vasopressin receptor 2 antagonist. 
Clinical trials demonstrated that Tolvaptan slowed the GFR decline and kidney growth in 
patients with early ADPKD
19
, but further analysis on potential advantages and disadvantages 
have to be taken into consideration. Other possible targets for therapies are the inhibition of 
mTOR and CoA reductase activity
20, 21
. 
 
1.1.2 ARPKD 
ARPKD is a rarer disease, with an incidence of about 1:20.000 – 30.000 live births. ARPKD 
is a congenital hepatorenal syndrome, caused by a single gene mutation
5
. The mutation occurs 
on the polycystic kidney and hepatic disease 1 (PKHD1) gene. PKHD1 is located on the cell 
membrane of kidney cells, primary cilia and, in lower level, in liver and pancreas
22
. ARPKD 
is typically an infantile disorder with a significant neonatal mortality and childhood morbidity 
rate
23
. Neonates present a massively enlarged kidneys with the presence of multiple cysts, 
pulmonary hypoplasia, liver changes like ductal plate malformation, that lead to progressive 
hepatic fibrosis
24-26
. It is estimated that 20 – 30% of patients dye shortly after birth due to 
respiratory insufficiency as consequence of pulmonary hypoplasia
24, 26
. In the remaining 70% 
of patients, the disease progresses to ESRD during adolescence
25, 27
. A minority of patients 
develop extrarenal and extrahepatic disorders such as pancreatic abnormalities
28
. As 
consequence of the high mortality rate and the severe and fast progression of the disease, 
patients usually undergo a combined kidney-liver transplantation within the first decade of 
life. To this day no pharmacologic therapy has been developed for ARPKD.  
 
1.1.3 NPHP 
NPHP is a group of autosomal recessive tubulointerstitial cystic kidney diseases, which are 
genetically heterogeneous. A single gene mutation, on NPHP gene, is responsible for the 
triggering of the disease. Nowadays, about 20 genes have been described to be involved in 
NPHP
29
. Frequently, NPHP affect patients in the first decade of life or during adolescence and 
is one of the most common causes of ESRD in childhood
29
. NHPH has been classified into 
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three different forms: infantile, juvenile, and adolescent NPHP, which develop ESRD 
respectively, at the ages of 1, 13 and 19 years of age
30, 31
. Usually, the early clinical symptoms 
are polyuria, polydipsia and anaemia, even if ultrasound scans show normally sized kidneys
30
. 
As NPHP progresses, cysts start to manifest and kidney loses the corticomedullary 
differentiation. Further important histological manifestations are the deposition of fibrotic 
tissue, tubular atrophy and alteration of tubular basement membrane
32
. As for ADPKD, at the 
beginning of the disease, the symptoms are mild and the diagnosis of the disease is made 
when the progression is already ongoing. Currently, dialysis and transplantation appear to be 
the only therapeutic options for the patients. 
 
1.2 Genetic animal models 
Nowadays two main animal models of cystic kidney disease have been identified: all are 
spontaneous hereditary models. These models are often used for the characterization of the 
disease outcomes, the disease progression and to establish potential therapeutic strategies. In 
particular, two of the best described spontaneous hereditary models are the PKD/Mhm and 
PCK rats. 
1.2.1 PKD/Mhm rats 
In 1989 a spontaneous mutation resulting in PKD was noted in a Sprague Dawley (SD) 
colony in Hannover
33
. A group of animals died after 4 weeks of age, showing an increase in 
kidney volume and weight, a progressive renal failure, uraemia and hypertension. In the early 
1990s in Mannheim, Gretz et al. better characterized this animal model and the difference 
between homozygous (Cy/Cy), heterozygous (Cy/+) and healthy (+/+) rats
34, 35
. These studies 
highlighted that the cystogenesis process starts during the first week of life. While 
heterozygous animals develop a slow progression of renal cystic disease, homozygous rats are 
characterized by massive renal enlargement that leads to an early death in the first postnatal 
month. Morphologically, in PKD/Mhm (Cy/Cy) rat kidneys the penetrance of the mutation 
does not depend on the gender of the animals. Both female and male PKD/Mhm (Cy/+) rats 
manifest in fact, a slowly progressive development of cysts in renal tissues, leading to ESRD. 
Moreover, male rats display a more severe form of the pathology when compared to females. 
In 2006 a study was carried out to validate the PKD/Mhm as a model for PKD
36
. The study 
performed a comparison between the guanidine compound in blood and urine chemistry of 
humans and rats. Their results pointed out that PKD/Mhm rats present similar disease changes 
as PKD patients, such as increase in urea concentration and guanidinosuccinic acid
36
. Few 
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years later, the mutation on the gene leading to the pathology has been found. It was affecting 
Anks6, a gene located in the proximal cilium
37, 38
. Additional studies suggested that a 
mutation on both the copy of Anks6 could lead to NPHP16
39, 40
. This is reason why 
PKD/Mhm rats nowadays are used as animal model for both ADPKD and NPHP16 in order 
to understand the pathology mechanism of the diseases and to test innovative therapies. 
1.2.2 PCK rats 
At the beginning of the century, in Japan, Katusyama et al. identified female rats with both 
polycystic kidneys and liver cysts derived from a SD colony
41
. The spontaneous mutation 
developed in these rats was located on the Pkdh1 gene, the orthologous gene affected in 
human ARPKD
42
. Studies were conducted to better define the model
41, 43, 44
. When compared 
with SD rats with same age, PCK rats showed an increase of the body weight, related also to 
the increase of kidney and liver weight. As for other strains, male rats manifested a more 
severe form of the disease and their survival rate was lower when compared to female
41
. 
Compared to healthy animals, PCK rats manifested an increase of the creatinine plasma 
concentration and blood urea nitrogen (BUN) levels
44
. Since the beginning, PCK was not only 
resembling human ARPKD but also Caroli’s disease, a pathology characterized by a 
congenital intrahepatic biliary dilatation usually associated with congenital hepatic fibrosis of 
autosomal recessive polycystic kidney disease
41, 43
. Hepatic analysis showed and enlargement 
of the organ with cyst formation already in the first weeks of age and dilatation of the 
intrahepatic bile ducts. Also the values of hepatic transaminases in the blood chemistry were 
increased when compared with SD rats; likewise proteinuria levels
45
.  
In the last few years PCK rats have been frequently used as a model for the understanding of 
both kidney and liver disease but also to test potential and innovative therapeutic approaches. 
 
1.3 (Potential) Stem cells therapy for Cystic Kidney Disease 
Therapeutic approaches in nephrology are aiming to reduce the injury and delay, if not arrest, 
the progression of the renal disorders. Unfortunately, especially in CKD, the only available 
possibilities for patients are dialysis or renal transplantation. Recently, a promising 
therapeutic approach is the use of stem cells therapy to reduce the renal pathology. Several 
studies, indeed, assessed the therapeutic potential of mesenchymal stem cells (MSCs) in 
kidney disorders, likes acute or chronic kidney injury, diabetic nephropathy and autoimmune 
disease
46-48
. Nowadays, only two published studies show the possible therapeutic effects of 
allogeneic stem cells in rats demonstrating first of all the safety and tolerability of MSCs and 
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secondly, the capability of MSCs to ameliorate renal function and limit the cysts formation in 
PKD animal model
49, 50
. Taken into consideration the dramatic increase of the incidence of 
diseases and the few available cures, in this study the potential therapeutic effects of human 
adipose derived stromal cells (ASC) and human ABCB5+ cells will be tested.  
1.3.1 ASC 
Over the years, bone marrow has been the main source for the isolation of MSCs. 
Nevertheless, the harvesting of bone marrow cells is a highly invasive procedure and is prone 
with the increasing age to a decline of proliferation and differentiation potential of MSCs
51-53
. 
Therefore, at the beginning of the century Zuk et al. searched for an alternative stem cell 
source: the adipose tissue
54
. Advantages of this new source are the less invasive method and 
the possibility to obtain larger quantities. In fact, adipose tissue is collected by needle or 
liposuction aspiration and, ASC can be easily isolated from the tissues
55
 (figure 1.4).  
 
 
Figure 1.4 Adipose tissue processing and ASC isolation55. 
 
When tested, ASCs lack the expression of hematopoietic stem cell marker CD45 and CD34 
and are positive for stem cell-specific surface markers, such as CD90,CD105, CD73, 
CD44and CD166
56
. 
1.3.2 ABCB5+ 
In the last 10 years, Schatton et al. characterized a new type of non-hematopoietic cell 
showing immune-regulatory function similar to stem cells in the human reticular dermis 
(DIRCs)
57
. These cells express the ATP-binding cassette member B5 (ABCB5). ABCB5+ 
cells have been tested for the negativity of the CD34, marker of dermal dendritic cells and 
hematopoietic stem cells, and CD45. Nevertheless, ABCB5+ cells were expressing MSC 
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markers such as CD29, CD44, CD105 and CD166
58
. The main outcome of this study was that 
ABCB5+ cells are a phenotypically unique dermal cell subset with multipotent differentiation 
plasticity (figure 1.5). These properties make ABCB5+ cells a valid therapeutic candidate for 
cell-based immunotherapies in the regenerative medicine field
58
.  
 
 
Figure 1.5 ABCB5 identifies immunoregulatory dermal cells58. 
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2. Aim of the study 
 
The main goal of this study was to investigate the potential therapeutic effects of different 
types of human stem cells and their conditioned media on genetic animal models of PKD, 
since stem cells are not the usual application in monogenic diseases. The aim, in fact, was not 
to act directly on the genetic mutation characteristics of the pathology but to test whether stem 
cell therapy could ameliorate the renal function by improving, directly or indirectly, pathways 
such as metabolism or signal transduction. 
In order to achieve this goal, we first characterized two different genetic animal models: the 
PKD/Mhm (Cy/+) and the PCK rats. In a second step, the long-term effects of human ASC 
and human ABCB5
+
 cells, together with ASC conditioned media and a co-culture of ABCB5
+
 
and macrophages media were tested. 
PKD/Mhm (Cy/+) and PCK rats were bred in our core facility in accordance with the local 
authority law and the EC directive 2010/63 EU. To qualify renal damage and disease 
progression, the principal parameter for renal function, such as creatinine and urea levels, 
were tested through chemistry analysis and histological analysis were performed.  
ASC cells have been provided by Professor Karen Bieback´s group, from the Institute of 
Transfusion Medicine of Mannheim. Cells were mostly obtained by lipoaspirates from 
healthy donors undergoing liposuction, according to Mannheim Ethics Commission II (vote 
numbers 2010-262 N-MA, 2009-210 N-MA, 49/05 and 48/05). 
ABCB5
+
 cells were isolated from different healthy donors, cultured and characterized by 
Ticeba-RHEACELL GmbH & Co. (Heidelberg, Germany) laboratories and send to us in a 
ready to use solution.  
In the past years, major importance was attached to the effects not only of stem cells but also 
of the factors they release into the culture medium. For this reason we also tested the effect of 
two different types of conditioned media: firstly, a medium in which ASC cells were growth, 
without any external or added stimuli and at a later stage, TICEBA Company provided us 
with a co-culture of ABCB5
+
 cell and macrophages M1 stimulated with Interferon γ (INFγ) 
and lipopolysaccharide (LPS). 
To better characterize the effect of the treatments on the kidney function, plasma and urine 
analysis within GFR measurement were carry out. 
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3. Animals, material and methods 
 
3.1 Animals 
All experiments were conducted in accordance with the German Animal Protection Law and 
approved by the local authority (Regierungspräsidium Nordbaden, Karlsruhe Germany in 
agreement with EU guideline 2010/63/EU). 
Kidneys of PKD/Mhm animals were palpated at the age of 8 weeks under isoflurane 
anesthesia. Heterozygous (Cy/+) can be distinguished from the wild type animals by means of 
the slightly enlarged kidney and altered kidney surface in the heterozygous animals.  
A total of 42 male PCK rats and 42 male PKD/Mhm (Cy/+) were engaged in the long term 
experiment (animal permit G19/17). From these, 36 PCK and 36 PKD/Mhm (Cy/+) rats were 
used in the cell therapy studies while 6 PCK and 6 PKD/Mhm (Cy/+) rats were assigned to 
the untreated group as control for the evolution of the pathology. 
Animals were housed in pair in individual cages with food and water ad libitum. 
 
3.2 Experimental schedule 
Animals were enrolled in the trial at the age of 8 weeks. Therapy began with a single 
intraperitoneal (i.p.) or intravenous (i.v.) injection of stem cells or i.v. injection of conditioned 
media. The injections were repeated in monthly intervals. Before the start of the experiment a 
basal examination of renal function was performed by determination of the GFR measurement 
and the renal function parameters (plasma and urine samples). These examinations were 
repeated, for each animal, every 4 weeks up to the age of 8 months (figure 3.1). After the 
baseline assessment, animals were randomly assigned in four different groups depending on 
the received treatment on day 1: (i) a group that did not received any treatment, (ii) 
conditioned media group, (iii) stem cells i.p. administration group and (iv) stem cells i.v. 
administration group. (table 3.1). 
 
Figure 3.1 6 months experimental set up for the assessment of human ABCB5+ and ASC and derived conditioned media. 
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Strain Treatment Number of animals 
PKD/Mhm (Cy/+)  6 
 + CoCM+ 6 
 + CM 6 
 + i.p. ABCB5+ 6 
 + i.p. ASC 6 
 + i.v. ABCB5+ 6 
 + i.v. ASC 6 
PCK  6 
 + CoCM+ 6 
 + CM 6 
 + i.p. ABCB5+ 6 
 + i.p. ASC 6 
 + i.v. ABCB5+ 6 
 + i.v. ASC 6 
Table 3.1 Number of animals enrolled in the experiment.  
 
3.3 Plasma and urine collection 
Plasma samples were collected monthly, the day before starting the trial, via retro-bulbar vein 
plexus (orbital sinus) under anaesthesia (5% isoflurane at 3 min/L airflow) in lithium-
heparinized tubes using capillaries for blood collection. Afterwards, samples were centrifuged 
and the plasma collected in 1.5 ml vials and stored at -20°C until analysis. 
Urine collection was performed by placing the animals overnight into metabolic cages for a 
period of 16 hours. During this time the animals had free access to water and food. At the end 
of the 16 hours, urine was weighed and samples centrifuged to get rid of the precipitate. Urine 
aliquots were then placed in 2 ml collecting tubes and immediately frozen at-20°C until 
analysed. 
Cobas c311 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) was used to evaluate 
plasma and urine parameters. The urinary albumin level was determined by ELISA and 
osmolarity was analysed using an osmometer (2020 Multi-Sample Osmometer, Advanced 
Instruments Inc., Norwood, MA). 
 
3.4 GFR measurement  
3.4.1 ABZWCY-HCD 
The selected agent for GFR measurement is ABZWCY-HβCD, a zwitterionic agent with an 
emission wavelength in the near infrared (NIR) region developed by Huang et al. in 2017
59
. 
The kidney can excrete efficiently and fully the agent
59
. The suitable fluorescence, deep 
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penetration depth, high hydrophilicity and non-toxicity properties of ABZWCY-HβCD make 
it the ideal candidate for the GFR measurement. 
3.4.2 Device for the GFR measurement 
GFR measurement was performed using a miniaturized electronic device (MediBeacon 
GmbH, Mannheim, Germany) (figure 3.2)
60-62
. The device consists of an optical part formed 
by two light-emitting diodes (LEDs) with an excitation at 706 nm, an emission at 790 nm 
(NIR region) and a photodiode detecting the agent’s fluorescent light. Energy was supplied by 
a lithium polymer rechargeable battery with a voltage of 3.7 V and a capacity of 50 mAh. The 
device holds also an internal memory that records the digital data. By using a micro-USB 
cable the data can be read out onto a PC for analysis.  
 
Figure 3.2: Miniaturized device for the transcutaneous GFR measurement.  
 
3.4.3 Procedure and ABZWCY-HβCD half-life (t1/2) determination 
A dosage of ABZWCY-HβCD was 15 mg/100g rat’s body weight (BW). Initially a stock 
solution at a concentration of 160 mg/ml of dye was created. Then it was stored protected 
from light to minimize the time of the anaesthesia and the potential related risks.  
Animals were depilated on part of the back under short isoflurane anaesthesia (5% isoflurane 
at 3 L/min airflow, decreased to 2% isoflurane at 1.5 L/min airflow). We used an electric 
shaver for small rodents to ensure a proper fixation of the electronic device. After the shaving, 
the device with its battery was placed on a double-sided adhesive patch (figure 3.3A), fixed 
on the hairless area and secured with a tubular net bandage plus two strips of adhesive tape to 
prevent the animal from removing it. 
Once the device was correctly fixed, the proper dose of ABZWCY- HβCD was administrated 
intravenously and the measurement performed for 2 hours. During this period the animal was 
awake and freely moving (figure 3.3B). 
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Figure 3.3 Placement of the device. A) Device and battery are placed on a double-sided adhesive patch; B) During the period 
of measurement, after ABZWCY- HβCD administration, the animal is awake and freely moving. 
 
After the recording period, the device was removed and connected by a USB cable to a PC to 
download the data using the basic software provided by the company.  
To quantify the half-life (t1/2) excretion of the administered fluorescent dye, a 3-compartment 
model was applied using the specific software designed by our group 
(http://www.mathworks.com/products/compiler/matlab-runtime.html)
63
. 
  
3.5 ASC and ABCB5+ administration  
3.5.1 ASC administration  
ASC cells were isolated by Professor Karen Bieback´s group, from the Institute of 
Transfusion Medicine and Immunology of Mannheim. Cells were obtained from lipoaspirates 
taken from healthy donors undergoing beauty surgery procedures. In summary, the raw 
lipoaspirate was washed with sterile PBS 1X, to remove cellular remains and red blood cells. 
Then it was digested with 0.15% w/v collagenase type I (Sigma-Aldrich, Munich, Germany). 
DMEM/10% human serum (blood-type AB) (AB-HS) was then added to inhibit the 
collagenase activity and the sample was centrifuged to obtain the stromal vascular fraction 
(SVF) pellet. Afterwards, the pellet was re-suspended in a DMEM/10% AB-HS, low glucose 
medium and filtered through a 100 μm nylon mesh filter to remove cellular fragments. Once 
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again, the filtrate was centrifuged and the re-suspended SVF cells were plated in cell culture 
flasks and incubated overnight at 37°C, 5% CO2. After one day, the culture plates were 
washed to remove non-adherent and red blood cells. After cells had started to form colonies, 
they were tested to assess the multipotent MSC criteria. A differentiation assay was 
performed and the expression of CD90, CD37 and CD105 and lack of expression of CD34 
and HLA-DR.81 was tested. 
In a second step, cells were cultured in our laboratory. Briefly, cells were re-suspended in 
DMEM/10% AB-HS medium in T175 cell culture flasks at a concentration of 1.3 x 10
5
 and 
incubated at 37°C, 5% CO2. Every 48 hours, cells were washed with PBS 1X to remove cell 
debris, and fresh media (DMEM/10% AB-HS) was added.  
On injections day, ASCs were trypsinized (0.25% trypsin) and incubated for 5 min at 37°C, 
fresh DMEM/10% AB-HS medium was used to inhibit the trypsin activity and the cells were 
centrifuged. The supernatant was collected to obtain the conditioned medium (CM), while the 
cells pellet was re-suspended in fresh medium at a concentration of 1x10
7 
cells/ml. 
3.5.2 ABCB5+ administration  
ABCB5+ ready to use cell suspension (1x10
7 
cells/ml) and conditioned media were provided 
by Ticeba-RHEACELL GmbH & Co. (Heidelberg, Germany).  
ABCB5+ cells were purified from the skin of healthy donors of different sex, age and 
nationality by Ticeba-RHEACELL Gmbh.  
The conditioned medium was derived by collecting the supernatant of a co-culture of 
ABCB5+ cell and THP-1 derived macrophages (CoCM+) stimulated with IFN-γ and LPS. 
On the seeding day cells were stimulated with 50 IU/ml IFN-γ and, the day after with 50 
IU/ml IFN-γ + 20 ng/ml LPS. The third day, conditioned medium was harvested and 
immediately frozen and stored at -20°C until used. The THP-1 derived macrophages were 
able to polarize in anti-inflammatory macrophages M2 thanks to the presence of the above 
mentioned stimuli and ABCB5+ cells. 
 
3.6 Histological analysis 
After the 6 months of treatment, the animals underwent perfusion. Prior to the perfusion, 
animals were weighted and anesthetized by i.p. injection of ketamine/xylazine (xylazin 
5mg/kg BW and ketamine 100mg/kg BW). Once the animal was deeply anesthetized, the 
abdominal cavity was opened through a cut along the linea alba. The left kidney was removed 
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before starting the perfusion, weighted, cut, placed in a cryotube and deep frozen in liquid 
nitrogen prior to storage at –80°C for future analysis (section 3.7).  
Perfusion was performed through the abdominal aorta: a butterfly cannula was inserted about 
0.5 – 1.0 cm from its distal bifurcation and the vena cava was opened. Saline/heparin solution 
(3 minutes, 280 mbar) was used to wash out the blood from the body of the animals, followed 
by fixation in 4% PFA pH 7.4 (3 minutes, 230 mbar). After the perfusion portions of right 
kidney, liver, lungs, heart, spleen and pancreas were collected, placed in embedding plastic 
boxes for the routine paraffin embedding procedure. Each organ was sliced (3 μm section) 
and stained with haematoxylin and eosin (H&E) or stored for following immunohistological 
analysis.  
To evaluate the fibrosis level in liver and kidney tissue the Masson-Goldner staining was 
performed, using light green as a specific stain for the connective tissue.  
Immunofluorescence (IF) staining combined with Tunel reaction, was executed to assess the 
percentage of apoptosis and cell proliferation. Briefly, 3 μm kidney section where pre-treated 
with Citrate buffer pH 6.0 (20 minutes, 100°C) and incubated first with Tunel mix (In Situ 
Cell Death Detection Kit – Fluorescein, ROCHE), in the dark, 1h at room temperature (RT) 
and after overnight at 4°C with the primary rabbit anti-Ki67 antibody (1:50, ab15580, 
Abcam). After the primary antibody incubation, slides were further incubated with secondary 
antibody Alexa Fluor® 647 donkey anti-rabbit (1:100, ab150075, Abcam), 45 minutes at RT. 
Samples were counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) for 
nucleus identification. 
All the slides were imaged with the slide scanner Axio ScanZ1 (Zeiss) with a 20x objective. 
Whole kidney sections were evaluated both with Zen Software (Zeiss) and ImageJ program 
(Fiji). 
 
3.7 RNA isolation and sequencing 
Total RNA of the samples was extracted from whole kidney tissue with the RNeasy mini Kit 
(QIAGEN).  
Approximately 30 mg of frozen tissue were homogenized with lysis buffer. The homogenate 
was then centrifuged to precipitate any cellular debris and the supernatant were transferred in 
a 1.5 ml tube. An equal volume of 70% ethanol was added and the total amount transferred 
into a spin column and centrifuged.  
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Afterwards, always according to the kit instructions, washing were performed with solutions 
at decreasing salt concentrations to clean RNA bound to the silica membrane of the columns. 
Finally, the purified RNA was eluted in RNase-free water.  
RNA concentration was measured by using the Spark 10M (TECAN). 
To determine RNA quality, the Agilent 2100 Bioanalyzer (Agilent (Waldbronn)) was used 
and RNA integrity number (RIN) was calculated by a specific Agilent software tool. Samples 
with low RNA, too much protein-contaminated or with RIN values below 7 were repeated. 
RNA sequencing was performed by BGI Tech Solutions Co (Hong Kong) using the BGISEQ-
500 method. 
R Bioconducor software was applied to analyse RNA sequencing data. For annotation, the 
ENTREZ-based software package TxDb.Hsapiens.UCSC.hg19.knownGene was used and 
differential gene expression analysis was performed by a DESeq2 package. As a level of 
significance α= 0.05 with FDR correction was chosen. Gene set enrichment analysis (GSEA) 
was performed to determine statistically significant differences between treated and untreated 
animal groups. Pathway analysis was done with the help of the public KEGG (Kyoto 
Encyclopaedia of Genes and Genome) database to transform the list of individual genes into a 
set of pathways. 
 
3.8 Statistical analysis 
All data are represented as mean ± standard deviation (Std Dev). Values are rounded to 1 
digit; this could explain why sometimes same numeric values present a different significant 
expression. 
All the statistical analyses were performed using the software JMP® Genomics 7.  
The effect of stem cells or conditioned media therapy was assessed by one-way ANOVA. 
After confirming a normal data distribution, Tukey-Kramer test of pairwise comparisons was 
applied to evaluate differences between biochemistry parameters and histologically 
quantitative parameters in all the groups through the different time points while, in paired 
measurements, T-test was used to compare the means. If the data distribution was not normal, 
nonparametric statistics was performed using the Steel-Dwass test. Statistical significance 
was defined as p<0.05. 
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4. Results 
 
4.1 Characterization of the genetic animal models of Cystic Kidney Disease  
4.1.1 Changes in BW and kidney morphology 
BW was recorded monthly, during the whole experiment. During the six months of 
investigation, animal’s BW progressively increased over time in a hyperbolic pattern. 
However, already after 25 days the PCK rats show a higher weight gain than PKD/Mhm 
(Cy/+) rats: 404.0  13.3 vs. PCK 455.3  24.1. At day 167, compared to the baseline, the BW 
was increased 1.5 and 1.6-fold in PKD/Mhm (Cy/+) and PCK respectively (figure 4.1). 
 
Figure 4.1 Changes over the time in BW in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). Data are shown as means ± 
Std.Dev  
 
On the perfusion day, left kidney weight was lower in PKD/Mhm (Cy/+) rats (PKD/Mhm 
(Cy/+) 3.1  0.8 vs. PCK 5.3  0.3), as well as the kidney/body weight ratio (Kw/BW) 
(PKD/Mhm (Cy/+) 0.6  0.0 vs. PCK 0.1  0.0).  
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H&E staining of kidney sections revealed, in both strains, the loss of the renal structures 
equally distributed all along the cortex and medulla regions, in particular the corticomedullary 
alteration due to the presence of numerous single layer epithelial cysts of different size. 
Glomerular and tubular segments appeared to be decreased in number, probably because of 
interstitial changes. The renal parenchyma appeared tightened. The interstitium presented 
inflammatory cell infiltration, predominantly mononuclear, and deposition of massive fibrotic 
tissue (figure 4.2). 
 
 
Figure 4.2 Altered renal morphology in cystic animal models. Whole kidney scan of A) SD rat, B) PKD/Mhm (Cy/+) rat, C) 
PCK rat. D) Fibrotic tissue in PKD/Mhm (Cy/+) rat kidney, E) Single layer epithelium cysts in PCK rat kidney. H&E 
staining. Images acquired with Axio Scan.Z1 microscope (ZEISS), 20x objective, D) and E) are zoomed in, for the real size 
check scale bar. 
 
The presence of apoptotic bodies was detected in the lumen of tubules and cysts. An 
increment of apoptotic and proliferation marker positive cells was noticed, after IF staining 
(as explained in section 3.6) in cystic animals when compared to healthy wild type SD rats 
(figure 4.3, table 4.1). 
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Figure 4.3 Examples for the quantification of apoptotic and proliferative positive marker (histologies for PCK rats are not 
shown as they are similar to the pictures of PKD/Mhm (Cy/+) rats). A-B) Dapi signal in SD (A) and PKD/Mhm (Cy/+) (B) 
rats; C-D) Ki67 signal in SD (C) and PKD/Mhm (Cy/+) (D) rats; E-F) Tunel signal in SD (E) and PKD/Mhm (Cy/+) (F) rats; 
G-H) Merged signals in SD (G) and PKD/Mhm (Cy/+) (H) rats; I-J) Graphic quantification of apoptotic and proliferative 
positive marker on whole imaged kidney section of SD, PKD/Mhm (Cy/+) and PCK rats (n=6 in each strain). (I) total Tunel 
positive cells, (J) total Ki67 positive cells. Data are shown as box plots with the median, upper and lower quartile 
(interquartile range (IQR)) and whiskers (1.5x IQR). Values significantly different from control (SD) are indicated as 
*p<0.05, **p<0.005, ***p=0.001. Co-staining Tunel-Ki67. Images were acquired with Axio Scan.Z1 microscope (ZEISS), 
20x objective, A-H) are zoomed in, for the real size check scale bar. 
 
 
 
Strain Tunel positive cells Ki67 positive cells 
SD 124.7  31.0 101.0  65.6 
PKD/Mhm (Cy/+) 1370.0  237.7*** 1239.5  250.7*** 
PCK 1460.5  324.6** 1721.0  1369.8* 
Table 4.1 Quantification of Tunel and Ki67 positive nuclei in SD, PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). 
Analysis was performed on whole 3 μm kidney sections. Data are shown as mean ± Std.Dev. Values significantly different 
from control (SD) are indicated as *p<0.05, **p<0.005, ***p=0.0001. 
 
While no significant alteration was noted in liver sections of PKD/Mhm (Cy/+) animals, PCK 
rat livers show a mild deposit of fibrotic tissue and bile duct dilatation (figure 4.4). 
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Figure 4.4 Altered hepatic morphology in a PCK rat. Yellow asterisk: fibrotic tissue; black arrow: bile duct dilatation. H&E 
staining. Images acquired with Axio Scan.Z1 microscope (ZEISS), 20x objective.  
 
 
4.1.2 Plasma chemistry, urine analysis and renal function 
The standard plasma indicators to assess renal function are creatinine and urea. Both model 
strains show a rise in these parameters during the experimental period. Notably, already from 
the first measurement (baseline) levels of creatinine and urea concentration in PKD/Mhm 
(Cy/+) rats were higher than in PCK rats (p<0.05). However, on day 167, a 2.5-fold increase 
of plasma creatinine was recorded in both strains (figure 4.5).  
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Figure 4.5 Alteration over the time in plasma creatinine and urea levels in PKD/Mhm (Cy/+) and PCK rats (n=6 in each 
group). (A) plasma creatinine levels, (B) plasma urea levels. Data are shown as means ± Std.Dev. Values significantly 
different (time point vs baseline) are indicated as *p<0.05, **p<0.005, ***p=0.0001 and (PKD/Mhm (Cy/+) vs PCK) as 
‡p<0.05, ‡‡p<0.005, ‡‡‡p=0.0001. 
 
 
The opposite was true for plasma cholesterol and triglycerides concentration. Indeed, since 
the beginning of the study, in PCK rats the cholesterol levels were increased by 1.4-fold. 
Significant differences of glucose (p<0.05) and protein (p<0.005) concentrations were found 
among the groups at day 167 (table 4.2, for individual days see appendix 1). 
 
 
Parameter Strain Baseline Day 167 
Creatinine (mg/dl) PKD/Mhm (Cy/+) 0.3  0.1
‡
 0.7  0.1*** 
‡‡
 
 PCK 0.2  0.0 0.5  0.1*** 
Urea (mg/dl) PKD/Mhm (Cy/+) 68.4  18.2
‡
 87.4  11.0
‡‡
 
 PCK 31.6  2.8 56.6  3.2*** 
Na (mmol/l) PKD/Mhm (Cy/+) 144.3  0.8
‡‡‡
 144.8 1.9 
 PCK 139.2  1.2 143.8  1.8** 
K (mmol/l) PKD/Mhm (Cy/+) 5.4  0.3 5.1  0.2 
 PCK 5.4  0.3 5.1  0.2 
Ca (mmol/l) PKD/Mhm (Cy/+) 2.5  0.2 2.7  0.1
‡
 
 PCK 2.7  0.1 2.8  0.1 
PO4
 
(mmol/l) PKD/Mhm (Cy/+) 2.4  0.5 2.1  0.3 
 PCK 2.3  0.3 2.2  0.1 
Cholesterol (mg/dl) PKD/Mhm (Cy/+) 97.3  7.5
‡‡
 154.3  15.5*** 
‡‡
 
 PCK 140.3  15.6 301.2  62.1*** 
Triglycerides (mg/dl) PKD/Mhm (Cy/+) 69.2  26.3 108.8  48.3 
 PCK 86.8  15.0 160.5  46.9** 
Glucose (mg/dl) PKD/Mhm (Cy/+) 169.0  9.0 184.3  7.4
‡
 
 PCK 166.8  10.6 150.3  24.0 
 4. Results  - 23 - 
 
Protein (mg/dl) PKD/Mhm (Cy/+) 62.0  1.7 65.3  2.7
‡‡
 
 PCK 62.2  1.8 69.5  2.1 
Table 4.2 Plasma biochemistry in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group) at baseline and day 167. Data are 
shown as mean ± Std.Dev. Values significantly different (time point vs baseline) are indicated as **p<0.005, ***p=0.0001 
and (PKD/Mhm (Cy/+) vs PCK) as ‡p<0.05, ‡‡p<0.005, ‡‡‡p=0.0001. 
 
Aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) plasma concentration 
are useful parameter to assess a proper liver function. The levels of these parameters were 
increased, but more or less stable (table 4.3). 
 
Time point  AST  (U/l) ALT (U/l) 
Baseline PKD/Mhm (Cy/+) 88.3  8.8 
‡
 43.2  6.3 
‡‡
 
 PCK 134.0  42.1 82.5  20.4 
Day25 PKD/Mhm (Cy/+) 89.3  10.9 53.3  6.2 
 PCK 124.4  40.4 69.3  22.1 
Day 53 PKD/Mhm (Cy/+) 113.3  69.5 58.5  13.8 
‡
 
 PCK 144.5  36.3 90.0  21.3 
Day 81 PKD/Mhm (Cy/+) 92.5  14.9 57.8  7.1
‡
 
 PCK 134.3  46.1 90.3  19.2 
Day 109 PKD/Mhm (Cy/+) 81.8  5.7 48.7  6.5 
 PCK 162.5  84.6 77.5  22.6 
Day 137 PKD/Mhm (Cy/+) 138.5  44.6 53.7  8.9 
 PCK 113.8  33.3 66.5 34.9 
Day 167 PKD/Mhm (Cy/+) 72.2  12.4 48.8  10.3 
 PCK 135.2  144.9 64.2  53.9 
Table 4.3 Changes in plasma AST and ALT in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). Data are shown as 
mean ± Std.Dev. Values significantly different (PKD/Mhm (Cy/+) vs PCK) are indicated as ‡p<0.05, ‡‡p<0.005. 
 
Urine was collected overnight during 16 h in metabolic cages, every month before the start of 
each experiment. Besides diuresis, food and water intake were also measured using metabolic 
cages. Table 4.4 shows the changes of these parameters during the time, in both strains.  
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Table 4.4 Changes in diuresis, food intake and water intake after metabolic cages in PKD/Mhm (Cy/+) and PCK rats (n=6 in 
each group). Values significantly different (time point vs baseline) are indicated as *p<0.05, **p<0.005 and (PKD/Mhm 
(Cy/+) vs PCK) as ‡p<0.05, ‡‡p<0.005. 
 
All urinary parameters were normalized to the urine volume of the 16 hours. Urine parameters 
at baseline and day 167 are summarized in Table 4.5. In particular a remarkable increase, in 
both strains, of proteinuria and albumin levels was detected, in contrast with a decrease of 
glycosuria levels in PCK (for individual days see appendix 2). 
 
 Parameter Strain Baseline Day 167 
Creatinine (mg/16h) PKD/Mhm (Cy/+) 8.3  1.7 16.9  8.6** 
 PCK 8.1  1.1 14.8  3.1** 
Urea (mg/16h) PKD/Mhm (Cy/+) 572.9  178.1 830.5  376.6 
 PCK 709.3  120.7 681.6  91.3 
Na (mmol/16h) PKD/Mhm (Cy/+) 1.6  0.7 1.7  1.4 
 PCK 1.6  0.6 1.3  0.2 
K (mmol/16h) PKD/Mhm (Cy/+) 3.1  1.0 4.2  2.6 
 PCK 3.9  1.0 3.5  0.4 
Ca (mmol/16h) PKD/Mhm (Cy/+) 0.01  0.01
‡
 0.04  0.04 
 PCK 0.06  0.04 0.08  0.03 
PO4
 
(mmol/16h) PKD/Mhm (Cy/+) 0.1  0.1 0.1  0.1 
 PCK 0.1  0.1 0.1  0.1 
Glucose (mg/16h) PKD/Mhm (Cy/+) 1.2  0.4
‡
 1.7  1.7 
 PCK 5.2  1.9 1.9  1.5 
Protein (mg/16h) PKD/Mhm (Cy/+) 10.6  5.2 154.5  177.7
‡
 
 PCK 9.6  4.9 436.8  101.5*** 
Albumin (mg/16h) PKD/Mhm (Cy/+) 2.3  1.6
‡
 103.9  108.5** 
 PCK 0.7  0.3 140.6  71.2** 
Table 4.5 Urine biochemistry in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group) at baseline and day 167. Data are 
shown as mean ± Std.Dev. Values significantly different (time point vs baseline) are indicated as *p<0.05, **p<0.005, 
***p=0.001 and (PKD/Mhm (Cy/+) vs PCK) as ‡p<0.05. 
 
Time point Strain Diuresis (ml) Food intake (g) Water intake (ml) 
Baseline PKD/Mhm (Cy/+) 20.3  4.9 15.9  7.0 36.6  8.9 
 PCK 16.1  3.1 21.8  5.6 33.8  2.9 
Day25 PKD/Mhm (Cy/+) 29.4  3.5
‡
 17.9  2.1 53.0  9.3
‡‡
 
 PCK 21.7  4.4 17.4  5.0 37.7  4.5 
Day 53 PKD/Mhm (Cy/+) 26.8  7.4
‡
 16.7  3.0 47.2  10.5
‡
 
 PCK 17.6  5.0 17.0  3.9 31.3  3.6 
Day 81 PKD/Mhm (Cy/+) 31.2  11.2
‡
 13.0  6.6 50.2  29.1 
 PCK 18.1  2.7 14.6  2.6* 26.2  6.4 
Day 109 PKD/Mhm (Cy/+) 44.6  10.4
‡
 17.8  5.9 60.0  25.1
‡
 
 PCK 44.6  21.6 14.1  2.7* 32.3  6.4 
Day 137 PKD/Mhm (Cy/+) 44.6  10.4
‡‡
 17.6  5.1 55.5  13.3
‡‡
 
 PCK 21.4  5.5 15.6  0.7 24.0  11.0 
Day 167 PKD/Mhm (Cy/+) 55.8  54.5 12.3  4.3 56.0  15.6
‡
 
 PCK 25.3  2.7** 10.8  3.5** 33.2  4.4 
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Kidney function was assessed via a transcutaneous GFR measurement. A 3-compartment 
model was used to analyse the ABZWCY-HβCD elimination curve. The analysis shows an 
impairment of kidney filtration capacity due to the progression of the disease. In both 
PKD/Mhm (Cy/+) and PCK rats the ABZWCY-HβCD t1/2 values were significantly 
increased, compared to the baseline, already at day 109 respectively of 1.9 and 1.8-fold, and 
remained high till the end of the experiments (2.5-fold) indicating a decline of the renal 
function (figure 4.6, table 4.6). 
 
 
Figure 4.6 Alteration over the time in ABZWCY-HβCD t½ levels in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). 
Data are shown as means ± Std.Dev. Values significantly different (time point vs baseline) are indicated as *p<0.05, 
**p<0.005, ***p=0.001. 
 
 
Time point Strain ABZWCY-HCD t1/2 (min) 
Baseline PKD/Mhm (Cy/+) 26.7  9.3 
 PCK 29.9  10.8 
Day25 PKD/Mhm (Cy/+) 30.6  7.1 
 PCK 34.5  11.7 
Day 53 PKD/Mhm (Cy/+) 39.3  11.3 
 PCK 40.5  16.4 
Day 81 PKD/Mhm (Cy/+) 42.3  6.4 
 PCK 44.0  15.9 
Day 109 PKD/Mhm (Cy/+) 51.4  16.8 
 PCK 53.2  14.4 
Day 137 PKD/Mhm (Cy/+) 60.7  29.9* 
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 PCK 62.5  10.9** 
Day 167 PKD/Mhm (Cy/+) 66.0  11.4** 
 PCK 75.5  11.6*** 
Table 4.6 Changes in ABZWCY-HCD half-life in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). Data are shown as 
mean ± Std.Dev. Values significantly different (time point vs baseline) are indicated as *p<0.05, **p<0.005, ***p=0.001. 
 
At day 167, all the variations of the main parameters of renal function in both animal models 
show a loss of the kidney function (table 4.7).  
 
Parameter Strain Day 167 
ABZWCY-HCD t1/2 (min) PKD/Mhm (Cy/+) 66.0  11.4 
 PCK 75.5  11.6 
Creatinine (mg/dl) PKD/Mhm (Cy/+) 0.7  0.1‡‡ 
 PCK 0.5  0.1 
Urea (mg/dl) PKD/Mhm (Cy/+) 87.4  11.0‡‡ 
 PCK 56.6  3.2 
Table 4.7 ABZWCY-HCD half-life, plasma creatinine and urea in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group) at 
day 167. Data are shown as mean ± Std.Dev. Values significantly different (PKD/Mhm (Cy/+) vs PCK) are indicated as 
‡‡p<0.005. 
 
4.1.3 Gene expression profiling 
After isolating the RNA (see section 3.7) gene expression analysis was performed.  
The raw data from the RNAseq analyses were investigated in terms of differential expression 
compared to SD rats. From the 19239 genes identified on average in PKD/Mhm (Cy/+) and 
PCK, 11326 genes were significantly differentially expressed (adj.p < 0.05) in PKD/Mhm 
(Cy/+) (5490 upregulated and 5836 downregulated genes) and only 4602 genes were affected 
in PCK rats (2264 upregulated and 2338 downregulated genes). Venn diagrams in figure 4.7 
show that 1619 and 1817 genes were found in both strains respectively up- and 
downregulated.  
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Figure 4.7 Venn diagrams of differentially expressed genes in PKD/Mhm (Cy/+) and PCK rats. A) Upregulated genes, B) 
Downregulated genes.  
 
GSEA was performed by using the KEGG database. Genes were clustered in pathways and 
divided into 6 main categories, according to the KEGG database terminology. Significantly 
differentially expressed pathways were classified with a higher (or lower) normalized 
enrichment score (NES) (adj.p<0.05). The NES represents upregulated pathways with 
positive values and downregulated pathways with negative values. Table 4.8 (A-B) and 
figure 4.8 show the numbers and main categories of the up- and downregulated pathways. 
 
 
A Analysed pathways  305 
 Significantly regulated pathways (adj. p-value < 0.05) 199 
 Significantly upregulated pathways (adj. p-value < 0.05) 140 
 Significantly downregulated pathways (adj. p-value < 0.05) 59 
Table 4.8A Overview of GSEA displaying the numbers of up- and downregulated pathways in PKD/Mhm (Cy/+) rats 
 
B Analysed pathways 305 
 Significantly regulated pathways (adj. p-value < 0.05) 156 
 Significantly upregulated pathways (adj. p-value < 0.05) 119 
 Significantly downregulated pathways (adj. p-value < 0.05) 37 
Table 4.8B Overview of GSEA displaying the numbers of up- and downregulated pathways in PCK rats 
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Figure 4.8 Pie charts showing the distribution of pathways containing significantly up- and downregulated genes sorted by 
main categories of KEGG database. The numbers around the pie charts indicate the number of up- and downregulated 
pathways of each category. 
 
 
In both strains, pathways related to the metabolism were downregulated and, above all, a shift 
from the oxidative phosphorylation to the glycolysis process was detected (table 4.9 A-B). As 
evidence to support these results, table 4.10 highlights the significantly differentially 
expressed genes, among all, involved in gluconeogenesis (Gpi, G6pc, Pgm1, Pgk1) and 
glycolysis (Hk2, Pfkp, Ldha). 
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Table 4.9A GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PKD/Mhm (Cy/+) vs SD). For each pathway the NES is given. Downregulated pathways are displayed 
in green, upregulated pathways are displayed in red 
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Table 4.9B GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PCK vs SD). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red. 
SYMBOL GENE NAME logFC PKD/Mhm (Cy/+) log FC PCK 
Gpi glucose-6-phosphate isomerase 0.04 -0.10 
G6pc glucose-6-phosphatase, catalytic subunit -1.45 0.50 
Pgm1 phosphoglucomutase 1 -0.76 -0.07 
Pgk1 phosphoglycerate kinase 1 -0.51 0.01 
Hk2 hexokinase 2 0.16 -0.01 
Pfkp phosphofructokinase, platelet -0.29 -0.29 
Ldha lactate dehydrogenase A -0.36 0.19 
Table 4.10 List of significantly differentially regulated genes in PKD/Mhm (Cy/+) and PCK rats. Significantly (adj. p<0.05) 
differentially regulated genes (model vs SD). Negative log fold changes (logFC) are displayed in green, positive logFC are 
displayed in red. 
 
Proteasome and ribosome pathways were downregulated in the PCK model. Protein 
processing pathway was downregulated both in PKD/Mhm (Cy/+) and PCK models, while 
DNA replication was upregulated (table 4.11 A-B). 
 
Table 4.11A GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PKD/Mhm (Cy/+) vs SD). For each pathway the NES is given. Downregulated pathways are displayed 
in green, upregulated pathways are displayed in red. 
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Table 4.11B GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PCK vs SD). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red. 
 
Upregulation of signal transduction pathways was detected in PKD/Mhm (Cy/+) model (table 
4.12A), likewise in PCK (table 4.12B). Also pro-inflammatory mediators such as tumor 
necrosis factor (TNF)-α and nuclear factor (NF)-B were upregulated, mainly in the 
PKD/Mhm (Cy/+) model, as well Janus kinase (JAK)1 and 2 (table 4.12C) implying the 
upregulation of JAK-STAT, NF-B and TNF signaling pathways.   
 
 
Table 4.12A GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PKD/Mhm (Cy/+) vs SD). For each pathway the NES is given. Downregulated pathways are displayed 
in green, upregulated pathways are displayed in red. 
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Table 4.12B GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PCK vs SD). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red. 
 
 
 
Table 4.12C List of significantly differentially regulated genes in PKD/Mhm (Cy/+) and PCK rats. Significantly (adj. 
p<0.05) differentially regulated genes (model vs SD). Positive logFC are displayed in red. 
 
 
 
As expected, an upregulation of cell growth and proliferation pathways was seen in both 
PKD/Mhm (Cy/+) (table 4.13A) and PCK (table 4.13B) rats.  
 
KEGG Pathways Main_Category Sub_Category NES PCK
Cytokine-cytokine receptor interaction Environmental Information Processing 3.3. Signaling molecules and interaction 2.06
JAK-STAT signaling pathway Environmental Information Processing 3.2. Signal transduction 2
ECM-receptor interaction Environmental Information Processing 3.3. Signaling molecules and interaction 1.99
PI3K-Akt signaling pathway Environmental Information Processing 3.2. Signal transduction 1.94
Cell adhesion molecules (CAMs) Environmental Information Processing 3.3. Signaling molecules and interaction 1.9
ErbB signaling pathway Environmental Information Processing 3.2. Signal transduction 1.88
MAPK signaling pathway Environmental Information Processing 3.2. Signal transduction 1.78
TNF signaling pathway Environmental Information Processing 3.2. Signal transduction 1.78
Sphingolipid signaling pathway Environmental Information Processing 3.2. Signal transduction 1.75
Rap1 signaling pathway Environmental Information Processing 3.2. Signal transduction 1.71
Phospholipase D signaling pathway Environmental Information Processing 3.2. Signal transduction 1.7
NF-kappa B signaling pathway Environmental Information Processing 3.2. Signal transduction 1.69
Hedgehog signaling pathway Environmental Information Processing 3.2. Signal transduction 1.68
Ras signaling pathway Environmental Information Processing 3.2. Signal transduction 1.66
Apelin signaling pathway Environmental Information Processing 3.2. Signal transduction 1.61
FoxO signaling pathway Environmental Information Processing 3.2. Signal transduction 1.61
HIF-1 signaling pathway Environmental Information Processing 3.2. Signal transduction 1.6
Wnt signaling pathway Environmental Information Processing 3.2. Signal transduction 1.43
cGMP-PKG signaling pathway Environmental Information Processing 3.2. Signal transduction 1.37
B 
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Table 4.13A GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PKD/Mhm (Cy/+) vs SD). For each pathway the NES is given. Downregulated pathways are displayed 
in green, upregulated pathways are displayed in red. 
 
Table 4.13B GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PCK vs SD). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red. 
 
Inflammatory pathways, such as complement cascade and chemokine signaling pathways, 
were upregulated in both strains, while PPAR signaling pathway was downregulated either in 
PKD/Mhm (Cy/+) or PCK (table 4.14 A-B). 
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Table 4.14A GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PKD/Mhm (Cy/+) vs SD). For each pathway the NES is given. Downregulated pathways are displayed 
in green, upregulated pathways are displayed in red. 
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Table 4.14B GSEA analysis using KEGG database sorted by main category. Significantly (adj. p<0.05) differentially 
expressed pathways (PCK vs SD). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red.  
 
4.2 Long term effects of stem cells and conditioned media therapy in PKD/Mhm (Cy/+) 
rats 
4.2.1 Changes in BW and kidney histology  
BW of treated PKD/Mhm (Cy/+) groups was monitored monthly. As outlined for the 
untreated group, a constant rise of the BW was recorded in the treated groups but no 
significant differences were observed between them (figure 4.9). Moreover, no differences of 
left kidney weight or Kw/BW ratio were noted among all the groups (table 4.15 A-B).  
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Figure 4.9 Effect on BW of different treatments in PKD/Mhm (Cy/+) (n=6 in each group). Data are shown as means ± 
Std.Dev. 
 
A Animal group Left kidney (g) Kw/BW ratio 
 Untreated  3.1  0.8 0.6  0.1 
 + ABCB5+ derived CoCM+ 2.8  0.6 0.6  0.1 
 + i.p. ABCB5+ 2.8  0.5 0.6  0.1 
 + i.v. ABCB5+ 2.6  0.5 0.5  0.1 
Table 4.15A Effect of different treatments on left kidney weight and Kw/BW ratio in PKD/Mhm (Cy/+) groups (n=6 in each 
group). Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Data are shown as mean 
± Std.Dev. 
 
B Animal group Left kidney (g) Kw/BW ratio 
 Untreated 3.1  0.8 0.6  0.1 
 + ASC derived CM 3.1  0.1 0.6  0.1 
 + i.p. ASC 3.0  0.1 0.6  0.0 
 + i.v. ASC 3.2  0.3 0.6  0.1 
Table 4.15B Effect of different treatments on left kidney weight and Kw/BW ratio in PKD/Mhm (Cy/+) groups (n=6 in each 
group). Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated Data are shown as mean ± Std.Dev. 
 
H&E and Masson-Goldner trichrome stainings were performed on 3 μm kidney sections. We 
noted a decrease of cyst number in the i.p. ABCB5+ and ASC derived CM groups (p<0.05) 
and, in the same groups a proportional reduction of the percentage of renal tissue covered by 
them. A reduction of the percentage of cyst area was observed also in i.v. ABCB5+ and 
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ABCB5+ derived CoCM+ groups. However, in i.p. and i.v. ABCB5+ and ABCB5+ derived 
CoCM+ groups, a rise of the average cyst size was registered (table 4.16A). 
 
Masson-Goldner staining allowed the quantification of fibrotic tissue on the whole kidney 
section. All the treated groups presented an increase of the fibrotic tissue when compared to 
the untreated group, especially i.p. or i.v. ABCB5+ and ABCB5+ derived CoCM+ groups 
(table 4.16 A-B, figure 4.10).  
 
Masson-Goldner staining was performed also on 3 μm liver sections. The percentage of 
fibrosis was only 1.2 ± 0.4 in the untreated group and no differences were noted in the 
comparison between treated and untreated groups. Indeed, the percentage of cyst area in all 
the groups was lower than 0.1±0.1 (data not shown). 
 
A Animal group Cyst number Average size 
(pixels) 
% cyst area % fibrosis 
 Untreated 4210.6  500.0 426.2  79.0 18.1  3.3 7.9  3.3 
 + ABCB5+ derived CoCM+ 1682.7  1305.9 648.6  257.1 9.8  5.0 21.9  12.1 
 + i.p. ABCB5+ 1072.0  788.8* 826.9  159.8 8.6  5.0 20.4  9.2 
 + i.v. ABCB5+ 1396.3  1532.3 679.2  232.8 7.9  5.6 16.3  8.3 
Table 4.16A Effect of different treatments on cyst number, average size, percentage of cyst and fibrosis area in PKD/Mhm 
(Cy/+) groups (n=6 in each group). Comparison between ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ groups and 
untreated. Analysis was performed on whole kidney section (3μm). Data are shown as mean ± Std.Dev. Values significantly 
different (treated vs untreated) are indicated as * p<0.05. 
 
B Animal group Cyst number Average size 
(pixels) 
% cyst area % fibrosis 
 Untreated 4210.6  500.0 426.2  79.0 18.1  3.3 7.9  3.3 
 + ASC derived CM 2606.5  919.9* 376.5  81.3 12.3  5.0 10.3  2.3 
 + i.p. ASC 4333.0  713.7 402.0  28.4
 
17.3  2.1 9.6  3.2 
 + i.v. ASC 4117.2  793.5 409.7  59.5 16.2  4.2 10.3  2.8 
Table 4.16B Effect of different treatments on cyst number, average size, percentage of cyst and fibrosis area in PKD/Mhm 
(Cy/+) groups (n=6 in each group). Comparison between ASC derived CM, i.v. or i.p. ASC groups and untreated. Analysis 
was performed on whole kidney section (3μm). Data are shown as mean ± Std.Dev. Values significantly different (treated vs 
untreated) are indicated as * p<0.05. 
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Figure 4.10 Fibrosis in PKD/Mhm (Cy/+) kidneys (n=6 in each group). A) Whole kidney scan of PKD/Mhm (Cy/+) rat, 
Masson-Goldner trichrome staining, light green stains fibrotic tissue; B) Graphic quantification of fibrosis after different 
treatments in PKD/Mhm (Cy/+) model. Data are shown as box plots with the median, upper and lower quartile (interquartile 
range (IQR)) and whiskers (1.5x IQR). Image acquired with Axio Scan.Z1 microscope (ZEISS), 20x objective.  
 
The analysis of the co-staining of Tunel and Ki67 on whole kidney sections outlined a 
considerable reduction of apoptotic and proliferative positive cells in all treated groups (table 
4.17 A-B). 
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A Animal group Tunel positive cells Ki67 positive cells 
 Untreated 1370.0  237.7 1239.5  250.7 
 + ABCB5+ derived CoCM+ 977.7  133.3** 900.2  147.7* 
 + i.p. ABCB5+ 1058.3  106.6* 880.9  112.0* 
 + i.v. ABCB5+ 1066.4  84.7* 948.2  145.7* 
Table 4.17A Effect of different treatments on Tunel and Ki67 positive nuclei in in PKD/Mhm (Cy/+) groups (n=6 in each 
group). Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Analysis was performed 
on whole kidney section (3μm). Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are 
indicated as *p<0.05, ** p<0.005. 
 
B Animal group Tunel positive cells Ki67 positive cells 
 Untreated 1370.0  237.7 1239.5  250.7 
  + ASC derived CM 974.5 ± 290.2 781.0 ± 280.4* 
  + i.p. ASC 1001.4 ± 73.7 976.4 ± 78.3 
  + i.v. ASC 984.0 ± 287.1* 804.2 ± 271.5* 
Table 4.17B Effect of different treatments on Tunel and Ki67 positive nuclei in in PKD/Mhm (Cy/+) groups (n=6 in each 
group). Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Analysis was performed on whole 
kidney section (3μm). Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated 
as *p<0.05. 
 
4.2.2 Plasma chemistry, urine analysis and renal function 
From now on, only the results of day 167 will be shown. Further results are displayed in the 
appendix. 
 
Plasma creatinine levels were reduced in both i.p. ABCB5+ and i.p. ASC groups while no 
variations were registered in all the others treated groups, when compared to the untreated. 
Conversely, conflicting results were noted concerning urea levels. In fact, the plasma levels 
slightly decreased in i.p. and i.v. ABCB5+ groups and increased in i.p. and i.v. ASC and ASC 
derived CM groups.  
A decline of cholesterol and triglycerides levels were seen in i.p. and i.v. ABCB5+ and ASC 
and ABCB5+ derived CoCM+. The ASC derived CM group showed a reduction of 
triglycerides levels but no difference concerning the cholesterol levels. A minor decrease of 
glucose levels was recorded in all the treated groups, in particular in the i.p. ABCB5+ group. 
Sodium levels visibly decreased in i.p. and i.v. ABCB5+ and i.p. ASC groups (p<0.05). 
Calcium levels were decreased in i.p. ABCB5+ (p<0.05) while a significant increment of 
potassium was detected in i.p. ASC group (p<0.05). Table 4.18 (A-B) illustrates the plasma 
parameters that were analysed for each group (for individual days see appendix 3). 
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A Parameter Animal group Day 167 
 Creatinine Untreated 0.7 ± 0.1 
 (mg/dl) + ABCB5+ derived CoCM+ 0.7 ± 0.2 
  + i.p. ABCB5+ 0.6 ±0.1 
  + i.v. ABCB5+ 0.7 ± 0.1 
 Urea Untreated 87.4 ± 11.0 
 (mg/dl) + ABCB5+ derived CoCM+ 86.5 ± 23.2 
  + i.p. ABCB5+ 79.6 ± 17.7 
  + i.v. ABCB5+ 72.3 ± 12.4 
 Na Untreated 144.8 ± 1.9 
 (mmol/l) + ABCB5+ derived CoCM+ 142.2 ± 1.7 
  + i.p. ABCB5+ 141.9 ± 1.6* 
  + i.v. ABCB5+ 142.0 ± 2.0* 
 K Untreated 5.1 ± 0.2 
 (mmol/l) + ABCB5+ derived CoCM+ 5.3 ± 0.4 
  + i.p. ABCB5+ 4.9 ± 0.2 
  + i.v. ABCB5+ 5.0 ± 0.2 
 Ca Untreated 2.7 ± 0.1 
 (mmol/l) + ABCB5+ derived CoCM+ 2.4 ± 0.2 
  + i.p. ABCB5+ 2.4 ± 0.2* 
  + i.v. ABCB5+ 2.5 ± 0.2 
 PO4 Untreated 2.1 ± 0.3 
 (mmol/l) + ABCB5+ derived CoCM+ 2.2 ± 0.2 
  + i.p. ABCB5+ 2.1 ± 0.1 
  + i.v. ABCB5+ 1.9 ± 0.2 
 Cholesterol Untreated 154.3 ± 15.5 
 (mg/dl) + ABCB5+ derived CoCM+ 138.3 ± 30.9 
  + i.p. ABCB5+ 135.1 ± 23.0 
  + i.v. ABCB5+ 134.0 ± 29.3 
 Triglycerides Untreated 108.8 ± 48.3 
 (mg/dl) + ABCB5+ derived CoCM+ 69.8 ± 23.4 
  + i.p. ABCB5+ 79.3 ± 29.0 
  + i.v. ABCB5+ 72.1 ± 29.6 
 Glucose Untreated 184.3 ± 7.4 
 (mg/dl) + ABCB5+ derived CoCM+ 171.7 ± 12.0 
  + i.p. ABCB5+ 168.0 ± 14.5 
  + i.v. ABCB5+ 178.1 ± 14.6 
 Protein Untreated 65.3 ± 2.7 
 (mg/dl) + ABCB5+ derived CoCM+ 61.3 ± 2.4* 
  + i.p. ABCB5+ 64.1 ± 1.9 
  + i.v. ABCB5+ 63.1 ± 1.6 
 AST Untreated 72.2 ± 12.4 
 (U/l) + ABCB5+ derived CoCM+ 88.2 ± 15.1 
  + i.p. ABCB5+ 79.6 ± 9.5 
  + i.v. ABCB5+ 81.4 ± 14.6 
 ALT Untreated 48.8 ± 10.3 
 (U/l) + ABCB5+ derived CoCM+ 47.7 ± 3.7 
  + i.p. ABCB5+ 47.6 ± 8.4 
  + i.v. ABCB5+ 46.3 ± 4.3 
Table 4.18A Plasma biochemistry in PKD/Mhm (Cy/+) groups (untreated; ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. 
ABCB5+; n=6 in each group) at day 167. Data are shown as mean ± Std.Dev. Values significantly different (treated vs 
untreated) are indicated as *p<0.05. 
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B Parameter Animal group Day 167 
 Creatinine Untreated 0.7 ± 0.1 
 (mg/dl) + ASC derived CM 0.7 ± 0.2 
  + i.p. ASC  0.6 ± 0.1 
  + i.v. ASC 0.7 ± 0.1 
 Urea Untreated 87.4 ± 11.0 
 (mg/dl) + ASC derived CM 98.7 ± 21.6 
  + i.p. ASC  90.8 ± 12.7 
  + i.v. ASC 95.6 ± 10.6 
 Na Untreated 144.8 ± 1.9 
 (mmol/l) + ASC derived CM 145.3 ± 2.2 
  + i.p. ASC  138.5 ± 5.0* 
  + i.v. ASC 139.5 ± 4.4 
 K Untreated 5.1 ± 0.2 
 (mmol/l) + ASC derived CM 5.7 ± 0.4 
  + i.p. ASC  6.1 ± 0.5** 
  + i.v. ASC 5.7 ± 0.4 
 Ca Untreated 2.7 ± 0.1 
 (mmol/l) + ASC derived CM 2.7 ± 0.1 
  + i.p. ASC  2.6 ± 0.1 
  + i.v. ASC 2.6 ± 0.1 
 PO4 Untreated 2.1 ± 0.3 
 (mmol/l) + ASC derived CM 2.0 ± 0.4 
  + i.p. ASC  1.8 ± 0.3 
  + i.v. ASC 1.9 ± 0.2 
 Cholesterol Untreated 154.3 ± 15.5 
 (mg/dl) + ASC derived CM 152.3 ± 22.0 
  + i.p. ASC  144.7 ± 10.6 
  + i.v. ASC 149.5 ± 17.3 
 Triglycerides Untreated 108.8 ± 48.3 
 (mg/dl) + ASC derived CM 63.3 ± 36.2 
  + i.p. ASC  98.8 ± 42.2 
  + i.v. ASC 63.5 ± 17.2 
 Glucose Untreated 184.3 ± 7.4 
 (mg/dl) + ASC derived CM 173.0 ± 9.3 
  + i.p. ASC  174.7 ± 17.1 
  + i.v. ASC 174.5 ± 9.9 
 Protein Untreated 65.3 ± 2.7 
 (mg/dl) + ASC derived CM 66.3 ± 1.7 
  + i.p. ASC  66.3 ± 2.8 
  + i.v. ASC 65.2 ± 1.5 
 AST Untreated 72.2 ± 12.4 
 (U/l) + ASC derived CM 73.3 ± 5.0 
  + i.p. ASC  98.5 ± 59.0 
  + i.v. ASC 69.3 ± 4.0 
 ALT Untreated 48.8 ± 10.3 
 (U/l) + ASC derived CM 54.0 ± 14.4 
  + i.p. ASC  51.7 ± 7.5 
  + i.v. ASC 51.0 ± 14.6 
Table 4.18B Plasma biochemistry in PKD/Mhm (Cy/+) groups (untreated; ASC derived CM; i.p. ASC; i.v. ASC; n=6 in each 
group) at day 167. Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated as 
*p<0.05, ** p<0.005. 
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Animals were placed in metabolic cages overnight for 16 hours, afterwards urine samples 
were collected. Table 4.19 (A-B) summarizes diuresis, food and water intake values at day 
167 in all the groups (for individual days see appendix 4). 
   
A Parameter Animal group Day 167 
 Diuresis (ml) Untreated 55.8  54.5 
  + ABCB5+ derived CoCM+ 28.4 ± 10.1 
  + i.p. ABCB5+ 26.3 ± 7.3 
  + i.v. ABCB5+ 48.1 ± 20.6 
 Food intake  Untreated 12.3  4.3 
 (g) + ABCB5+ derived CoCM+ 10.1 ± 4.3 
  + i.p. ABCB5+ 12.1 ± 3.4 
  + i.v. ABCB5+ 11.6 ± 2.4 
 Water intake  Untreated 56.0  15.6 
 (g) + ABCB5+ derived CoCM+ 33.5 ± 15.5 
  + i.p. ABCB5+ 32.3 ± 9.8 
  + i.v. ABCB5+ 55.9 ± 21.8 
Table 4.19A Effect of different treatments on diuresis, food intake and water intake in PKD/Mhm (Cy/+) groups (n=6 in 
each group) at day 167. Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Data are 
shown as mean ± Std.Dev. 
 
B Parameter Animal group Day 167 
 Diuresis (ml) Untreated 55.8  54.5 
  + ASC derived CM 28.9 ± 5.6 
  + i.p. ASC  28.4 ± 13.6 
  + i.v. ASC 33.6 ± 13.1 
 Food intake  Untreated 12.3  4.3 
 (g) + ASC derived CM 9.9 ± 2.7 
  + i.p. ASC  11.5 ± 3.5 
  + i.v. ASC 10.1 ± 2.2 
 Water intake  Untreated 56.0  15.6 
 (g) + ASC derived CM 40.9 ± 12.5 
  + i.p. ASC  43.1 ± 13.6 
  + i.v. ASC 41.1 ± 14.5 
Table 4.19B Effect of different treatments on diuresis, food intake and water intake in PKD/Mhm (Cy/+) groups (n=6 in each 
group) at day 167. Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Data are shown as mean ± 
Std.Dev. 
 
Urine biochemistry results showed a decrease in creatinine and urea levels in all the treated 
groups, likewise the proteinuria and albumin levels. Table 4.20 (A-B) illustrates the analysed 
urine parameters (for individual days see appendix 5). 
 
A Parameter Animal group Day 167 
 Creatinine Untreated 16.9 ± 8.6 
 (mg/16h) + ABCB5+ derived CoCM+ 12.3 ± 2.3 
  + i.p. ABCB5+ 12.5 ± 0.6 
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  + i.v. ABCB5+ 14.2 ± 2.6 
Urea Untreated 830.4 ± 376.6 
 (mg/16h) + ABCB5+ derived CoCM+ 552.0 ± 142.1 
  + i.p. ABCB5+ 610.5 ± 54.9 
  + i.v. ABCB5+ 702.9 ± 149.6 
Na Untreated 1.7 ± 1.4 
 (mmol/16h) + ABCB5+ derived CoCM+ 1.5 ± 0.5 
  + i.p. ABCB5+ 1.4 ± 0.4 
  + i.v. ABCB5+ 1.7 ± 0.6 
K Untreated 4.2 ± 2.6 
 (mmol/16h) + ABCB5+ derived CoCM+ 3.1 ± 1.1 
  + i.p. ABCB5+ 1.7 ± 1.1 
  + i.v. ABCB5+ 3.7 ± 0.8 
Ca Untreated 0.04 ± 0.04 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.02 ± 0.01 
  + i.p. ABCB5+ 0.01 ± 0.01 
  + i.v. ABCB5+ 0.02 ± 0.00 
PO4 Untreated 0.1 ± 0.1 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.1 ± 0.1 
  + i.p. ABCB5+ 0.0 ± 0.0 
  + i.v. ABCB5+ 0.1 ± 0.0 
Glucose Untreated 1.7 ± 1.7 
 (mg/16h) + ABCB5+ derived CoCM+ 0.9 ± 0.8 
  + i.p. ABCB5+ 1.4 ± 0.9 
  + i.v. ABCB5+ 1.4 ± 0.6 
Protein Untreated 154.5 ± 177.7 
 (mg/16h) + ABCB5+ derived CoCM+ 49.8 ± 16.4 
  + i.p. ABCB5+ 68.4 ± 35.0 
  + i.v. ABCB5+ 58.8 ± 36.5 
Albumin Untreated 103.9 ± 108.5 
 (mg/16h) + ABCB5+ derived CoCM+ 39.1 ± 16.2 
  + i.p. ABCB5+ 58.1 ± 37.5 
  + i.v. ABCB5+ 52.6 ± 37.7 
Table 4.20A Urine biochemistry in PKD/Mhm (Cy/+) groups (untreated; ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. 
ABCB5+; n=6 in each group) at day 167. Data are shown as mean ± Std.Dev. 
 
B Parameter Animal group Day 167 
 Creatinine Untreated 16.9 ± 8.6 
 (mg/16h)  + ASC derived CM 13.6 ± 0.6 
   + i.p. ASC 10.9 ± 2.9 
   + i.v. ASC 13.8 ± 1.8 
Urea Untreated 830.5 ± 376.6 
 (mg/16h)  + ASC derived CM 644.5 ± 99.6 
   + i.p. ASC 557.6 ± 199.5 
   + i.v. ASC 666.2 ± 92.6 
Na Untreated 1.7 ± 1.4 
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 (mmol/16h)  + ASC derived CM 1.0 ± 0.2 
   + i.p. ASC 1.6 ± 0.9 
   + i.v. ASC 1.1 ± 0.3 
K Untreated 4.2 ± 2.6 
 (mmol/16h)  + ASC derived CM 3.1 ± 0.6 
   + i.p. ASC 2.8 ± 1.0 
   + i.v. ASC 3.0 ± 0.8 
Ca Untreated 0.04 ± 0.04 
 (mmol/16h)  + ASC derived CM 0.03 ± 0.02 
   + i.p. ASC 0.01 ± 0.01 
   + i.v. ASC 0.02 ± 0.01 
PO4 Untreated 0.1 ± 0.1 
 (mmol/16h)  + ASC derived CM 0.1 ± 0.1 
   + i.p. ASC 0.1 ± 0.1 
   + i.v. ASC 0.1 ± 0.1 
Glucose Untreated 1.7 ± 1.7 
 (mg/16h)  + ASC derived CM 1.3 ± 1.4 
   + i.p. ASC 1.9 ± 1.2 
   + i.v. ASC 1.8 ± 0.8 
Protein Untreated 154.5 ± 177.7 
 (mg/16h)  + ASC derived CM 81.3 ± 15.8 
   + i.p. ASC 76.0 ± 41.1 
   + i.v. ASC 83.6 ± 25.5 
Albumin Untreated 103.9 ± 108.5 
 (mg/16h)  + ASC derived CM 39.0 ± 6.6 
   + i.p. ASC 64.2 ± 34.6 
   + i.v. ASC 60.4 ± 26.1 
Table 4.20B Urine biochemistry in PKD/Mhm (Cy/+) groups (untreated; ASC derived CM; i.p. ASC; i.v. ASC; n=6 in each 
group) at day 167. Data are shown as mean ± Std.Dev. 
 
A significant reduction of ABZWCY-HβCD t1/2 in i.p. ABCB5+ and i.p. ASC groups 
(p<0.05) was observed, as shown in table 4.21 (A-B) (for individual days see appendix 6). A 
slight decrease was also recorded in i.v. ABCB5+ and ASC, ABCB5+ derived CoCM+ and 
ASC derived CM groups (figure 4.11). 
 
A Parameter Animal group Day 167 
 ABZWCY-HβCD t1/2 (min) Untreated 66.0 ± 11.4 
   + ABCB5+ derived CoCM+ 55.0 ± 12.0 
   + i.p. ABCB5+ 41.2 ± 15.5* 
   + i.v. ABCB5+ 43.9 ± 19.1 
Table 4.21A Effect of different treatments on ABZWCY-HCD t1/2 in PKD/Mhm (Cy/+) groups (n=6 in each group) at day 
167. Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Data are shown as mean ± 
Std.Dev. Values significantly different (treated vs untreated) are indicated as *p<0.05. 
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B Parameter Animal group Day 167 
 ABZWCY-HβCD t1/2 (min) Untreated 66.0 ± 11.4 
   + ASC derived CM 49.6 ± 15.7 
   + i.p. ASC 38.8 ± 8.1* 
   + i.v. ASC 43.0 ± 19.8 
Table 4.21B Effect of different treatments on ABZWCY-HCD t1/2 in PKD/Mhm (Cy/+) groups (n=6 in each group) at day 
167. Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Data are shown as mean ± Std.Dev. 
Values significantly different (treated vs untreated) are indicated as *p<0.05. 
 
 
Figure 4.11 Effect of different treatments on ABZWCY-HβCD t1/2 in PKD/Mhm (Cy/+) model (n=6 in each group). Data are 
shown as box plots with the median, upper and lower quartile (interquartile range (IQR)) and whiskers (1.5x IQR). Values 
significantly different (treatment vs PKD/Mhm (Cy/+)) are indicated as *p<0.05. 
 
Table 4.22 (A-B) shows plasma levels of creatinine and urea in correlation with the 
ABZWCY-HβCD t1/2 values. 
 
A Animal group  ABZWCY-HβCD t1/2 (min) Creatinine (mg/dl) Urea (mg/dl) 
 Untreated 66.0 ± 11.4 0.7 ± 0.1 87.4 ± 11.0 
  + ABCB5+ derived 
CoCM+ 
55.0 ± 12.0 0.7 ± 0.2 86.5 ± 23.2 
  + i.p. ABCB5+ 41.2 ± 15.5* 0.6 ±0.1 79.6 ± 17.7 
  + i.v. ABCB5+ 43.9 ± 19.1 0.7 ± 0.1 72.3 ± 12.4 
Table 4.22A Effect of different treatments on ABZWCY-HCD t1/2, plasma creatinine and urea in PKD/Mhm (Cy/+) groups 
(n=6 in each group) at day 167. Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. 
Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated as *p<0.05. 
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B Animal group  ABZWCY-HβCD t1/2 (min) Creatinine (mg/dl) Urea (mg/dl) 
 Untreated 66.0 ± 11.4 0.7 ± 0.1 87.4 ± 11.0 
  + ASC derived CM 49.6 ± 15.7 0.7 ± 0.2 98.7 ± 21.6 
  + i.p. ASC 38.8 ± 8.1* 0.6 ± 0.1 90.8 ± 12.7 
  + i.v. ASC 43.0 ± 19.8 0.7 ± 0.1 95.6 ± 10.6 
Table 4.22B Effect of different treatments on ABZWCY-HCD t1/2, plasma creatinine and urea in PKD/Mhm (Cy/+) groups 
(n=6 in each group) at day 167. Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Data are 
shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated as *p<0.05. 
 
4.2.3 Gene expression profiling 
Gene expression analysis was performed on each treated PKD/Mhm group compared to the 
untreated. Table 4.23 (A-B) summarizes the up- and downregulated pathways identified for 
each treated group. 
 
A Animal group   
  Total analysed pathways 304 
 +ABCB5+ derived 
CoCM+ 
Significantly regulated pathways (adj. p-value < 0.05) 185 
  Significantly upregulated pathways (adj. p-value < 0.05) 37 
  Significantly downregulated pathways (adj. p-value < 0.05) 148 
 + i.p. ABCB5+ Significantly regulated pathways (adj. p-value < 0.05) 165 
  Significantly upregulated pathways (adj. p-value < 0.05) 46 
  Significantly downregulated pathways (adj. p-value < 0.05) 119 
 + i.v. ABCB5+ Significantly regulated pathways (adj. p-value < 0.05) 142 
  Significantly upregulated pathways (adj. p-value < 0.05) 47 
  Significantly downregulated pathways (adj. p-value < 0.05) 95 
Table 4.23A Overview of GSEA displaying the numbers of up- and downregulated pathways in PKD/Mhm (Cy/+) groups 
(ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. ABCB5+; n=6 in each group).  
 
B Animal group   
  Total analysed pathways 305 
 +ASC derived CM Significantly regulated pathways (adj. p-value < 0.05) 42 
  Significantly upregulated pathways (adj. p-value < 0.05) 31 
  Significantly downregulated pathways (adj. p-value < 0.05) 11 
 + i.p. ASC Significantly regulated pathways (adj. p-value < 0.05) 101 
  Significantly upregulated pathways (adj. p-value < 0.05) 55 
  Significantly downregulated pathways (adj. p-value < 0.05) 46 
 + i.v. ASC Significantly regulated pathways (adj. p-value < 0.05) 122 
  Significantly upregulated pathways (adj. p-value < 0.05) 48 
  Significantly downregulated pathways (adj. p-value < 0.05) 74 
Table 4.23B Overview of GSEA displaying the numbers of up- and downregulated pathways in PKD/Mhm (Cy/+) groups 
(ASC derived CM; i.p. ASC; i.v. ASC; n=6 in each group). Total analysed pathways are 305 in the ASC derived CM; i.p. 
ASC; i.v. ASC groups while 304 in the ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. ABCB5+ groups because GSEA 
analyses were performed over two different years.  
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Figure 4.12 exemplifies the main categories of up- and downregulated pathways taken into 
account in different stem cells and conditioned media administration. Figure 4.13 shows the 
number of common pathways between each pair of the same stem cells administration route 
and conditioned media.  
 
 
 
Figure 4.12 Pie charts showing the distribution of pathways containing significantly up- and downregulated genes sorted by 
main categories of KEGG database. A) ABCB5+ derived CoCM+, i.p.ABCB5+ and i.v. ABCB5+ treatment; B) ASC derived 
CM, i.p. ASC and i.v. ASC treatment. The numbers around the pie charts indicate the number of up- and downregulated 
pathways contained in each category.  
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Figure 4.13 Venn diagrams showing the common significant up- and downregulated pathways in PKD/Mhm (Cy/+). A) 
ABCB5+ derived CoCM+, i.p. ABCB5+ or i.v. ABCB5+ treatment; B) ASC derived CM, i.p. ASC or i.v. ASC treatment. 
The numbers inside the Venn diagrams indicate the number of un- and downregulated pathways contained in each category.  
 
As described in figure 4.14, i.v. ASC and i.v. ABCB5+ groups have in common 32 and 44 
pathways respectively up and downregulated, while there are 36 and 37 common pathways 
among i.p. ASC and i.p. ABCB5+ groups and lastly, ASC derived CM and ABCB5+ derived 
CoCM+ groups present 17 and 5 up and downregulated common pathways.  
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Figure 4.14 Venn diagrams showing the common significant up- and downregulated pathways between PKD/Mhm (Cy/+) 
treatments. A) i.v. ASC and ABCB5+ treatments, B) i.p. ASC and ABCB5+ treatments, C) ASC derived CM and ABCB5+ 
derived CoCM+ treatments. The numbers inside the Venn diagrams indicate the number of up- and downregulated pathways 
contained in each category.  
 
Both ASC and ABCB5+ administrations show an upregulation of the principal metabolism 
related pathways such as oxidative phosphorylation, citrate cycle and amino acid metabolism, 
involving a shift of the metabolism pathways from glycolysis to the gluconeogenesis pathway 
(table 4.24 A-B). 
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Table 4.24A GSEA analysis using KEGG database sorted by main category: Metabolism. ABCB5+ derived CoCM+; 
i.p.ABCB5+; i.v. ABCB5+ groups. Significantly (adj. p<0.05) differentially expressed pathways (PKD/Mhm (Cy/+) + 
treatment vs PKD/Mhm (Cy/+)). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red. 
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Table 4.24B GSEA analysis using KEGG database sorted by main category: Metabolism. ASC derived CM; i.p. ASC; i.v. 
ASC groups. Significantly (adj. p<0.05) differentially expressed pathways (PKD/Mhm (Cy/+) + treatment vs PKD/Mhm 
(Cy/+)). For each pathway the NES is given. Downregulated pathways are displayed in green, upregulated pathways are 
displayed in red. 
 
Apoptotic pathways, along with cellular senescence, focal adhesion pathways were 
downregulated in all the treated groups, with the exception of cellular senescence pathway 
that was upregulated in the ASC derived CM group (table 4.25 A-B).  
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Table 4.25A GSEA analysis using KEGG database sorted by main category: Cellular Processes. ABCB5+ derived CoCM+; 
i.p. ABCB5+; i.v. ABCB5+ groups. Significantly (adj. p<0.05) differentially expressed pathways (PKD/Mhm (Cy/+) + 
treatment vs PKD/Mhm (Cy/+)). For each pathway the NES is given. Downregulated pathways are displayed in green, 
upregulated pathways are displayed in red. 
 
 
Table 4.25B GSEA analysis using KEGG database sorted by main category: Cellular Processes. ASC derived CM; i.p. ASC; 
i.v. ASC groups. Significantly (adj. p<0.05) differentially expressed pathways (PKD/Mhm (Cy/+) + treatment vs PKD/Mhm 
(Cy/+)). For each pathway the NES is given. Downregulated pathways are displayed in green, upregulated pathways are 
displayed in red. 
 
Pathways involved in the translation and transcription were mainly upregulated (table 4.26 A-
B). 
 
 
Table 4.26A GSEA analysis using KEGG database sorted by main category: Genetic Information Processing. ABCB5+ 
derived CoCM+; i.p. ABCB5+, i.v. ABCB5+ groups. Significantly (adj. p<0.05) differentially expressed pathways 
(PKD/Mhm (Cy/+) + treatment vs PKD/Mhm (Cy/+)). For each pathway the NES is given. Downregulated pathways are 
displayed in green, upregulated pathways are displayed in red. 
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Table 4.26B GSEA analysis using KEGG database sorted by main category: Genetic Information Processing. ASC derived 
CM; i.p. ASC; i.v. ASC groups. Significantly (adj. p<0.05) differentially expressed pathways (PKD/Mhm (Cy/+) + treatment 
vs PKD/Mhm (Cy/+)). For each pathway the NES is given. Downregulated pathways are displayed in green, upregulated 
pathways are displayed in red. 
 
Pathways related to the signal transduction were mainly downregulated. Table 4.27 (A-B) 
shows the differentially expressed pathways involved in signal transduction, immune and 
endocrine system. 
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Table 4.27A GSEA analysis using KEGG database sorted by main categories: Environmental Information Processing and 
Organismal Systems. ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. ABCB5+ groups. Significantly (adj. p<0.05) 
differentially expressed pathways (PKD/Mhm (Cy/+) + treatment vs PKD/Mhm (Cy/+)). For each pathway the NES is given. 
Downregulated pathways are displayed in green, upregulated pathways are displayed in red. 
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Table 4.27B GSEA analysis using KEGG database sorted by main categories: Environmental Information Processing and 
Organismal Systems. ASC derived CM; i.p ASC; i.v. ASC groups. Significantly (adj. p<0.05) differentially expressed 
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pathways (PKD/Mhm (Cy/+) + treatment vs PKD/Mhm (Cy/+)). For each pathway the NES is given. Downregulated 
pathways are displayed in green, upregulated pathways are displayed in red. 
 
4.3 Long term effects of stem cells and conditioned media therapy in PCK rats  
4.3.1 Changes in BW and kidney histology 
A gradual and constant increase in the BW was recorded in all the treated PCK groups (figure 
4.15), with no significant differences when compared to the BW values of the untreated 
group. 
 
Figure 4.15 Effect on BW of different treatments in PCK (n=6 in each group). Data are shown as means ± Std.Dev. 
  
Left kidney weight and the Kw/BW ratio were slightly increased in ABCB5+ derived CoCM+ 
and ASC derived CM+ groups in comparison to the untreated group (table 4.28 A-B). 
 
A Animal group Left kidney (g) Kw/BW ratio 
 Untreated 5.3  0.3 0.9  0.1 
 + ABCB5+ derived CoCM+ 5.8  0.9 1.0  0.2 
 + i.p. ABCB5+ 5.4  1.4 1.0  0.3 
 + i.v. ABCB5+ 5.2  0.8 1.0  0.1 
Table 4.28A Effect of different treatments on left kidney weight and Kw/BW ratio in PCK groups (n=6 in each group). 
Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Data are shown as mean ± 
Std.Dev. 
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B Animal group Left kidney (g) Kw/BW ratio 
 Untreated 5.3  0.3 0.9  0.1 
 + ASC derived CM 6.0  1.0 1.1  0.2 
 + i.p. ASC 5.0  1.2 0.9  0.2 
 + i.v. ASC 5.4  0.4 1.0  0.1 
Table 4.28B Effect of different treatments on left kidney weight and Kw/BW ratio in PCK groups (n=6 in each group). 
Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Data are shown as mean ± Std.Dev. 
 
Histological staining of 3 μm kidney sections highlighted an increase of cysts number in the 
renal tissue, with the exception of i.p. ABCB5+ treatment. However, the average size was 
decreased in ASC derived CM, i.v. and i.p. ASC groups. In the same groups, a slight, but no 
significant, reduction of fibrosis was detected (table 4.29 A-B, figure 4.16). 
 
A Animal group Cyst number Average size 
(pixels) 
% cyst area % fibrosis  
 Untreated  1320.8 ± 621.7 972.5 ± 607.7 10.0 ± 4.5 13.7 ± 20.8 
  + ABCB5+ derived 
CoCM+ 
1499.8 ± 1059.1 982.5 ± 437.2 12.1 ± 4.3 12.1 ± 4.6 
  + i.p. ABCB5+ 1284.5 ± 535.9 1016.8 ± 499.3 12.2 ± 5.2 11.0 ± 3.6 
  + i.v. ABCB5+ 1847.3 ± 1137.7 1060.9 ± 490.4 15.2 ± 3.9 14.0 ± 2.7 
Table 4.29A Effect of different treatments on cyst number, average size, percentage of cyst and fibrosis area in PCK groups 
(n=6 in each group). Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Analysis 
was performed on whole 3 μm kidney section. Data are shown as mean ± Std.  
 
B Animal group Cyst number Average size 
(pixels) 
% cyst area % fibrosis  
 Untreated 1320.8 ± 621.7 972.5 ± 607.7 10.0 ± 4.5 13.7 ± 20.8 
  + ASC derived 
CM 
1779.3 ± 423.1 760.1 ± 169.8 13.1 ± 4.1 8.2 ± 6.3 
  + i.p. ASC 1917.2 ± 583.3 638.1 ± 258.5 12.1 ± 4.5 8.2 ± 4.3 
  + i.v. ASC 2008.6 ± 322.3 617.0 ± 131.9 12.5 ± 3.3 7.8 ± 3.6 
Table 4.29B Effect of different treatments on cyst number, average size, percentage of cyst and fibrosis area in PCK groups 
(n=6 in each group). Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Analysis was performed 
on whole 3 μm kidney section. Data are shown as mean ± Std.  
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Figure 4.16 Fibrosis in PCK kidneys (n=6 in each group). (A) Whole kidney scan of PCK rat, Masson-Goldner trichrome 
staining, light green stains fibrotic tissue; (B) Graphic quantification of fibrosis after different treatments on PCK kidneys. 
Data are shown as box plots with the median, upper and lower quartile (interquartile range (IQR)) and whiskers (1.5x IQR). 
Images acquired with Axio Scan.Z1 microscope (ZEISS), 20x objective.  
 
Evaluation of the cyst number and fibrosis was performed also on 3 μm liver slices stained 
with Masson-Goldner.  
An increase of the cyst number and size was registered in the i.v. and i.p. ASC and ASC 
derived CM groups. Cyst number was reduced in i.v. and i.p. ABCB5+ groups but in the same 
groups an increase of the cyst size was detected. A major increase of fibrotic tissue in the liver 
was detected in all the treated groups, compared to the untreated (table 4.30 A-B). 
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A Animal group Cyst number Average size 
(pixels) 
% cyst area % fibrosis 
 Untreated 579.0 ± 86.3 673.3 ± 203.2 3.8 ± 0.9 4.8 ± 3.0 
  + ABCB5+ derived 
CoCM+ 
547.3 ± 161.1 983.8 ± 372.9 5.2 ± 3.1 16.7 ± 7.6 
  + i.p. ABCB5+ 385.8 ± 242.2 1018.1 ± 298.4 3.9 ± 3.0 12.3 ± 8.1 
  + i.v. ABCB5+ 379.7 ± 97.6 937.3 ± 356.4 3.6 ± 1.9 10.5 ± 2.6 
Table 4.30A Effect of different treatments on cyst number, average size, percentage of cyst and fibrosis area in PCK groups 
(n=6 in each group). Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Analysis 
was performed on whole 3 μm liver section. Data are shown as mean ± Std.Dev.  
 
B Animal group Cyst number Average size 
(pixels) 
% cyst area % fibrosis 
 Untreated 579.0 ± 86.3 673.3 ± 203.2 3.8 ± 0.9 4.8 ± 3.0 
  + ASC derived 
CM 
958.0 ± 291.9 926.2 ± 254.1 8.1 ± 3.2 12.3 ± 8.0 
  + i.p. ASC 741.0 ± 317.1 801.4 ± 327.5 6.4 ± 4.7 10.2 ± 5.0 
  + i.v. ASC 752.7 ± 305.1 988.6 ± 303.4 7.9 ± 4.0 11.1 ± 6.5 
Table 4.30B Effect of different treatments on cyst number, average size, percentage of cyst and fibrosis area in PCK groups 
(n=6 in each group). Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Analysis was performed 
on whole 3 μm liver section. Data are shown as mean ± Std.Dev.  
 
A reduction of Tunel signal was noted in all the treated groups, in particular ABCB5+ derived 
CoCM + (p<0.005), ASC derived CM, i.v. and i.p. ABCB+ (p<0.05), when compared to the 
control. The signal of Ki67 positive cells was decreased in all the groups, indicating a 
reduction of apoptosis and proliferation levels in cells (table 4.31 A-B). 
 
A Animal group Tunel positive cells  Ki67 positive cells 
 Untreated 1460.5 ± 324.6 1721.0 ± 1369.8 
  + ABCB5+ derived CoCM+ 953.8 ± 145.5** 884.5 ± 87.4 
  + i.p. ABCB5+ 1038.5 ± 160.4* 1018.2 ± 271.1 
  + i.v. ABCB5+ 1024.3 ± 131.8* 934.0 ± 118.8 
Table 4.31A Effect of different treatments on Tunel and Ki67 positive nuclei in in PCK groups (n=6 in each group). 
Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Analysis was performed on 
whole 3 μm kidney section. Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are 
indicated as *p<0.05, **p<0.005. 
 
B Animal group Tunel positive cells Ki67 positive cells 
 Untreated 1460.5 ± 324.6 1721.0 ± 1369.8 
  + ASC derived CM 1121.0 ± 192.5 1025.4 ± 203.3 
  + i.p. ASC 1022.5 ± 331.9 893.0 ± 310.4 
  + i.v. ASC 926.3 ± 159.2* 730.3 ± 215.2 
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Table 4.31B Effect of different treatments on Tunel and Ki67 positive nuclei in in PCK groups (n=6 in each group). 
Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Analysis was performed on whole 3 μm 
kidney section. Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated as 
*p<0.05. 
 
4.3.2 Plasma chemistry, urine analysis and renal function 
Plasma biochemistry results show, at day 167, a slight increase in creatinine levels in i.p. 
ABCB5+ and ASC derived CM groups. No alterations were recorded in ABCB5+ derived 
CoCM+, i.v. ABCB5+, i.v. and i.p. ASC groups. Urea levels were slight decreased in 
ABCB5+ derived CoCM+, i.p. and i.v. ABCB5+ groups when compared to the untreated, 
while no changes were noted in ASC derived CM, i.p. and i.v. ASC groups. Sodium levels 
were significantly decreased in i.p. ABCB5+ and ABCB5+ derived CoCM+ groups. AST and 
ALT concentrations in the plasma were also tested for monitoring the hepatic function. Table 
4.32 (A-B) shows the results of the plasma biochemistry analysis (for individual days see 
appendix 7). 
 
A Parameter  Animal group Day 167 
 Creatinine Untreated 0.5 ± 0.1 
 (mg/dl)  + ABCB5+ derived CoCM+ 0.5 ± 0.1 
   + i.p. ABCB5+ 0.6 ± 0.2 
   + i.v. ABCB5+ 0.5 ± 0.1 
Urea Untreated 56.6 ± 3.2 
 (mg/dl)  + ABCB5+ derived CoCM+ 50.7 ± 8.9 
   + i.p. ABCB5+ 54.1 ± 16.5 
   + i.v. ABCB5+ 50.3 ± 10.6 
Na Untreated 143.8 ± 1.8 
 (mmol/l)  + ABCB5+ derived CoCM+ 139.3 ± 2.3* 
   + i.p. ABCB5+ 140.3 ± 2.2* 
   + i.v. ABCB5+ 141.0 ± 1.9 
K Untreated 5.1 ± 0.2 
 (mmol/l)  + ABCB5+ derived CoCM+ 5.1 ± 0.5 
   + i.p. ABCB5+ 5.0 ± 0.4 
   + i.v. ABCB5+ 4.7 ± 0.5 
Ca Untreated 2.8 ± 0.1 
 (mmol/l)  + ABCB5+ derived CoCM+ 2.7 ± 0.2 
   + i.p. ABCB5+ 2.7 ± 0.1 
   + i.v. ABCB5+ 2.7 ± 0.1 
PO4 Untreated 2.2 ± 0.1 
 (mmol/l)  + ABCB5+ derived CoCM+ 2.1 ± 0.3 
   + i.p. ABCB5+ 2.2 ± 0.2 
   + i.v. ABCB5+ 2.1 ± 0.2 
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Cholesterol Untreated 301.2 ± 62.1 
 (mg/dl)  + ABCB5+ derived CoCM+ 273.5 ± 76.3 
   + i.p. ABCB5+ 294.0 ± 67.9 
   + i.v. ABCB5+ 266.2 ± 44.5 
Triglycerides Untreated 160.5 ± 46.9 
 (mg/dl)  + ABCB5+ derived CoCM+ 143.7 ± 45.0 
   + i.p. ABCB5+ 153.5 ± 47.8 
   + i.v. ABCB5+ 118.2 ± 34.7 
Glucose Untreated 150.3 ± 24.0 
 (mg/dl)  + ABCB5+ derived CoCM+ 147.2 ± 18.2 
   + i.p. ABCB5+ 145.8 ± 23.3 
   + i.v. ABCB5+ 143.8 ± 11.8 
Protein Untreated 69.5 ± 2.1 
 (mg/dl)   + ABCB5+ derived CoCM+ 69.3 ± 6.4 
   + i.p. ABCB5+ 67.5 ± 3.8 
   + i.v. ABCB5+ 68.3 ± 4.9 
ALT Untreated 73.3 ± 40.0 
 (U/l)  + ABCB5+ derived CoCM+ 61.0 ± 17.8 
   + i.p. ABCB5+ 69.3 ± 16.3 
   + i.v. ABCB5+ 66.1 ± 13.4 
AST Untreated 135.2 ± 144.9 
 (U/l)  + ABCB5+ derived CoCM+ 144.0 ± 67.3 
   + i.p. ABCB5+ 136.8 ± 87.8 
   + i.v. ABCB5+ 119.5 ± 59.1 
Table 4.32A Plasma biochemistry in PCK groups (untreated; ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. ABCB5+; n=6 in 
each group) at day 167. Data are shown as mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated 
as *p<0.05. 
 
B Parameter  Animal group Day 167 
 Creatinine Untreated 0.5 ± 0.1 
 (mg/dl)  + ASC derived CM 0.6 ± 0.1 
   + i.p. ASC 0.5 ± 0.1 
   + i.v. ASC 0.5 ± 0.1 
Urea Untreated 56.6 ± 3.2 
 (mg/dl)  + ASC derived CM 56.7 ± 7.0 
   + i.p. ASC 57.3 ± 10.6 
   + i.v. ASC 56.1 ± 3.5 
Na Untreated 143.8 ± 1.8 
 (mmol/l)  + ASC derived CM 141.7 ± 1.4 
   + i.p. ASC 141.8 ± 1.5 
   + i.v. ASC 142.3 ± 1.4 
K Untreated 5.1 ± 0.2 
 (mmol/l)  + ASC derived CM 5.5 ± 0.5 
   + i.p. ASC 5.3 ± 0.2 
   + i.v. ASC 5.0 ± 0.5 
Ca Untreated 2.8 ± 0.1 
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 (mmol/l)  + ASC derived CM 2.8 ± 0.0 
   + i.p. ASC 2.8 ± 0.1 
   + i.v. ASC 2.8 ± 0.1 
PO4 Untreated 2.2 ± 0.1 
 (mmol/l)  + ASC derived CM 2.0 ± 0.4 
   + i.p. ASC 2.1 ± 0.4 
   + i.v. ASC 1.9 ± 0.3 
Cholesterol Untreated 301.2 ± 62.1 
 (mg/dl)  + ASC derived CM 222.8 ± 64.3 
   + i.p. ASC 257.3 ± 52.7 
   + i.v. ASC 252.8 ± 46.7 
Triglycerides Untreated 160.5 ± 46.9 
 (mg/dl)  + ASC derived CM 148.2 ± 30.2 
   + i.p. ASC 126.5 ± 16.0 
   + i.v. ASC 143.0 ± 30.7 
Glucose Untreated 150.3 ± 24.0 
 (mg/dl)  + ASC derived CM 142.8 ± 23.0 
   + i.p. ASC 141.0 ± 12.0 
   + i.v. ASC 127.0 ± 18.4 
Protein Untreated 69.5 ± 2.1 
 (mg/dl)  + ASC derived CM 72.2 ± 4.0 
   + i.p. ASC 69.7 ± 4.1 
   + i.v. ASC 70.5 ± 2.7 
ALT Untreated 73.3 ± 40.0 
 (U/l)  + ASC derived CM 81.3 ± 15.4 
   + i.p. ASC 80.9 ± 20.4 
   + i.v. ASC 83.6 ± 15.48 
AST Untreated 135.2 ± 144.9 
 (U/l)  + ASC derived CM 325.2 ± 146.4 
   + i.p. ASC 155.7 ± 74.9 
   + i.v. ASC 256.0 ± 127.5 
Table 4.32B Plasma biochemistry in PCK groups (untreated; ASC derived CM; i.p. ASC; i.v. ASC; n=6 in each group) at 
day 167. Data are shown as mean ± Std.Dev.  
 
Urine samples were collected after placing the animals into metabolic cages overnight for 16 
hours. Table 4.33 shows the difference of diuresis, food and water intake values between 
treated and untreated groups at day 167 (for individual days see appendix 8). 
 
A Parameter Animal group Day 167 
 Diuresis (ml) Untreated 25.3  2.7 
  + ABCB5+ derived CoCM+ 24.7  8.8 
  + i.p. ABCB5+ 22.4  3.7 
  + i.v. ABCB5+ 18.7  5.9 
Food intake  Untreated 10.8  3.5 
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 (g) + ABCB5+ derived CoCM+ 15.6  5.1 
  + i.p. ABCB5+ 14.5  2.9 
  + i.v. ABCB5+ 15.0  4.2 
Water intake  Untreated 33.2  4.4 
 (g) + ABCB5+ derived CoCM+ 31.8  9.9 
  + i.p. ABCB5+ 30.7  15.9 
  + i.v. ABCB5+ 24.2  13.0 
Table 4.33A Effect of different treatments on diuresis, food intake and water intake in PCK groups (n=6 in each group) at 
day 167. Comparison between ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ groups and untreated. Data are shown as mean 
± Std.Dev. 
 
B Parameter Animal group Day 167 
 Diuresis (ml) Untreated 25.3  2.7 
  + ASC derived CM 29.3  12.2 
  + i.p. ASC  25.4  4.3 
  + i.v. ASC 26.8  6.3 
Food intake  Untreated 10.8  3.5 
 (g) + ASC derived CM 17.4  4.7 
  + i.p. ASC  14.9  3.4 
  + i.v. ASC 14.2  5.8 
Water intake  Untreated 33.2  4.4 
 (g) + ASC derived CM 38.5  17.0 
  + i.p. ASC  38.3  6.9 
  + i.v. ASC 46.4  19.7 
Table 4.33B Effect of different treatments on diuresis, food intake and water intake in PCK groups (n=6 in each group) at 
day 167. Comparison between ASC derived CM, i.v. or i.p. ASC groups and untreated. Data are shown as mean ± Std.Dev. 
 
Table 4.34 (A-B) illustrates the urine parameters analysed at day 167 (for individual days see 
appendix 9). Despite no significant differences were detected, proteinuria levels were 
decreased in all the treated groups when compared to the untreated, while albumin levels 
increased. 
 
A Parameter  Animal group Day 167 
 Creatinine Untreated 14.8 ± 3.2 
 (mg/16h) + ABCB5+ derived CoCM+ 11.9 ±1.8 
  + i.p. ABCB5+ 12.0 ± 2.4 
  + i.v. ABCB5+ 12.5 ± 1.7 
Urea Untreated 681.6 ± 91.3 
 (mg/16h) + ABCB5+ derived CoCM+ 586.1 ± 147.9 
  + i.p. ABCB5+ 610.0 ± 148.5 
  + i.v. ABCB5+ 571.4 ± 105.2 
Na Untreated 1.3 ± 0.2 
 (mmol/16h) + ABCB5+ derived CoCM+ 1.6 ± 0.8 
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  + i.p. ABCB5+ 1.5 ± 0.6 
  + i.v. ABCB5+ 1.4 ± 0.9 
K Untreated 3.5 ± 0.4 
 (mmol/16h) + ABCB5+ derived CoCM+ 4.3 ± 1.5 
  + i.p. ABCB5+ 3.7 ± 0.9 
  + i.v. ABCB5+ 3.6 ± 1.0 
Ca Untreated 0.08 ± 0.03 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.10 ± 0.03 
  + i.p. ABCB5+ 0.08 ± 0.03 
  + i.v. ABCB5+ 0.06 ± 0.03 
PO4 Untreated 0.1 ± 0.1 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.1 ± 0.1 
  + i.p. ABCB5+ 0.1 ± 0.1 
  + i.v. ABCB5+ 0.3 ± 0.3 
Glucose Untreated 1.9 ± 1.5 
 (mg/16h) + ABCB5+ derived CoCM+ 2.3 ± 0.6 
  + i.p. ABCB5+ 3.0 ± 0.7 
  + i.v. ABCB5+ 2.4 ± 0.9 
Protein Untreated 436.8 ± 101.5 
 (mg/16h) + ABCB5+ derived CoCM+ 290.1 ± 114.7 
  + i.p. ABCB5+ 311.9 ± 161.3 
  + i.v. ABCB5+ 288.1 ± 117.3 
Albumin Untreated 140.6 ± 71.2 
 (mg/16h) + ABCB5+ derived CoCM+ 200.6 ± 68.5 
  + i.p. ABCB5+ 319.8 ± 220.3 
  + i.v. ABCB5+ 200.0 ± 52.9 
Table 4.34A Urine biochemistry in PCK groups (untreated; ABCB5+ derived CoCM+; i.p. ABCB5+; i.v. ABCB5+; n=6 in 
each group) at day 167. Data are shown as mean ± Std.Dev.  
 
B Parameter  Animal group Day 167 
 Creatinine Untreated 14.8 ± 3.2 
 (mg/16h) + ASC derived CM 12.3 ± 1.0 
  + i.p. ASC  12.4 ± 1.2 
  + i.v. ASC 12.4 ± 1.7 
Urea Untreated 681.6 ± 91.3 
 (mg/16h) + ASC derived CM 628.7 ± 81.8 
  + i.p. ASC  658.9 ± 111.4 
  + i.v. ASC 659.8 ± 99.8 
Na Untreated 1.3 ± 0.2 
 (mmol/16h) + ASC derived CM 1.8 ± 0.6 
  + i.p. ASC  1.3 ± 0.3 
  + i.v. ASC 1.7 ± 0.8 
K Untreated 3.5 ± 0.4 
 (mmol/16h) + ASC derived CM 4.2 ± 1.4 
  + i.p. ASC  4.0 ± 0.5 
  + i.v. ASC 3.9 ± 0.4 
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Ca Untreated 0.08 ± 0.03 
 (mmol/16h) + ASC derived CM 0.07 ± 0.03 
  + i.p. ASC  0.08 ± 0.02 
  + i.v. ASC 0.07 ± 0.01 
PO4 Untreated 0.1 ± 0.1 
 (mmol/16h) + ASC derived CM 0.1 ± 0.1 
  + i.p. ASC  0.1 ± 0.1 
  + i.v. ASC 0.1 ± 0.1 
Glucose Untreated 1.9 ± 1.5 
 (mg/16h) + ASC derived CM 5.9 ± 4.5 
  + i.p. ASC  4.4 ± 1.6 
  + i.v. ASC 3.7 ± 2.2 
Protein Untreated 436.8 ± 101.5 
 (mg/16h) + ASC derived CM 398.2 ± 143.4 
  + i.p. ASC  350.4 ± 79.0 
  + i.v. ASC 320.6 ± 63.2 
Albumin Untreated 140.6 ± 71.2 
 (mg/16h) + ASC derived CM 152.7 ± 66.9 
  + i.p. ASC  197.7 ± 59.3 
  + i.v. ASC 154.8 ± 28.7 
Table 4.34B Urine biochemistry in PCK groups (untreated; ASC derived CM; i.p. ASC; i.v. ASC; n=6 in each group) at day 
167. Data are shown as mean ± Std.Dev.  
 
Table 4.35 (A-B) shows a reduction of ABZWCY-HβCD t1/2 in PCK treated groups at day 
167. In particular, a significant reduction was recorded in the i.p. ABCB5+ group (p<0.05). A 
minor decline was also detected in ABCB5+ derived CoCM+, i.v. ABCB5+, i.p. and i.v. ASC 
groups (figure 4.17, for individual days see appendix 10). 
 
A Parameter Animal group Day 167 
 ABZWCY-HβCD t1/2 (min) Untreated 75.5 ± 11.6 
   + ABCB5+ derived CoCM+ 66.5 ± 15.1 
   + i.p. A BCB5+ 45.5 ± 22.7* 
   + i.v. ABCB5+ 50.9 ± 10.12 
Table 4.35A Effect of different treatments on ABZWCY-HCD t1/2 in PCK groups (n=6 in each group) at day 167. 
Comparison between ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Data are shown as mean ± 
Std.Dev. Values significantly different (treated vs untreated) are indicated as *p<0.05. 
B Parameter  Animal group Day 167 
 ABZWCY-HβCD t1/2 (min) Untreated 75.5 ± 11.6 
   + ASC derived CM 72.5 ± 24.8 
   + i.p. ASC 52.7 ± 4.9 
   + i.v. ASC 54.5 ± 9.3 
Table 4.35B Effect of different treatments on ABZWCY-HCD t1/2 in PCK groups (n=6 in each group) at day 167. 
Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Data are shown as mean ± Std.Dev. Values 
significantly different (treated vs untreated) are indicated as *p<0.05. 
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Figure 4.17 Effect of different treatments on ABZWCY-HβCD t1/2 in PCK model (n=6 in each group). Data are shown as 
box plots with the median, upper and lower quartile (interquartile range (IQR)) and whiskers (1.5x IQR). Values significantly 
different (treatment vs PKD/Mhm (Cy/+)) are indicated as *p<0.05. 
 
Table 4.36 (A-B) summarizes the results obtained for ABZWCY-HβCD t1/2 and traditional 
plasma parameters for renal function (creatinine and urea) in each PCK group. 
 
A Animal group ABZWCY-HβCD t1/2 (min) Creatinine (mg/dl) Urea (mg/dl) 
 Untreated 75.5 ± 11.6 0.5 ± 0.1 56.6 ± 3.2 
  + ABCB5+ derived 
CoCM+ 
66.5 ± 15.1 0.5 ± 0.1 50.7 ± 8.9 
  + i.p. ABCB5+ 45.5 ± 22.7* 0.6 ± 0.2 54.1 ± 16.5 
  + i.v. ABCB5+ 50.9 ± 10.1 0.5 ± 0.1 50.3 ± 10.6 
Table 4.36A Effect of different treatments on ABZWCY-HCD t1/2, plasma creatinine and urea in PCK groups (n=6 in each 
group) at day 167. Comparison between ABCB5+ CoCM+, i.p. or i.v. ABCB5+ groups and untreated. Data are shown as 
mean ± Std.Dev. Values significantly different (treated vs untreated) are indicated as *p<0.05. 
B Animal group ABZWCY-HβCD t1/2 (min) Creatinine (mg/dl) Urea (mg/dl) 
 Untreated 75.5 ± 11.6 0.5 ± 0.1 56.6 ± 3.2 
  + ASC derived CM 72.5 ± 24.8 0.6 ± 0.1 56.7 ± 7.0 
  + i.p. ASC 52.7 ± 4.9 0.5 ± 0.1 57.3 ± 10.6 
  + i.v. ASC 54.5 ± 9.3 0.5 ± 0.1 56.1 ± 3.5 
Table 4.36B Effect of different treatments on ABZWCY-HCD t1/2, plasma creatinine and urea in PCK groups (n=6 in each 
group) at day 167. Comparison between ASC derived CM, i.p. or i.v. ASC groups and untreated. Data are shown as mean ± 
Std.Dev. 
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4.3.3 Gene expression profiling 
The GSEA analysis was performed on each treated PCK group in comparison with the 
untreated group. Table 4.37 (A-B) illustrates the number of up and downregulated pathways 
in each treated group.  
 
A Animal group   
  Analysed pathways 304 
 +ABCB5+ derived 
CoCM+ 
Significantly regulated pathways (adjusted p-value < 0.05) 51 
  Significantly up-regulated pathways (adjusted p-value < 0.05) 14 
  Significantly down-regulated pathways (adjusted p-value < 0.05) 37 
 + i.p. ABCB5+ Significantly regulated pathways (adjusted p-value < 0.05) 124 
  Significantly up-regulated pathways (adjusted p-value < 0.05) 31 
  Significantly down-regulated pathways (adjusted p-value < 0.05) 93 
 + i.v. ABCB5+ Significantly regulated pathways (adjusted p-value < 0.05) 27 
  Significantly up-regulated pathways (adjusted p-value < 0.05) 12 
  Significantly down-regulated pathways (adjusted p-value < 0.05) 15 
Table 4.37A Overview of GSEA displaying the numbers of up- and downregulated pathways in PCK groups (ABCB5+ 
derived CoCM+; i.p. ABCB5+; i.v. ABCB5+; n=6 in each group). 
 
B Animal group   
  Analysed pathways 305 
 +ASC derived 
CM 
Significantly regulated pathways (adjusted p-value < 0.05) 139 
  Significantly up-regulated pathways (adjusted p-value < 0.05) 74 
  Significantly down-regulated pathways (adjusted p-value < 0.05) 65 
 + i.p. ASC Significantly regulated pathways (adjusted p-value < 0.05) 69 
  Significantly up-regulated pathways (adjusted p-value < 0.05) 43 
  Significantly down-regulated pathways (adjusted p-value < 0.05) 26 
 + i.v. ASC Significantly regulated pathways (adjusted p-value < 0.05) 57 
  Significantly up-regulated pathways (adjusted p-value < 0.05) 15 
  Significantly down-regulated pathways (adjusted p-value < 0.05) 42 
Table 4.37B Overview of GSEA displaying the numbers of up- and downregulated pathways in PCK groups (ASC derived 
CM; i.p. ASC; i.v. ASC; n=6 in each group). 
 
Figure 4.18 gives the main categories of pathways taken into account while Venn diagrams in 
figure 4.19 shows the number of common pathways between each stem cell treatment and 
conditioned media. 
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Figure 4.18 Pie charts showing the distribution of pathways containing significantly up- and downregulated genes sorted by 
main categories of KEGG database. A) ABCB5+ derived CoCM+, i.p. or i.v. ABCB5+ treatment, B) ASC derived CM, i.p. 
or i.v. ASC treatment. The numbers around the pie charts indicate the number of up- and downregulated pathways contained 
in each category.  
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Figure 4.19 Venn diagrams showing the common significant up- and downregulated pathways in PCK. A) ABCB5+ derived 
CoCM+, i.p. and i.v. ABCB5+ treatment, B) ASC derived CM, i.p. and i.v. ASC treatment. The numbers inside the Venn 
diagrams indicate the number of un- and downregulated pathways contained in each category 
 
 
Figure 4.20, shows the common up- and downregulated pathways between the different stem 
cells and conditioned media administrations. Only 1 common upregulated pathway between 
ASC derived CM and ABCB5+ derived CoCM+ groups was identified, no one between i.p. 
ASC and i.p. ABCB5+ or i.v ASC and i.v. ABCB5+. Three common pathways were found 
downregulated between i.v. ASC and ABCB5+ and no one within i.p. ASC and ABCB5+ or 
ASC derived CM and ABCB5+ derived CoCM+ groups.  
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Figure 4.20 Venn diagrams showing the common significant up- and downregulated pathways between PCK treatments. A) 
i.v. ASC and ABCB5+ treatments, B) i.p. ASC and ABCB5+ treatments, C) ASC derived CM and ABCB5+ derived CoCM+ 
treatments. The numbers inside the Venn diagrams indicate the number of un- and downregulated pathways contained in each 
category.  
 
Figure 4.19 and figure 4.20 emphasized the different outcomes of the treatments in the PCK 
rats. The principal difference is related to metabolic pathways. While oxidative 
phosphorylation, citrate cycle and metabolic pathways are upregulated in i.v. and i.p. 
ABCB5+ and ABCB5+ derived CoCM+ groups, the same pathways were downregulated in 
the i.v. and i.p. ASC and ASC derived CM groups (table 4.38 A-B).  
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Table 4.38A GSEA analysis using KEGG database sorted by main category: Metabolism. ABCB5+ derived CoCM+, i.p. or 
i.v. ABCB5+ groups. Significantly (adj. p<0.05) differentially expressed pathways (PCK + treatment vs PCK). For each 
pathway the NES is given. Downregulated pathways are displayed in green, upregulated pathways are displayed in red. 
 
 
Table 4.38B GSEA analysis using KEGG database sorted by main category: Metabolism. ASC derived CM, i.p. or i.v. ASC 
groups. Significantly (adj. p<0.05) differentially expressed pathways (PCK + treatment vs PCK). For each pathway the NES 
is given. Downregulated pathways are displayed in green, upregulated pathways are displayed in red. 
 
Table 4.39 (A-B) shows the significantly differentially expressed pathways, in each treated 
group, involved in the genetic information. 
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Table 4.39A GSEA analysis using KEGG database sorted by main category: Genetic Information Processing. ABCB5+ 
derived CoCM+, i.p. or i.v. ABCB5+ groups. Significantly (adj. p<0.05) differentially expressed pathways (PCK + treatment 
vs PCK). For each pathway the NES is given. Downregulated pathways are displayed in green, upregulated pathways are 
displayed in red. 
 
 
Table 4.39B GSEA analysis using KEGG database sorted by main category: Genetic Information Processing. ASC derived 
CM, i.p. or i.v. ASC groups. Significantly (adj. p<0.05) differentially expressed pathways (PCK + treatment vs PCK). For 
each pathway the NES is given. Downregulated pathways are displayed in green, upregulated pathways are displayed in red. 
 
Immune system related pathways were mainly downregulated in ABCB5+ derived CoCM+, 
i.p. and i.v. ABCB5+ groups and upregulated in ASC derived CM, i.p. and i.v. ASC groups. 
PPAR signalling pathways was upregulated in ABCB5+ derived CoCM+, i.p. and i.v. 
ABCB5+ groups and downregulated in ASC derived CM and i.v. ASC groups (table 4.40 A-
B).  
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Table 4.40A GSEA analysis using KEGG database sorted by main categories: Environmental Information Processing and 
Organismal Systems. ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ groups. Significantly (adj. p<0.05) differentially 
expressed pathways (PCK + treatment vs PCK). For each pathway the NES is given. Downregulated pathways are displayed 
in green, upregulated pathways are displayed in red. 
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Table 4.40B GSEA analysis using KEGG database sorted by main categories: Environmental Information Processing and 
Organismal Systems. ASC derived CM, i.v. or i.p. ASC groups. Significantly (adj. p<0.05) differentially expressed pathways 
(PCK + treatment vs PCK). For each pathway the NES is given. Downregulated pathways are displayed in green, upregulated 
pathways are displayed in red. 
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Table 4.41 (A-B) exemplifies the results of related cellular processes pathways. 
 
Table 4.41A GSEA analysis using KEGG database sorted by main category: cellular processes. ABCB5+ derived CoCM+, 
i.p. or i.v. ABCB5+ groups. Significantly (adj. p<0.05) differentially expressed pathways (PCK + treatment vs PCK). For 
each pathway the NES is given. Downregulated pathways are displayed in green, upregulated pathways are displayed in red. 
 
 
Table 4.41B GSEA analysis using KEGG database sorted by main category: cellular processes. ASC derived CM, i.p. or i.v. 
ASC groups. Significantly (adj. p<0.05) differentially expressed pathways (PCK + treatment vs PCK). For each pathway the 
NES is given. Downregulated pathways are displayed in green, upregulated pathways are displayed in red. 
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5. Discussion 
 
In this study we monitored the progression of cystic disease by analysing plasma and urine 
biochemistry, GFR transcutaneous measurement and gene expression profiling. Briefly, 
PKD/Mhm (Cy/+) and PCK rats showed profound alterations of the kidney cytoarchitecture 
due to the presence of cysts, fibrosis and infiltration of inflammatory cells. We also noted in 
PCK liver fibrosis. Apoptosis and cell proliferation were found in both strains. Further altered 
parameters, suggesting a decline of the renal function, were the plasma creatinine, urea, 
albumin, proteinuria and ABZWCY-HCD half-life increase in both the strains. The gene 
expression showed a significant downregulation of the pathways involved in the metabolism 
and an upregulation of apoptosis and cell cycle pathways. 
The same parameters were evaluated to test the potential therapeutic effect of the ABCB5+ 
and ASC cells and their derived conditioned media. We noted a reduction of cyst number in 
PKD/Mhm (Cy/+) i.p. ABCB5+ and ASC derived CM groups. A decrease of apoptotic and 
active proliferative cells was detected in all the PKD/Mhm (Cy/+) treated groups. No 
significant differences were noted in the urine biochemistry results. ABZWCY-HCD half-
life was decreased in all the treated groups, in particular in i.p. ABCB5+ and i.p. ASC groups. 
GSEA analyses showed important genetic changes. The metabolism related pathways were 
upregulated in all the treated groups likewise the PPAR signaling pathway.  
No morphological ameliorations were detected in PCK treated groups; instead an increase of 
hepatic fibrosis was noted. Apoptotic and proliferative positive cells were reduced in all the 
treated groups. No important ameliorations were noted in the plasma parameters. The 
proteinuria was slightly decreased in the treated groups. ABZWCY-HCD half-life was 
significantly reduced in the i.p. ABCB5+ group. GSEA analyses highlighted different genetic 
changes between ABCB5+ and ABCB5+ derived CoCM+ groups and ASC and ASC derived 
CM groups in the metabolic pathways.  
 
Cystic kidney diseases are a heterogeneous group of chronic disorders. Despite the common 
pathological features, a wide range of manifestations, due to different genes mutations, 
characterizes these diseases. Within all the cystic diseases, the most common and clinically 
significant are ADPKD, ARPKD and NPHP
4
. Current therapeutic alternatives for patients 
include dialysis and transplantation. Because of this and the chronic nature of the diseases, 
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ADPKD, ARPKD and NPHP have an important socio-economic impact
64-66
. In the last years, 
experimental approaches and clinical trial were performed in order to discover and validate 
new medical targets
19, 67-69
.  
The aim of our study was to examine the therapeutic effects of stem cells and conditioned 
media in animal models resembling human ARPKD and NPHP16. We investigated the effects 
of ASC and ABCB5+ cells. ASCs were isolated from lipoaspirates of healthy individuals 
undergoing liposuction. ABCB5
+
 cells, obtained from skin of healthy donors of different 
nationality, age and gender, were provided by Ticeba-RHEACELL GmbH & Co. 
(Heidelberg, Germany). ASC and ABCB5+ cells were administrated either via i.v. or i.p. 
injection. It is known from literature that, when injected i.v., cells might be trapped in the 
lungs with the risk of causing an emboli
70-73
. On this basis, i.p. injection appears a valid and 
safety alternative. 
In the last few years more attention was paid to the mode of action of stem cells. Scientists 
focused their attention on the possible paracrine action of the cells and on what the cells may 
release into the medium in which they grow
74-76
. Based on these findings, we decided to test, 
as an alternative therapy, conditioned media (CM) derived by ASC and conditioned media 
derived by a co-culture of ABCB5
+
 cell and macrophages M1 stimulated with INFγ and LPS 
(CoCM+). 
 
5.1 Genetic animal models of Cystic Kidney Disease 
In literature, two different types of animal models for the cystic kidney disease have been 
described which developed spontaneously cystic disease
77
. For our study we decided to use 
two spontaneous models: PKD/Mhm (Cy/) and PCK. PKD/Mhm (Cy/) rats resemble the 
human ADPKD and, as recently discovered, NPHP 16. These animals present a mutation on 
the Ank6 gene that is correlated with NPHP 16
40, 78
. On the other hand, PCK are an 
orthologous model for the ARPKD
79
. Despite both the strains present similar features, they 
differ for severity degrees and penetration of the pathology. These models are characterized 
by an increased size of the kidney due to the massive presence of cysts in the cortical and 
medullary region. Besides cysts, an infiltration of inflammatory cells was noted as well as 
fibrosis. Morphological analyses showed higher cyst number in the PKD/Mhm (Cy/+) rats 
kidney when compared to the PCK. Fibrotic tissue was almost two times more frequent in the 
PCK rats compared to PKD/Mhm (Cy/+).  
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ARPKD is associated with hepatic disorder
28, 80-82
. This is the reason why we evaluated and 
demonstrated the presence of cysts and fibrosis in hepatic tissue of PCK rats. Our results 
showed a dilatation of the bile duct, cyst growth and fibrotic tissue surrounding the cystic area 
in the liver tissue. The fibrosis may be linked to an unbalanced production and reabsorption of 
extracellular matrix and collagen. Fibrosis and cyst grow was evaluated also in the PKD/Mhm 
(Cy/+) rats. In this strain, however, 1% of hepatic tissue was occupied by fibrosis and the 
percentage of cyst area was roughly 0.1%. Further histological analyses highlighted an 
increase of apoptotic and active proliferative cells. When compared to the SD rats, both 
strains presented at least 10 times more apoptotic and proliferative positive cells (table 4.1). 
These results are in line with the literature. It is known, that polycystin, present on the 
primary cilia, are involved in the regulation of cell cycle by regulating apoptosis and cell 
cycle arrest
83, 84
. Therefore, an alteration of these genes might lead to a misregulation of these 
cellular processes. 
 
Blood and urine parameters were analysed in order to monitor the progression of the disease. 
Plasma creatinine and urea are the standard markers for the evaluation of renal function. Both 
markers showed an increase over time. The creatinine increase was already significant, in 
both strains, at day 53 and remained altered until the end of the experiment. Although, in the 
PKD/Mhm (Cy/+) model, at day 25 the creatinine raised 1.4-fold compared to the first 
measurement (baseline). A rise of urine levels was also detected among the strains, especially 
in PCK (figure 4.5). Our results showed also an alteration of the plasma cholesterol and 
triglycerides levels. Cholesterol levels increased constantly over time with an 1.5-fold 
increase at day 53 in PCK and, 1.4-fold at day 109 in PKD/Mhm (Cy/+). In both strains, these 
levels were considerably increased at day 167, respectively of 1.6 and 2.2-fold in PKD/Mhm 
(Cy/+) and PCK. Triglycerides levels were stable during the first part of the experimentation 
but rose in the last measurements. Plasma levels increased 1.6-fold in PKD/Mhm (Cy/+) rats 
and 1.9-fold in PCK rats (appendix 1). Once again our findings are in accordance with 
previous studies, which already highlighted an increase of cholesterol and triglycerides in 
PCK rats
85, 86
. 
Urine analysis of both strains underlined a massive increase of albumin- and proteinuria 
levels. In PKD/Mhm (Cy/+) rats, protein- and albuminuria levels were increased 6-fold at day 
109 and day 53, respectively. PCK rats showed an increase of proteinuria 3-fold already at 
day 25. In both strains, these levels raised dramatically until the end of the experiment 
(appendix 2). Another important parameter is the urine volume. In PKD/Mhm (Cy/+) rats, 
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diuresis doubled on day 109 and remained high until the end of the experiment, along with an 
increase of water intake. Also in PCK rats, diuresis was increased during the entire 
experiment while no significant fluctuations of water intake were noted (table 4.4). 
 
Plasma creatinine level can be affected by numerous factors such as age, gender, hepatic 
function and muscle mass
87-89
. Therefore, in this study, we evaluated the half-life of 
ABZWCY-HCD dye, used for a transcutaneous GFR measurement as GFR is considered 
one of the best indicators of renal function
90
. The results showed an increase of the half-life 
levels, indicating a deficit in the renal function, which corroborate what was observed in the 
plasma biochemistry (figure 4.6).  
 
RNAseq was used to perform gene expression analysis. Over 11326 genes were significantly 
and differentially expressed in PKD/Mhm (Cy/+) and 4602 genes in PCK rats. GSEA analysis 
was performed on genes defining pathways (KEGG database). The analysis outlined 199 
significantly and differently expressed pathways in PKD/Mhm (Cy/+) and 156 significant 
pathways in PCK. As described, PKD/Mhm (Cy/+) rats exhibit a reprogramming in the 
metabolism by enhancing the aerobic glycolysis rather than oxidative phosphorylation, known 
as the Warburg effect
91
. Typical of cancer cells, the Warburg effect is usually associated with 
a defect in the mitochondrial activity. Several studies highlighted the dysfunctional 
mitochondrial activity in the pathophysiology of cystic kidney disease
92-95
. Few other studies 
demonstrated the Warburg effect in other animal models for cystic kidney disease but no one 
documented it in PCK rats
96, 97
. Unfortunately, in this study it was not possible to test the 
mitochondria activity. Nevertheless, the oxidative phosphorylation and pyruvate metabolism 
pathways were found downregulated in both strains (table 4.9). 
 
In accordance with the literature, in this study we confirmed, in both models, the upregulation 
of apoptosis, p53, NF-B, Notch, cell cycle and cellular senescence pathways (figure 4.12 
and figure 4.13)
5, 79, 98-101
. As expected, also MAPK signaling pathway was upregulated. The 
upregulation of these pathways leads to an alteration of the cellular proliferation and tissue 
degeneration. Among these pathways, one of the most representatives is NF-B pathway, 
which does not only regulate the apoptosis and the cellular growth but also inflammatory 
genes. Moreover, it was demonstrated that its inhibition may modulated the cystic disease
102
. 
On the basis of this, it is not surprising that inflammatory pathways were abnormally 
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regulated in PKD/Mhm (Cy/+) and PCK rats. GSEA analysis outlined also an upregulation of 
the JAK-STAT, WNT and PI3K-Akt pathways.  
 
In summary, taking into account the morphological, functional and genetic changes, we can 
assert that both animal models show a severe cystic phenotype. This renal condition, present 
in both strains, was the starting point to evaluate the therapeutic potential of ASC and 
ABCB5+ cells and their derived conditioned media. 
 
5.2 Therapeutic effect of stem cells and conditioned media in PKD/Mhm (Cy/+) rats 
PKD/Mhm (Cy/+) model was used over the years to better understand and characterized the 
progression and development of ADPKD and NPHP 16 in terms of morphology, genetics and 
biochemical analysis
35, 103, 104
. As far as we know, this animal model was never involved in 
trial for therapeutic treatment with MSCs. 
 
We investigated the treated PKD/Mhm (Cy/+) groups for the same morphological parameter 
analysed in the untreated group. No remarkable differences were noted concerning the BW, 
kidney weight or Kw/BW ratio among the groups (figure 4.9 and table 4.15). However, 
staining performed on whole kidney sections highlighted some histological changes in the 
treated groups, such as the reduction in cyst number in i.v. and i.p. ABCB5+, ABCB5+ 
derived CoCM+, i.v. ASC and ASC derived CM groups. On the other hand, i.p. ASC group 
presented a slight increase of the cyst number but with minor average size (table 4.16). 
Surprisingly, fibrotic tissue deposition in the kidney appeared increased in each treated group 
with respect to the untreated (figure 4.10). The PKD/Mhm (Cy/+) model is characterized by 
an alteration of the cellular cycle, especially in tubular cells, co-staining of Tunel and Ki67 
was performed on 3μm kidney sections. A major reduction of apoptotic positive cells was 
encountered in all the treated groups, as well as a decrease of proliferation marker positive 
cells (table 4.17).  
 
The same plasma and urine parameters were analysed to monitor the progression of the 
disease in the untreated and the treated groups. A slight reduction of creatinine levels in both 
i.p. ABCB5+ and i.p. ASC, and glucose levels in all the treated groups was registered. The 
cholesterol and triglycerides plasma levels improved (table 4.18). One of the mechanisms of 
cyst formation in ADPKD is the loss of PKD genes function and consequently the disruption 
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of calcium homeostasis within the cells, which could also lead to an abnormal response of 
cAMP
105
. In our study, the plasma calcium
 
concentration was reduced in ABCB5+ derived 
CoCM+ and both i.p. and i.v. ABCB+ and i.p. and i.v. ASC groups. In particular a significant 
decline was recorded in the i.p. ABCB5+ group. Thus we were not surprised to detect that 
treated groups expressing a reduction of calcium levels also presented a minor number of 
cysts in the kidney tissue (table 4.18). ABZWCY-HCD half-life was reduced, at day 167 
1.5-fold in both i.v. ABCB5+ and ASC groups, 1.6-fold in i.p. ABCB5+ and 1.7-fold in i.p. 
ASC groups, revealing an improvement in kidney function. A minor reduction of ABZWCY-
HCD half-life was also recorded in ABCB5+ derived CoCM+ and ASC derived CM groups 
(figure 4.11). A minor reduction of the albumin and protein levels in the urine was detected in 
all the treated groups, all other urine parameters remained relatively constant (table 4.20). 
 
Altogether, analyses of renal function as well as plasma and urine biochemistry show a 
moderate amelioration of the renal function in ABCB5+ and ASC groups. ABCB5+ derived 
CoCM+ and ASC derived CM group resulted in milder, but still promising improvements. 
 
GSEA analysis was performed to examine the effects of ABCB5+, ASC, ASC derived CM 
and ABCB5+ derived CoCM+ on kidney. The analysis revealed major differences between 
treated and untreated groups. Even though minor variances in the different expression of few 
pathways among the treated groups were noted, the main trend was unchanged. The analysis 
showed a profound change of metabolism related pathways in all the treated groups. In fact, 
oxidative phosphorylation, citrate cycle and gluconeogenesis were upregulated, likewise 
pyruvate metabolism (table 4.24). These results, along with the upregulation of PPAR 
signalling pathway and the downregulation of cAMP and calcium signalling pathways (table 
4.27), outlined a potential improvement of the metabolism in the treated animals. Besides 
that, the downregulation of apoptosis and NF-B pathways suggest that the new cells lose the 
tumor-like attitude (Warburg effect) reported in the untreated group. Major changes were 
noticed also in other pathways involved in the signal transduction like MAPK, PI3K-Akt, 
TGF-beta and Wnt, which were downregulated (table 4.27). Downregulation of apoptosis and 
cell cycle pathways (table 4.25) was also in line with the results noted in the histological 
analysis. The principal pathways involved in cellular interaction, as focal adhesion, adherens 
junction and gap junction, were downregulated (table 4.25). While an upregulation of these 
pathways was recorded in the untreated group. This might be also an explanation for the 
reduced presence of cysts in the kidneys, perhaps leading to a mesenchymal to epithelial 
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transition of the cells. i.v. and i.p. ABCB5+ along with ABCB5+ derived CoCM+ groups 
pointed out a downregulation of pathways involved in the immune system. A similar trend 
was noted also in i.p. and i.v. groups but not in the ASC derived CM, suggesting an 
attenuation of the inflammation. In line with literature
95
, an amelioration of metabolic related 
pathways could lead to a decrease in the number of cysts and their growth as observed in 
ABCB5+ derived CoCM+, i.p. and i.v. ABCB5+ treated groups (table 4.16). 
 
Taking into account the above-discussed results the treated groups showed important changes, 
far apart from those observed in the untreated group. Moreover, better results in terms of 
kidney function improvement were achieved in the i.p. ABCB5+ treated group. When 
comparing the conditioned media groups, the parameters analysed seem to have a better 
outcome in the ABCB5+ derived CoCM+ group than the ASC derived CM. 
 
5.3 Therapeutic effect of stem cells and conditioned media in PCK rats 
Although, in the last decades, MSCs have represented a promising therapeutic approach, only 
two preclinical studies testing the potential therapeutic effect of stem cells in cystic kidney 
disease animal models have been published
49, 50
. Franchi et al. demonstrated that a single 
injection of allogenic Bone Marrow (BM) MSCs was adequate to induce, in PCK rats, renal 
function amelioration
50
. Conversely, Kelly et al. investigated multiple allogenic MSCs 
injections, demonstrating the beneficial restoration of the kidney function in PCK rats after 
the treatment
49
. In our study we investigated the putative therapeutic effects of ABCB5+ and 
ASC cells and derived conditioned media in PCK rats. 
 
The same morphological parameters as analysed in the untreated model were investigated in 
the treated groups. No differences were noted concerning the BW, kidney weight or Kw/BW 
ratio values among the groups. Moreover, no other macroscopic ameliorations were 
identified. Cyst number and percentage of area remained relatively constant among all the 
groups (table 4.29). As an orthologous model of the human ARPKD, PCK rats are 
characterized by a severe liver disorder. Numerous studies identified the presence of dilated 
bile ducts, development of cysts and fibrosis
106, 107
. In our study, we confirmed these 
alterations quantifying cyst number and percentage of fibrosis on 3 μm liver sections. 
Histological evaluation revealed, however, an increase in cyst number and fibrosis in the 
treated groups when compared to the untreated. In particular, the percentage of fibrosis was 
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increased more than 2.5-fold (table 4.30). PCK rats are characterized by an increase of 
apoptotic and proliferative cells. For this reason we performed a co-staining of Tunel and 
Ki67. Surprisingly, all the treated groups presented a reduction of apoptotic and proliferative 
positive markers in the kidney (table 4.31). 
 
To better characterize the biological changes in the treated groups, plasma and urine 
biochemistry analysis were performed. Plasma creatinine and urea, albumin- and proteinuria 
levels were analysed in order to evaluate changes in the kidney function. As previously 
described PCK model is characterized by hypercholesterolemia and hyperlipidemia. Overall, 
a slight reduction of these parameters was observed in the treated groups (table 4.32). As 
aforementioned, an unbalance of calcium homeostasis correlates with the cyst formation and 
development. No fluctuations of plasma calcium levels were encountered within the groups. 
No significant improvements were observed in urine analysis results although we noted a 
slight decrease in proteinuria levels, while albuminuria was increased in all the treated groups.  
 
Surprisingly, ABZWCY-HCD half-life was reduced 1.7-fold in i.p. ABCB5+, 1.5-fold in i.v. 
ABCB5+ and 1.4-fold in i.v. and i.p. ASC groups. This means GFR improved. A minor 
decrease of ABZWCY-HCD half-life was also observed in ABCB5+ derived CoCM+ group. 
No important fluctuations were noted in the ASC derived CM group (figure 4.17). Overall, 
analyses of renal function, plasma and urine biochemistry performed in treated PCK groups, 
indicates a slight improvement of the renal function. 
 
The characterization of genetic changes of the treated groups was performed with GSEA 
analysis using KEGG database. The analysis highlighted different genetic changes when 
compared ABCB5+ and ABCB5+ derived CoCM+ within ASC and ASC derived CM groups. 
The different regulation of pathways involved in metabolism is the most obvious change. An 
upregulation of citrate cycle and oxidative phosphorylation pathways was observed in 
ABCB5+ derived CoCM+, i.v. and i.p. ABCB5+ groups, likewise for the pyruvate 
metabolism. In contrast, these pathways were downregulated in ASC derived CM groups, i.v. 
and i.p. ASC groups (table 4.38). cAMP signalling pathway was downregulated in i.v. and 
i.p. ABCB5+ groups while PPAR was upregulated. These results correlated with the 
histological cyst analyses. An opposite trend was noted in i.v. ASC group. i.p. ASC and ASC 
derived CM groups, which exhibited an upregulation of the cAMP pathways and a 
downregulation of the PPAR pathway (table 4.40). Apart from metabolism, another 
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differential expression was documented for the NF-B and apoptosis pathways. In fact, while 
these pathways were downregulated in i.v and i.p. ABCB5+ and ABCB5+ derived CoCM+, 
we noted an upregulation of the same pathways in ASC derived CM, i.v. and i.p. ASC groups. 
Instead, MAPK and JAK-STAT signalling pathways were downregulated in i.v. and i.p. 
ABCB+, i.v. ASC and ABCB5+ derived CoCM+ groups. A similar trend was noted also for 
cellular processes pathways likewise focal adhesion and adherens and thight junction (table 
4.40 and table 4.41). Immune system regulatory pathways were downregulated in i.v and i.p. 
ABCB5+ and ABCB5+ derived CoCM+ groups, while the opposite trend was observed in i.v 
and i.p. ASC and ASC derived CM groups (table 4.40). 
 
Based on the above-stated results, ABCB5+ and ABCB5+ derived CoCM+ administrations 
appear to induce beneficial genetic changes in the PCK model, in contrast to ASC and ASC 
derived CM treatments. In fact, a recovery of metabolism, cell cycle and the cellular 
interaction activity were observed in ABCB5+ derived CoCM+, i.p. and i.v. ABCB5+ groups. 
Undoubtedly furthers studies need to be performed, also to better understand the dramatic 
alteration of the hepatic morphology and function. 
 
5.4 Conclusions 
This study provides an extensive description of the differences in outcome obtained by 
treating PKD/Mhm (Cy/+) and PCK rats with ABCB5+ or ASC cells and derived conditioned 
media. Untreated and treated groups were characterized on the basis of plasma and urine 
parameters, ABZWCY-HCD t1/2 and histological changes. Moreover gene expression 
analysis was performed. The results observed in all the treated groups of PKD/Mhm model, 
highlighted an amelioration of the principal parameter investigated for renal function. In 
addition, the genetic profile emphasized changes in the cellular metabolism and behaviour. 
Conversely, discrepancies were documented in biochemical and genetic results of PCK 
treated groups. While ABCB5+ and ABCB5+ derived CoCM+ treatments seem to slightly 
ameliorate the kidney function, the administration of ASC and ASC derived CM appear to 
improve only few of these factors. The reason why the results are so discordant between the 
two models and, at the same time, in the PCKs themselves, is not clear yet. Certainly the 
different severity of the disease and genetic background of the two models played a 
considerable role in the outcome of the therapeutic approaches. In relation to PCK rats, a 
valid hypothesis could be a late starting of the therapies. These animals in fact, develop the 
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disease in the early stage of life. Furthermore, no clinical beneficial were observed, after 
treatments, in the PCK model concerning the liver function. The suggested mode of action of 
ABCB5+, ASC and derived conditioned media could be due to a paracrine effect, leading to a 
rearrangement of the fundamental cellular functions like metabolism, cell cycle and polarity 
or restoring renal function. Nevertheless, further studies should be performed to better 
characterize this paracrine effect. 
 
From our results we can assert that ABCB5+ or ASC cells administration, likewise ABCB5+ 
derived CoCM+ and ASC derived CM might be a valid alternative therapy for cystic kidney 
disease, in particular i.p. ABCB5+. Future studies have to be carried out in order to better 
define the mode of action and the side effects. Definitely the interspecies variability and 
different disease severity between the models is affecting the efficacy of the treatment.  
 
Moreover, we demonstrated that i.p. administration is a valid alternative route compared to 
the i.v. and certainly less risky. The gene expression analysis performed with RNAseq 
technology is also an innovation with respect to cystic kidney disease and treatment, as it 
allowed us to have the most complete overview and dep insight on possible mechanisms. 
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6. Summary 
 
Cystic kidney diseases are a global public problem, as the population of patients is increasing 
at a rate of approximately 7% per year
65
. Unfortunately, up to now there is a lack of efficient 
therapies that can prevent the progressive loss of renal function. Drug treatment is of limited. 
The only therapeutic alternatives are dialysis or kidney transplantation. Nevertheless, the 
human and economic impact of the diseases to affected individuals and to medical community 
and society alike is enormous. Therefore new therapies are urgently needed
64, 65
. Stem cell 
application represents a promising therapeutic approach. MSC therapies have been used 
extensively, in the recent years, as a possible therapy for other kidney diseases with the aim of 
slowing down the course of the disease. However, many aspects remain unclear or are under 
debate like the finding of an appropriate source of MSCs, the understanding of their modes of 
action and, not least, the dose and timing of the administration. 
Aim of this study was to evaluate the potential therapeutic effects of two different types of 
stem cells, and the derived conditioned media, in two animal models resembling human cystic 
kidney diseases. In order to achieve this goal, firstly we characterized, on a long-term basis, 
two different genetic animal models: the PKD/Mhm (Cy/+) and the PCK rats. Afterwards, we 
performed a 6 months trial, to test the long-term effects of human ASC and human ABCB5+ 
cells and ASC derived CM and ABCB5+ derived CoCM+. Animals were classified in four 
different groups, depending on the treatment received: (i) group that did not received 
treatment, (ii) ASC derived CM or ABCB5+ derive CoCM+ group, (iii) i.p. ASC or ABCB5+ 
group and (iv) i.v. ASC or ABCB5+ group. The progression of the disease and the effect of 
the treatments were determined on the basis of plasma and urine biochemistry, transcutaneous 
measurement of renal function, histology evaluation and gene expression profiling. 
Our results found a different disease severity in the two models. PCK rats presented, since the 
beginning of the project, worse clinical manifestations compared to PKD/Mhm (Cy/+) 
probably due to the different genetic background.  
ABCB5+ and ASC treatments led to an improvement in renal function reflected by GFR, 
plasma levels of creatinine, albuminuria and proteinuria, in PKD/Mhm (Cy/+) model. 
Histological evaluation of the kidney revealed a reduction of apoptosis and cell proliferation. 
Moreover, comparable genetic changes were reported after these treatments. Also the 
ABCB5+ derived CoCM+ treatment proved to ameliorate the biochemical parameters, while 
ASC derived CM treatment had a lesser pronounced outcome. Both after ABCB5+ derived 
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CoCM+ or ASC derived CM administration the histological changes in apoptosis and 
proliferation reduction was observed. Ultimately, these animals undergo to genetic changes 
similar to the one observed after the cells treatment. 
Concerning the PCK model. ABCB5+ and ABCB5+ derived CoCM+ treatments slightly 
ameliorated kidney function, plasma and urine parameter and likewise the levels of apoptotic 
and proliferative positive markers. Administration of ASC or ASC derived CM improved the 
renal function and decreased the apoptotic and proliferative positive cells but had only a mild 
effect on other parameter involved in the kidney function. Additionally, the gene expression 
profile did not highlight significant genetic changes after those treatments, while ABCB5+ 
and ABCB5+ derived CoCM+ administrations induced beneficial genetic changes. 
 
In conclusion, our results demonstrate that ABCB5+ or ASC cells administration, either i.v. 
or i.p., and ABCB5+ derived CoCM+ might be a valid alternative therapy for cystic kidney 
diseases. However, before a possible application in the clinical field further studies need to be 
carried out in order to better define the mode of action and the side effects of these therapies. 
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Appendix 1 Changes in plasma biochemistry in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). Data are shown as mean ± Std.Dev. Values 
significantly different (time point vs baseline) are indicated as **p<0.005, ***p=0.0001 and (PKD/Mhm (Cy/+) vs PCK) as ‡p<0.05, ‡‡p<0.005, 
‡‡‡p=0.0001. 
Parameter Strain Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
Creatinine PKD/Mhm (Cy/+) 0.3  0.1‡ 0.4  0.1‡‡ 0.6  0 1** ‡‡ 0.6  0.1** ‡‡ 0.6  0.1** ‡‡ 0.7  0.1*** ‡‡ 0.7  0.1*** ‡‡ 
(mg/dl) PCK 0.2  0.0 0.3  0.0 0.3  0.0* 0.3  0.0*  0.4  0.0*** 0.4  0.1*** 0.5  0.1*** 
Urea PKD/Mhm (Cy/+) 68.4  18.2‡ 69.4  9.9‡‡‡ 73.9  8.6‡‡‡ 88.4  11.7‡‡‡ 85.6  8.1‡‡‡ 85.1 13.0‡‡ 87.4  11.0‡‡ 
(mg/dl) PCK 31.6  2.8 35.0  4.3 32.5  2.9 36.3  6.2 42.1  5.1** 44.6  2.3*** 56.6  3.2*** 
Na PKD/Mhm (Cy/+) 144.3  0.8‡‡‡ 143.0  3.6‡‡‡ 142.3 6.9 141.3  2.3 144.3  2.3‡‡ 141.8  1.7 144.8 1.9 
(mmol/l) PCK 139.2  1.2 140.7  2.7 141.0  3.0 139.7  1.2 139.8  1.1 140.6  1.7 143.8  1.8** 
K PKD/Mhm (Cy/+) 5.4  0.3 5.1  0.6 5.2  0.7 5.3  0.4 5.3  0.2 5.7  0.4 5.1  0.2 
(mmol/l) PCK 5.4  0.3 5.0  0.5 5.3  0.3 5.2  0.4 5.4  0.4 5.2  0.4 5.0  0.2 
Ca PKD/Mhm (Cy/+) 2.5  0.2 2.6  0.0 2.6  0.1‡‡ 2.6  0.1‡‡ 2.6  0.0 2.4  0.1 2.7  0.1‡ 
(mmol/l) PCK 2.7  0.1 2.7  0.1 2.8  0.1 2.7  0.0 2.7  0.1 2.7  0.1 2.8  0.1 
PO4 PKD/Mhm (Cy/+) 2.4  0.5 2.2  0.1 2.6  0.2‡‡ 2.1  0.4 2.0  0.3 2.1  0.2 2.1  0.3 
(mmol/l) PCK 2.3  0.3 2.5  0.3 2.0  0.2 1.6  0.5* 2.0  0.4 2.0  0.4 2.2  0.1 
Cholesterol PKD/Mhm (Cy/+) 97.3  7.5‡‡ 99.7  6.7 110.0  9.1‡‡ 107.5  8.5‡‡‡ 131.7  10.0*** ‡‡‡ 131.7  10.2***‡‡ 154.3  15.5*** ‡‡ 
(mg/dl) PCK 140.3  15.6 166.2  16.8 211.5  29.1* 237.0  23.7** 289.5  36.5*** 312.6  39.0*** 301.2  62.1*** 
Triglycerides PKD/Mhm (Cy/+) 69.2  26.3 54.3  14.5 67.2  19.4 91.5  21.6 68.7  10.0‡‡ 60.2  15.0‡‡ 108.8  48.3 
(mg/dl) PCK 86.8  15.0 79.3  15.1 93.2  28.3 132.2  36.7 126.7  28.2 137.5  29.5 160.5  46.9** 
Glucose PKD/Mhm (Cy/+) 169.0  9.0 167.8  9.4‡‡ 183.8  18.7‡ 195.8  32.1 173.3  12.6 176.5  19.6‡ 184.3  07.4‡ 
(mg/dl) PCK 166.8  10.6 143.7  11.4 149.3  20.0 162.7  32.8 172.8  12.9 143.0  16.4 150.3  24.0 
Protein PKD/Mhm (Cy/+) 62.0  1.7 63.0  3.1 63.8  2.9 61.0  1.6 65.5  4.1 62.7  3.8 65.3  2.7‡‡ 
(mg/dl) PCK 62.2  1.8 66.0  4.2 82.3  31.3 63.2  4.8 64.0  4.0 66.2  3.1 69.5  2.1 
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Appendix 2 Changes in urine biochemistry in PKD/Mhm (Cy/+) and PCK rats (n=6 in each group). Data are shown as mean ± Std.Dev. Values 
significantly different (time point vs baseline) are indicated as **p<0.005, ***p=0.0001 and (PKD/Mhm (Cy/+) vs PCK) as ‡p<0.05, ‡‡p<0.005, 
‡‡‡p=0.0001. 
Parameter Strain Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
Creatinine PKD/Mhm (Cy/+) 8.3  1.7 10.8  2.3 10.1  2.6 9.8  1.6‡ 12.0  1.2‡ 15.8  2.9** 16.9  8.6** 
(mg/16h) PCK 8.1  1.1 11.2  2.0 11.1  2.9 13.3  2.5* 13.7  1.3** 13.9  2.5** 14.8  3.2** 
Urea PKD/Mhm (Cy/+) 572.9  178.1 793.6  121.1 699.4  220.2 562.3  185.4 741.9  175.6 890.7  160.2‡ 830.5  376.6 
(mg/16h) PCK 709.4  120.7 1033.9  689.6 729.7  256.7 701.3  85.4 679.7  65.4 662.2  151.2 681.6  91.3 
Na PKD/Mhm (Cy/+) 1.6  0.7 1.6  0.3 1.5  0.4 1.0  0.4 1.8  0.7 2.2  0.7‡ 1.7  1.4 
(mmol/16h) PCK 1.6  0.6 1.4  0.4 1.0  0.5 1.3  0.4 1.3  0.3 1.3  0.3 1.3  0.2 
K PKD/Mhm (Cy/+) 3.1  1.0 4.3  1.0 3.5  0.9 2.7  1.0 4.2  15.4 4.6  1.0 4.2  2.6 
(mmol/16h) PCK 3.9  1.0 4.5  0.9 2.9  1.4 3.5  1.0 4.3  0.4 3.6  1.3 3.3  0.4 
Ca PKD/Mhm (Cy/+) 0.01  0.01‡ 0.02  0.01 0.03  0.01 0.02  0.01‡ 0.03  0.02‡‡ 0.04  0.02‡‡‡ 0.04  0.04 
(mmol/16h) PCK 0.06  0.04 0.03  0.01 0.05  0.02 0.07  0.02 0.10  0.02 0.10  0.02* 0.08  0.03 
PO4 PKD/Mhm (Cy/+) 0.1  0.1 0.1  0.1 0.0  0.0 0.0  0.0 0.1  0.0 0.1  0.0 0.1  0.1 
(mmol/16h) PCK 0.1  0.1 0.1  0.1 0.1  0.2 0.1  0.1 0.1  0.1 0.1  0.1 0.1  0.1 
Glucose PKD/Mhm (Cy/+) 1.2  0.4‡ 1.3  0.8 2.7  2.2 2.0  1.6 2.5  2.3 2.3  1.2 1.7  1.7 
(mg/16h) PCK 5.2  1.9 3.5  2.8 2.9  1.2 3.0  1.4 3.5  2.3 3.5  1.2 1.9  1.5 
Protein PKD/Mhm (Cy/+) 10.6  5.2 19.5  5.2‡ 27.7  9.8‡ 32.7  4.6‡ 61.4  16.3‡‡‡ 96.8  26.5‡‡ 154.5  177.7‡ 
(mg/16h) PCK 9.6  4.9 31.5  12.5 94.6  44.5* 212.4  72.4*** 353.0  64.1*** 375.1  85.6*** 436.8  101.5*** 
Albumin PKD/Mhm (Cy/+) 2.3  1.6‡ 4.3  1.8 12.4  4.1‡ 22.4  11.4‡ 27.4  13.2‡‡ 25.4  11.3‡‡ 103.9  108.5** 
(mg/16h) PCK 0.7  0.3 13.5  11.1 69.7  34.8 103.3  61.1* 178.8  49.8*** 173.9  71.9*** 140.6  71.2*** 
 
Appendix 3A Changes in plasma biochemistry in PKD/Mhm (Cy/+) groups (n=6 in each group). Comparison between ABCB5+ derived CoCM+, 
i.v. or i.p. ABCB5+ groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05, 
**p<0.005. 
A Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated  0.3  0.1 0.4  0.1 0.6  0 1 0.6  0.2 0.6  0.1 0.7  0.1 0.7 ± 0.1 
 (mg/dl) + ABCB5+ derived CoCM+ 0.3 ± 0.1 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.7 ± 0.2 0.6 ± 0.1 0.7 ± 0.2 
  + i.p. ABCB5+ 0.3 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ±0.1 
  + i.v. ABCB5+ 0.3 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.7 ± 0.1 
 Urea Untreated  68.4  18.2 69.4  9.9 73.9  8.6 88.4  11.7 85.6  8.1 85.1 13.0 87.4 ± 11.0 
 (mg/dl) + ABCB5+ derived CoCM+ 57.5 ± 17.6 68.2 ± 19.9 80.5 ± 15.6 73.9 ± 20.8 74.8 ± 17.2 83.7 ± 20.9 86.5 ± 23.2 
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  + i.p. ABCB5+ 56.1 ± 10.4 66.6 ± 19.2 67.2 ± 14.7 68.9 ± 17.7 75.3 ± 16.0 74.9 ± 17.0 79.6 ± 17.7 
  + i.v. ABCB5+ 52.2 ± 16.2 55.3 ± 17.6 59.3 ± 15.6 65.0 ± 20.2 63.9 ± 18.6 66.8 ± 23.6 72.3 ± 12.4 
 Na Untreated  144.3  0.8 143.0  3.6 142.3 6.9 141.3  2.3 144.3  2.3 141.8  1.7 144.8 ± 1.9 
 (mmol/l) + ABCB5+ derived CoCM+ 141.2 ± 2.9 144.3 ± 3.6 144.0 ± 2.8 142.5 ± 3.1 144.3 ± 1.0 142.3 ± 3.2 142.2 ± 1.7 
  + i.p. ABCB5+ 143.3 ± 1.6 142.7 ± 2.3 144.3 ± 2.4 143.3 ± 3.2 144.3 ± 1.4 143.7 ± 2.5 141.9 ± 1.6* 
  + i.v. ABCB5+ 141.6 ± 2.2 142.7 ± 2.0 143.7 ± 2.8 143.1 ± 2.3 143.7 ± 1.3 143.0 ± 2.6 142.0 ± 2.0* 
 K Untreated  5.4  0.3 5.1  0.6 5.2  0.7 5.3  0.4 5.3  0.2 5.7  0.4 5.1 ± 0.2 
 (mmol/l) + ABCB5+ derived CoCM+ 5.2 ± 0.2 5.0 ± 0.2 5.0 ± 0.3 5.1 ± 0.4 4.9 ± 0.3 5.2 ± 0.3 5.3 ± 0.4 
  + i.p. ABCB5+ 5.3 ± 0.3 4.8 ± 0.1 5.0 ± 0.2 5.3 ± 0.6 5.2 ± 0.2* 5.1 ± 0.3* 4.9 ± 0.2 
  + i.v. ABCB5+ 5.2 ± 0.2 4.8 ± 0.2 4.9 ± .0.2 5.2 ± 0.3 4.9 ± 0.3 5.1 ± 0.3* 5.0 ± 0.2 
 Ca Untreated  2.5  0.2 2.6  0.0 2.6  0.1 2.6  0.1 2.6  0.0 2.6  0.1 2.7 ± 0.1 
 (mmol/l) + ABCB5+ derived CoCM+ 2.6 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 5.5 ± 7.3 2.6 ± 0.0* 2.6 ± 0.1 2.4 ± 0.2 
  + i.p. ABCB5+ 2.5 ± 0.1 2.5 ± 0.1* 2.5 ± 0.2 2.5 ± 0.2 2.5 ± 0.1** 2.7 ± 0.0 2.4 ± 0.2* 
  + i.v. ABCB5+ 2.5 ± 0.2 2.5 ± 0.1 2.5 ± 0.2 2.4 ± 0.3 2.6 ± 0.1 2.7 ± 0.5 2.5 ± 0.2 
 PO4 Untreated  2.4  0.5 2.2  0.1 2.6  0.2 2.1  0.6 2.0  0.3 2.1  0.2 2.1 ± 0.3 
 (mmol/l) + ABCB5+ derived CoCM+ 2.6 ± 0.3 2.5 ± 0.1 2.4 ± 0.2 2.3 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 2.2 ± 0.2 
  + i.p. ABCB5+ 2.7 ± 0.2 2.5 ± 0.1 2.5 ± 0.1* 2.1 ± 0.2 2.1 ± 0.2 2.1 ± 0.1 2.1 ± 0.1 
  + i.v. ABCB5+ 2.5 ± 0.3 2.4 ± 0.2 2.3 ± 0.1 2.2 ± 0.2 2.1 ± 0.2 2.0 ± 0.1 1.9 ± 0.2 
 Cholesterol Untreated  97.3  7.5 99.7  6.7 110.0  9.1 107.5  8.5 131.7  10.0 131.7  10.2 154.3 ± 15.5 
 (mg/dl) + ABCB5+ derived CoCM+ 89.7 ± 5.9 117.4 ± 39.0 102.3 ± 9.7 102.7 ± 18.6 110.5 ± 22.3 121.5 ± 16.7 138.3 ± 30.9 
  + i.p. ABCB5+ 88.3 ± 4.6 1010.3 ± 25.8 102.7 ± 12.5 97.7 ± 10.9 100.3 ± 12.6* 116.0 ± 14.2 135.1 ± 23.0 
  + i.v. ABCB5+ 88.6 ± 6.9 105.9 ± 37.4 94.0 ± 14.6 100.9 ± 22.7 104.4 ± 17.0* 109.9 ± 18.7 134.0 ± 29.3 
 Triglycerides Untreated  69.2  26.3 54.3  14.5 67.2  19.4 91.5  21.6 68.7  10.0 60.2  15.0 108.8 ± 48.3 
 (mg/dl) + ABCB5+ derived CoCM+ 75.7 ± 34.5 49.8 ± 19.2 44.3 ± 16.0 53.3 ± 24.6 60.7 ± 22.9 71.7 ± 32.0 69.8 ± 23.4 
  + i.p. ABCB5+ 77.7 ± 29.8 37.1 ± 7.8 49.0 ± 14.4 53.9 ± 23.3 72. 7 ± 42.7 69.0 ± 28.0 79.3 ± 29.0 
  + i.v. ABCB5+ 70.9 ± 30.7 52.0 ± 5.6 50.0 ± 13.2 56.9 ± 20.0 72.7 ± 34.3 72.9 ± 30.4 72.1 ± 29.6 
 Glucose Untreated  169.0  9.0 167.8  9.4 183.8  18.7 195.8  32.1 173.3  12.6 176.5  19.6 184.3 ± 7.4 
 (mg/dl) + ABCB5+ derived CoCM+ 168.7 ± 6.4 170.0 ± 10.0 168.0 ± 7.3 170.5 ± 7.2 170.2 ± 10.6 174.5 ± 9.3 171.7 ± 12.0 
  + i.p. ABCB5+ 168.3 ± 8.9 174.3 ± 14.7 176.4 ± 13.6 171.3 ± 14.4 177.0 ± 27.1 171.3 ± 11.3 168.0 ± 14.5 
  + i.v. ABCB5+ 170.0 ± 11.7 168.0 ± 10.1 181.4 ± 13.7 167.6 ± 13.8 166.0 ± 16.0 180.6 ± 19.3 178.1 ± 14.6 
 Protein Untreated  62.0  1.7 63.0  3.1 63.8  2.9 61.0  1.6 65.5  4.1 62.7  3.8 65.3 ± 2.7 
 (mg/dl) + ABCB5+ derived CoCM+ 60.5 ± 2.1 51.4 ± 24.0 62.1 ± 3.1 63.2 ± 2.4 62.0 ± 3.6 63.3 ± 2.4 61.3 ± 2.4* 
  + i.p. ABCB5+ 59.4 ± 2.2 51.4 ± 21.7 62.6 ± 2.8 62.3 ± 3.0 61.9 ± 3.7 64.1 ± 2.7 64.1 ± 1.9 
  + i.v. ABCB5+ 58.7 ± 3.6 44.5 ± 28.6 61.9 ± 1.6 65.0 ± 2.5 64.9 ± 3.7 6.6 ± 3.0 63.1 ± 1.6 
 AST Untreated  88.3  8.8 89.3  10.9 113.3  69.5 92.5  14.9 81.8  5.7 138.5  44.6 72.2 ± 12.4 
 (U/l) + ABCB5+ derived CoCM+ 78.0 ± 6.7 94.2 ± 23.9 80.8 ± 8.3 86.3 ± 13.6 84.2 ± 11.5 84.5 ± 20.9 88.2 ± 15.1 
  + i.p. ABCB5+ 111.9 ± 88.5 88.6 ± 13.4 91.7 ± 9.9 87.9 ± 7.6 85.9 ± 21.3 78.6 ± 13.3 79.6 ± 9.5 
  + i.v. ABCB5+ 79.7 ± 9.5 95.9 ± 18.2 83.6 ± 6.7 106.7 ± 39.4 80.1 ± 18.5 85.3 ± 13.1 81.4 ± 14.6 
 ALT Untreated  43.2  6.3 53.3  6.2 58.5  13.8 57.8  7.1 48.7  6.5 53.7  8.9 48.8 ± 10.3 
 (U/l) + ABCB5+ derived CoCM+ 41.2 ± 6.6 48.0 ± 5.5 47.7 ± 7.4 54.8 ± 7.3 53.8 ± 9.0 53.2 ± 12.1 47.7 ± 3.7 
  + i.p. ABCB5+ 39.7 ± 17.7 48.1 ± 9.9 48.0 ± 4.7 47.3 ± 4.1 56.9 ± 18.9 47.9 ± 7.3 47.6 ± 8.4 
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  + i.v. ABCB5+ 41.6 ± 6.7 54.0 ± 8.6 48.6 ± 5.0 53.3 ± 3.5 59.9 ± 18.4 48.7 ± 9.9 46.3 ± 4.3 
 
Appendix 3B Changes in plasma biochemistry in PKD/Mhm (Cy/+) groups (n=6 in each group). Comparison between ASC derived CM, i.v. or i.p. 
ASC groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05, **p<0.005. 
B Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 0.3  0.1 0.4  0.1 0.6  0 1 0.6  0.2 0.6  0.1 0.7  0.1 0.7 ± 0.1 
 (mg/dl) + ASC derived CM 0.3 ± 0.1 0.5 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.0 0.7 ± 0.1 0.7 ± 0.2 
  + i.p. ASC 0.3 ± 0.0 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1* 0.6 ± 0.1 0.6 ± 0.1 
  + i.v. ASC 0.3 ± 0.0 0.5 ± 0.1 0.6 ± 0.0 0.7 ± 0.1 0.6 ± 0.0 0.7 ± 0.1 0.7 ± 0.1 
 Urea Untreated 68.4  18.2 69.4  9.9 73.9  8.6 88.4  11.7 85.6  8.1 85.1 13.0 87.4 ± 11.0 
 (mg/dl) + ASC derived CM 67.9 ± 8.2 11.8 ± 13.4 93.3 ± 7.3 97.6 ± 7.8 94.4 ± 7.0 96.4 ± 8.2 98.7 ± 21.6 
  + i.p. ASC 66.0 ± 8.9 74.7 ± 10.7 84.5 ± 7.8 80.8 ± 11.7 81.1 ± 11.5 79.2 ± 9.7 90.8 ± 12.7 
  + i.v. ASC 63.9 ± 3.6 80.1 ± 7.0 91.3 ± 7.4 88.9 ± 12.3 86.8 ± 6.2 90.9 ± 6.5 95.6 ± 10.6 
 Na Untreated 144.3  0.8 143.0  3.6 142.3 6.9 141.3  2.3 144.3  2.3 141.8  1.7 144.8 ± 1.9 
 (mmol/l) + ASC derived CM 144.8 ± 4.0 140.0 ± 3.6 138.6 ± 2.6 140.5 ± 2.5 143.0 ± 2.9 145.0 ± 2.7 145.3 ± 2.2 
  + i.p. ASC 143.2 ± 2.1 141.4 ± 4.9 139.8 ± 3.3 145.3 ± 5.1 144.7 ± 1.9 144.3 ± 0.8 138.5 ± 5.0* 
  + i.v. ASC 144.0 ± 2.1 144.7 ± 3.5 140.0 ± 3.7 144.0 ± 6.5 143.8 ± 2.8 143.0 ± 0.9 139.5 ± 4.4 
 K Untreated 5.4  0.2 5.1  0.6 5.2  0.7 5.3  0.4 5.3  0.2 5.7  0.4 5.1 ± 0.2 
 (mmol/l) + ASC derived CM 6.0 ± 1.8 5.2 ± 0.5 5.2 ± 0.3 5.4 ± 0.4 5.3 ± 0.5 5.2 ± 0.4 5.7 ± 0.4 
  + i.p. ASC 5.0 ± 0.3 5.4 ± 0.9 5.4 ± 0.3 5.3 ± 0.4 5.2 ± 0.2 5.2 ± 0.3 6.1 ± 0.5** 
  + i.v. ASC 5.0 ± 0.4 5.9 ± 0.6 5.3 ± 0.5 5.2 ± 0.3 5.2 ± 0.4 5.0 ± 0.5 5.7 ± 0.4 
 Ca Untreated 2.5  0.2 2.6  0.0 2.6  0.1 2.6  0.1 2.6  0.0 2.6  0.1 2.9 ± 0.1 
 (mmol/l) + ASC derived CM 1.5 ± 0.2 2.6 ± 0.1 2.6 ± 0.0 2.5 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.7 ± 0.1 
  + i.p. ASC 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 
  + i.v. ASC 2.7 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 2.6 ± 0.0 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 
 PO4 Untreated 2.4  0.5 2.2  0.1 2.6  0.2 2.1  0.4 2.0  0.3 2.1  0.2 2.1 ± 0.3 
 (mmol/l) + ASC derived CM 2.5 ± 0.3 2.4 ± 0.2 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.2 ± 0.2 2.0 ± 0.4 
  + i.p. ASC 2.6 ± 0.3 2.7 ± 0.3 2.3 ± 0.3 2.2 ± 0.1 2.1 ± 0.1 2.2 ± 0.1 1.8 ± 0.3 
  + i.v. ASC 2.7 ± 0.2 2.5 ± 0.4 2.2 ± 0.3 2.3 ± 0.1 2.2 ± 0.1 2.3 ± 0.2 1.9 ± 0.2 
 Cholesterol Untreated 97.3  7.5 99.7  6.7 110.0  9.1 107.5  8.5 131.7  10.0 131.7  10.2 154.3 ± 15.5 
 (mg/dl) + ASC derived CM 99.8 ± 7.6 100.3 ± 9.7 107.4 ± 13.7 117.8 ± 12.8 127.0 ± 17.9 138.3 ± 23.4 152.3 ± 22.0 
  + i.p. ASC 95.8 ± 6.5 96.2 ± 7.8 100.5 ± 7.3 111.0 ± 5.4 111.0 ± 8.5 134.3 ± 5.7 144.7 ± 10.6 
  + i.v. ASC 97.0 ± 8.5 103.3 ± 5.1 99.7 ± 6.3 116.5 ± 8.4 119.0 ± 6.5 139.0 ± 13.1 149.5 ± 17.3 
 Triglycerides Untreated 69.2  26.3 54.3  14.5 67.2  19.4 91.5  21.6 68.7  10.0 60.2  15.0 108.8 ± 48.3 
 (mg/dl) + ASC derived CM 78.5 ± 14.5 82.5 ± 27.0 62.8 ± 28.2 81.3 ± 31.3 66.0 ± 7.0 80.8 ± 21.9 63.3 ± 36.2 
  + i.p. ASC 76.5 ± 17.8 77.0 ± 22.8 64.5 ± 23.1 99.0 ± 43.2 72.0 ± 16.6 78.0 ± 14.2 98.8 ± 42.2 
  + i.v. ASC 94.7 ± 28.1 93.0 ± 16.6 70.3 ± 15.0 70.7 ± 15.0 10.2 ± 30.7 85.7 ± 27.0 63.5 ± 17.2 
 Glucose Untreated 169.0  9.0 167.8  9.4 183.8  18.7 195.8  32.1 173.3  12.6 176.5  19.6 184.3 ± 7.4 
 (mg/dl) + ASC derived CM 167.0 ± 10.6 163.3 ± 14.3 170.6 ± 13.0 165.6 ± 6.8* 173.0 ± 17.4 166.5 ± 3.1 173.0 ± 9.3 
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  + i.p. ASC 165.0 ± 10.8 157.8 ± 14.5 181.8 ± 29.4 174.5 ± 10.1 172.8 ± 13.0 171.3 ± 12.3 174.7 ± 17.1 
  + i.v. ASC 172.5 ± 10.3 169.6 ± 8.0 185.8 ± 19.2 172.5 ± 21.5 174.2 ± 7.0 176.2 ± 31.0 174.5 ± 9.9 
 Protein Untreated 62.0  1.7 63.0  3.1 63.8  2.9 61.0  1.6 65.5  4.1 62.7  3.8 65.3 ± 2.7 
 (mg/dl) + ASC derived CM 61.7 ± 3.1 61.5 ± 1.5 61.8 ± 2.2 62.8 ± 2.8 62.8 ± 7.1 65.8 ± 3.5 66.3 ± 1.7 
  + i.p. ASC 59.5 ± 5.6 61.2 ± 2.8 62.3 ± 2.7 66.3 ± 1.0 67.3 ± 1.5 67.5 ± 1.9 66.3 ± 2.8 
  + i.v. ASC 59.0 ± 4.1 62.6 ± 3.2 60.7 ± 1.4 63.7 ± 1.4 64.0 ± 2.0 65.8 ± 4.0 65.2 ± 1.5 
 AST Untreated 88.3  8.8 89.3  10.9 113.3  69.5 92.5  14.9 81.8  5.7 138.5  44.6 72.2 ± 12.4 
 (U/l) + ASC derived CM 88.7 ± 11.7 93.0 ± 1.2 84.4 ± 10.8 87.8 ± 14.2 78.0 ± 15.1 83.3 ± 3.7 73.3 ± 5.0 
  + i.p. ASC 82.0 ± 12.1 85.0 ± 6.6 95.7 ± 45.9 79.8 ± 5.9 96.2 ± 25.1 81.2 ± 5.0 98.5 ± 59.0 
  + i.v. ASC 79.7 ± 8.9 81.8 ± 23.0 84.2 ± 18.8 78.2 ± 7.6 83.8 ± 15.9 103.5 ± 66.6 69.3 ± 4.0 
 ALT Untreated 43.2  6.3 53.3  6.2 58.5  13.8 57.8  7.1 48.7  6.5 53.7  8.9 48.8 ± 10.3 
 (U/l) + ASC derived CM 46.8 ± 4.3 53.3 ± 5.1 51.0 ± 10.0 47.5 ± 2.6 46.5 ± 9.1 52.5 ± 10.1 54.0 ± 14.4 
  + i.p. ASC 161.7 ± 286.8 51.0 ± 3.6 51.7 ± 12.2 52.0 ± 10.1 52.5 ± 5.4 59.3 ± 5.2 51.7 ± 7.5 
  + i.v. ASC 50.3 ± 3.0 153.8 ± 130.4 51.8 ± 4.0 55.7 ± 7.6 58.2 ± 14.6 60.2 ± 11.6 51.0 ± 14.6 
 
Appendix 4A Changes in diuresis, food intake and water intake after metabolic cages in PKD/Mhm (Cy/+) groups (n=6). Comparison between 
ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ groups and untreated. Data are shown as mean ± Std.Dev. 
A Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Diuresis (ml) Untreated 20.3  4.9 29.4  3.5 26.8  7.4 31.2  11.2 44.6  10.4 44.6  10.4 55.8  54.5 
  + ABCB5+ derived CoCM+ 21.3 ± 5.8 31.0 ± 7.6 26.0 ± 7.4 32.6 ± 5.2 39.5 ± 11.9 34.6 ± 7.8 28.4 ± 10.1 
  + i.p. ABCB5+ 18.7 ± 3.9 31.4 ± 11.4 27.3 ± 4.4 35.3 ± 13.2 65.7 ± 91.5 36.0 ± 11.4 26.3 ± 7.3 
  + i.v. ABCB5+ 18.5 ± 6.0 29.2 ± 5.2 42.7 ± 13.3 37.2 ± 12.2 40.9 ± 18.2 33.6 ± 19.5 48.1 ± 20.6 
 Food intake Untreated 15.9  7.0 17.9  2.1 16.7  3.0 13.0  6.6 17.8  5.9 17.6  5.1 12.3  4.3 
 (g) + ABCB5+ derived CoCM+ 18.0 ± 5.1 17.7 ± 4.7 14.5 ± 4.5 14.5 ± 3.0 14.3 ± 3.4 12.3 ± 2.8 10.1 ± 4.3 
  + i.p. ABCB5+ 19.1 ± 3.9 15.1 ± 2.9 15.6 ± 1.9 16.2 ± 3.4 13.7 ± 3.4 12.7 ± 3.1 12.1 ± 3.4 
  + i.v. ABCB5+ 18.1 ± 2.7 18.5 ± 2.2 16.0 ± 2.8 14.3 ± 3.3 13.0 ± 2.8 13.3 ± 2.5 11.6 ± 2.4 
 Water intake Untreated 36.6  8.9 53.0  9.3 47.2  10.5 50.2  29.1 60.0  25.1 55.5  13.3 56.0  15.6 
 (g) + ABCB5+ derived CoCM+ 40.8 ± 8.5 49.6 ± 9.1 37.8 ± 14.8 42.9 ± 6.0 52.7 ± 17.7 43.3 ± 11.4 33.5 ± 15.5 
  + i.p. ABCB5+ 39.2 ± 3.8 44.6 ± 13.6 38.9 ± 7.3 52.5 ± 16.4 42.8 ± 12.7 45.7 ± 13.8 32.3 ± 9.8 
  + i.v. ABCB5+ 37.3 ± 5.8 47.4 ± 5.1 55.0 ± 14.8 47.6 ± 12.4 51.7 ± 21.4 48.1 ± 18.3 55.9 ± 21.8 
 
Appendix 4B Changes in diuresis, food intake and water intake after metabolic cages in PKD/Mhm (Cy/+) groups (n=6). Comparison between 
ASC derived CM, i.v. or i.p. ASC groups and untreated. Data are shown as mean ± Std.Dev. 
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B Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Diuresis (ml) Untreated 20.3  4.9 29.4  3.5 26.8  7.4 31.2  11.2 44.6  10.4 44.6  10.4 55.8  54.5 
  + ASC derived CM 17.0 ± 5.6 30.0 ± 9.5 21.1 ± 10.0 29.5 ± 5.6 42.9 ± 9.0 42.1 ± 6.4 28.9 ± 5.6 
  + i.p. ASC 18.1 ± 6.0 28.8 ± 5.5 38.2 ± 20.2 32.9 ± 10.2 33.6 ± 14.4 35.0 ± 9.4 28.4 ± 13.6 
  + i.v. ASC 13.2 ± 2.3 27.4 ± 6.6 27.0 ± 3.6 30.9 ± 8.3 34.8 ± 9.0 40.3 ± 10.9 33.6 ± 13.1 
 Food intake Untreated 15.9  7.0 17.9  2.1 16.7  3.0 13.0  6.6 17.8  5.9 17.6  5.1 12.3  4.3 
 (g) + ASC derived CM 17.6 ± 3.7 16.3 ± 6.7 16.0 ± 3.7 19.0 ± 6.6 19.4 ± 4.8 18.0 ± 5.7 9.9 ± 2.7 
  + i.p. ASC 13.5 ± 5.7 18.9 ± 1.8 17.3 ± 3.4 19.3 ± 5.0 21.1 ± 5.8 17.3 ± 5.2 11.5 ± 3.5 
  + i.v. ASC 16.0 ± 4.9 19.3 ± 3.5 16.1 ± 1.6 15.2 ± 1.3 15.1 ± 8.2 17.3 ± 8.5 10.1 ± 2.2 
 Water intake Untreated 36.6  8.9 53.0  9.3 47.2  10.5 50.2  29.1 60.0  25.1 55.5  13.3 56.0  15.6 
 (g) + ASC derived CM 36.7 ± 7.3 54.9 ± 7.3 43.9 ± 9.7 52.8 ± 12.4 60.0 ± 8.1 55.1 ± 8.6 40.9 ± 12.5 
  + i.p. ASC 32.5 ± 15.0 48.9 ± 5.1 47.2 ± 12.3 49.8 ± 14.6 49.4 ± 12.3 47.8 ± 14.5 43.1 ± 13.6 
  + i.v. ASC 30.7 ± 6.0 47.1 ± 8.2 42.8 ± 3.9 46.9 ± 11.5 50.2 ± 15.8 47.8 ± 22.3 41.1 ± 14.5 
 
Appendix 5A Changes in urine biochemistry in PKD/Mhm (Cy/+) groups (n=6). Comparison between ABCB5+ derived CoCM+, i.v. or i.p. 
ABCB5+ groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
A Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 8.3 ± 1.7 10.8  2.3 10.1  2.6 9.8  1.6 12.0  1.2 15.8  3.0 16.9 ± 8.6 
 (mg/16h) + ABCB5+ derived CoCM+ 7.8 ± 1.1 11.2 ± 0.8 11.4 ± 1.8 12.2 ± 0.8 13.5 ± 1.1 13.3 ± 1.5 12.3 ± 2.3 
  + i.p. ABCB5+ 7.9 ± 1.1 11.3 ± 1.6 11.8 ± 1.3 12.5 ± 1.3 13.1 ± 1.0 13.7 ± 1.2 12.5 ± 0.6 
  + i.v. ABCB5+ 8.4 ± 1.1 11.6 ± 1.1 14.5 ± 3.8 13.5 ± 1.1 13.7 ± 1.5 12.5 ± 2.9 14.2 ± 2.6 
 Urea Untreated 572.9 ± 178.1 793.6  121.1 699.4  220.2 562.3  185.4 741.9  175.6 890.7  160.2 830.5 ± 376.6 
 (mg/16h) + ABCB5+ derived CoCM+ 606.2 ± 112.1 754.4 ± 57.6 659.4 ± 155.1 718.0 ± 73.6 729.0 ± 116.8 708.4 ± 110.0 552.0 ± 142.1 
  + i.p. ABCB5+ 602.0 ± 78.7 755.8 ± 172.6 718.7 ± 79.6 722.6 ± 126.3 676.2 ± 119.6 705.8 ± 118.3 610.5 ± 54.9 
  + i.v. ABCB5+ 619.3 ± 90.7 830.2 ± 111.1 881.9 ± 304.9 750.4 ± 57.5* 684.1 ± 121.7 628.1 ±184.5 702.9 ± 149.6 
 Na Untreated 1.6 ± 0.7 1.6  0.3 1.5  0.4 1.0  0.4 1.8  0.7 2.2  0.7 1.7 ± 1.4 
 (mmol/16h) + ABCB5+ derived CoCM+ 1.4 ± 0.6 1.5 ± 0.5 1.4 ± 0.5 1.4 ± 0.4 1.5 ± 0.7 1.4 ± 0.6 1.5 ± 0.5 
  + i.p. ABCB5+ 1.5 ± 0.2 1.4 ± 0.5 1.5 ± 0.3 1.3 ± 0.5 1.5 ± 0.6 1.4 ± 0.4 1.4 ± 0.4 
  + i.v. ABCB5+ 1.5 ± 0.5 1.5 ± 0.5 1.8 ± 0.6 1.6 ± 0.6 1.7 ± 0.5 1.3 ± 0.6 1.7 ± 0.6 
 K Untreated 3.1 ± 1.0 4.3  1.0 3.5  0.7 2.7  1.0 4.2  1.5 4.6  1.0 4.2 ± 2.6 
 (mmol/16h) + ABCB5+ derived CoCM+ 3.7 ± 0.8 3.8 ± 1.2 3.3 ± 0.8 3.9 ± 0.4 3.6 ± 1.6 3.4 ± 0.9 3.1 ± 1.1 
  + i.p. ABCB5+ 3.8 ± 0.4 4.0 ± 1.3 3.8 ± 0.7 4.1 ± 0.8 3.5 ± 1.1 3.7 ± 0.6 1.7 ± 1.1 
  + i.v. ABCB5+ 3.9 ± 0.6 4.7 ± 1.4 5.0 ± 1.6 4.4 ± 0.6 3.7 ± 0.7 3.0 ± 1.0 3.7 ± 0.8 
 Ca Untreated 0.01 ± 0.01 0.02  0.01 0.03  0.01 0.02  0.01 0.03  0.02 0.04  0.02 0.04 ± 0.04 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
  + i.p. ABCB5+ 0.01 ± 0.00 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.05 0.02 ± 0.01 0.01 ± 0.01 
  + i.v. ABCB5+ 0.02 ± 0.01 0.02 ± 0.00 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.00 0.01 ± 0.01 0.02 ± 0.00 
 PO4 Untreated 0.1 ± 0.1 0.1  0.1 0.0  0.0 0.0  0.0 0.1  0.0 0.1  0.0 0.1 ± 0.1 
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 (mmol/16h) + ABCB5+ derived CoCM+ 0.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
  + i.p. ABCB5+ 0.2 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 
  + i.v. ABCB5+ 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 
 Glucose Untreated 1.2 ± 0.4 1.3  0.8 2.7  2.2 2.0  1.6 2.5  2.3 2.3  1.2 1.7 ± 1.7 
 (mg/16h) + ABCB5+ derived CoCM+ 1.2 ± 0.9 2.6 ± 1.2 4.0 ± 3.7 3.5 ± 0.7 2.5 ± 1.5 1.5 ± 0.1 0.9 ± 0.8 
  + i.p. ABCB5+ 1.3 ± 0.4 1.8 ± 0.8 3.0 ± 1.7 2.4 ± 1.0 1.5 ± 1.1 1.2 ± 0.7 1.4 ± 0.9 
  + i.v. ABCB5+ 1.9 ± 0.8 2.4 ± 0.9 3.0 ± 2.6 3.0 ± 2.1 1.9 ± 1.2 1.0 ± 0.8* 1.4 ± 0.6 
 Protein Untreated 10.6 ± 5.2 19.5  5.2 27.7  9.8 32.7  4.6 61.4  16.3 96.8  26.5 154.5 ± 177.7 
 (mg/16h) + ABCB5+ derived CoCM+ 12.1 ± 5.5 19.7 ± 6.8 25.4 ± 12.9 33.8 ± 12.2 41.9 ± 16.7 50.2 ± 20.6 49.8 ± 16.4 
  + i.p. ABCB5+ 12.2 ± 2.3 19.1 ± 5.2 30.2 ± 12.7 36.4 ± 13.1 47.5 ± 19.5 51.9 ± 22.6 68.4 ± 35.0 
  + i.v. ABCB5+ 13.0 ± 3.5 20.3 ± 6.9 26.1 ± 10.2 34.4 ± 17.3 36.9 ± 19.5 39.4 ± 25.6* 58.8 ± 36.5 
 Albumin Untreated 2.3 ± 1.5 4.3  1.7 12.4  4.1 22.4  11.4 27.4  13.2 25.4  11.3 103.9 ± 108.5 
 (mg/16h) + ABCB5+ derived CoCM+ 1.8 ± 1.1 4.5 ± 2.0 9.4 ± 4.5 15.9 ± 6.4 24.8 ± 13.1 32.5 ± 26.4 39.1 ± 16.2 
  + i.p. ABCB5+ 1.9 ± 0.9 8.6 ± 5.0 14.4 ± 12.1 21.4 ± 13.2 30.6 ± 24.7 38.9 ± 23.0 58.1 ± 37.5 
  + i.v. ABCB5+ 1.6 ± 1.5 5.5 ± 3.7 9.1 ± 6.6 14.3 ± 8.7 20.9 ± 15.1 26.5 ± 24.6 52.6 ± 37.7 
 
Appendix 5B Changes in urine biochemistry in PKD/Mhm (Cy/+) groups (n=6). Comparison between ASC derived CM, i.v. or i.p. ASC groups 
and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
B Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 8.3 ± 1.7 10.6  2.3 10.1  2.6 9.8  1.6 12.0  1.2 15.8  2.9 16.9 ± 8.6 
 (mg/16h) + ASC derived CM 7.7 ± 1.9 9.8 ± 2.3 9.2 ± 3.8 11.0 ± 2.8 15.2 ± 4.3 14.0 ± 1.7 13.6 ± 0.6 
  + i.p. ASC 7.7 ± 1.8 9.1 ± 4.2 13.5 ± 2.4 12.7 ± 6.1 13.3 ± 3.4 12.4 ± 1.6 10.9 ± 2.8 
  + i.v. ASC 7.2 ± 2.0 10.4 ± 0.8 11.5 ± 5.3 11.9 ± 1.8 15.7 ± 3.1 16.5 ± 1.5 13.8 ± 1.8 
 Urea Untreated 572.9 ± 178.1 793.6  121.1 699.4  220.1 562.3  185.4 741.9  175.6 890.7  160.2 830.5 ± 376.6 
 (mg/16h) + ASC derived CM 525.9 ± 127.7 699.8 ± 180.7 564.6 ± 249.6 684.6 ± 194.9 1070.6 ± 388.2 867.8 ± 137.8 644.5 ± 99.6 
  + i.p. ASC 488.3 ± 152.6 789.2 ± 115.7 902.9 ± 163.9 856.6 ± 435.2* 880.4 ± 243.6 772.2 ± 109.1 557.6 ± 199.5 
  + i.v. ASC 497.2 ± .171.9 726.0 ± 128.7 822.9 ± 119.3 710.3 ± 99.8 971.0 ± 274.4 995.2 ± 243.7 666.2 ± 92.6 
 Na Untreated 1.6 ± 0.7 1.6  0.3 1.5  0.4 1.0  0.4 1.8  0.7 2.2  0.7 1.7 ± 1.4 
 (mmol/16h) + ASC derived CM 1.7 ± 0.8 1.5 ± 0.4 1.1 ± 0.6 1.3 ± 0.5 2.3 ± 0.5 2.1 ± 1.0 1.0 ± 0.2 
  + i.p. ASC 1.3 ± 0.4 1.7 ± 0.2 1.7 ± 0.2 1.8 ± 0.6 2.4 ± 0.6 1.7 ± 0.4 1.6 ± 0.9 
  + i.v. ASC 1.3 ± 0.7 1.6 ± 0.4 1.4 ± 0.4 1.4 ± 0.5 2.1 ± 0.7 2.3 ± 0.5 1.1 ± 0.3 
 K Untreated 3.1 ± 1.0 4.3  1.0 3.5  0.9 2.7  1.0 4.2  1.5 4.6  1.0 4.2 ± 2.6 
 (mmol/16h) + ASC derived CM 3.8 ± 1.4 3.7 ± 0.9 2.8 ± 1.4 3.6 ± 1.3 5.3 ± 1.9 5.1 ± 1.7 3.1 ± 0.6 
  + i.p. ASC 3.0 ± 0.6 4.0 ± 0.3 4.5 ± 1.0 4.8 ± 2.2 5.1 ± 1.5 3.9 ± 0.9 2.8 ± 1.0 
  + i.v. ASC 3.1 ± 0.8 3.9 ± 0.8 3.9 ± 1.0 3.9 ± 1.0 4.1 ± 1.1 5.0 ± 1.8 3.0 ± 0.8 
 Ca Untreated 0.01 ± 0.01 0.02  0.01 0.03  0.01 0.02  0.01 0.03  0.02 0.04  0.02 0.04 ± 0.04 
 (mmol/16h) + ASC derived CM 0.01 ± 0.00 0.02 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 0.03 ± 0.02 
  + i.p. ASC 0.01 ± 0.00 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.04 ± 0.03 0.02 ± 0.01 0.01 ± 0.01 
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  + i.v. ASC 0.01 ± 0.01 0.02 ± 0.00 0.03 ± 0.01 0.02 ± 0.01 0.04 ± 0.04 0.04 ± 0.03 0.02 ± 0.01 
 PO4 Untreated 0.1 ± 0.1 0.1  0.1 0.0  0.0 0.0  0.0 0.1  0.0 0.1  0.0 0.1 ± 0.1 
 (mmol/16h) + ASC derived CM 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 
  + i.p. ASC 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 
  + i.v. ASC 0.1 ± 0.1 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 
 Glucose Untreated 1.2 ± 0.4 1.3  0.8 2.7  2.2 2.0  1.6 2.5  2.3 2.3  1.2 1.7 ± 1.7 
 (mg/16h) + ASC derived CM 1.3 ± 0.8 5.5 ± 7.3* 3.5 ± 4.8 3.5 ± 2.3 3.3 ± 0.5 1.5 ± 0.8 1.3 ± 1.4 
  + i.p. ASC 0.8 ± 0.6 2.2 ± 1.6 3.0 ± 1.3 2.9 ± 1.2 2.1 ± 1.1 1.8 ± 0.3 1.9 ± 1.2 
  + i.v. ASC 0.8 ± 0.8 2.0 ± 0.9 4.2 ± 3.5 3.0 ± 1.3 3.9 ± 2.6 2.3 ± 0.7 1.8 ± 0.8 
 Protein Untreated 10.6 ± 5.2 19.5  5.2 27.7  9.8 32.7  4.6 61.4  16.3 96.8  26.5 154.5 ± 177.7 
 (mg/16h) + ASC derived CM 11.1 ± 3.2 18.6 ± 5.0 21.8 ± 12.0 35.6 ± 15.0 53.3 ± 18.3 63.7 ± 17.9 81.3 ± 15.8 
  + i.p. ASC 8.9 ± 3.2 18.8 ± 6.8 33.6 ± 5.6 38.6 ± 11.5 57.5 ± 15.7 66.2 ± 9.1 76.0 ± 41.1 
  + i.v. ASC 10.6 ± 5.3 14.9 ± 3.8 33.1 ± 13.5 36.2 ± 8.7 70.8 ± 32.0 88.1 ± 21.6 83.6 ± 25.5 
 Albumin Untreated 2.3 ± 1.5 4.3  1.8 12.4  4.1 22.4  11.4 27.4  13.2 25.4  11.3 103.9 ± 108.5 
 (mg/16h) + ASC derived CM 2.2 ± 1.9 6.6 ± 4.1 7.3 ± 4.8 16.0 ± 7.2 18.3 ± 16.3 30.2 ± 12.7 39.0 ± 6.6 
  + i.p. ASC 1.4 ± 0.9 4.7 ± 2.6 11.2 ± 6.2 18.0 ± 4.7 27.6 ± 17.2 31.0 ± 14.9 64.7 ± 34.6 
  + i.v. ASC 0.7 ± 0.2 3.5 ± 1.2 10.2 ± 5.4 11.6 ± 5.3 33.3 ± 15.3 28.6 ± 18.7 60.4 ± 26.1 
 
Appendix 6A Changes of ABZWCY-HCD half-life in PKD/Mhm (Cy/+) groups (n=6). Comparison between ABCB5+ derived CoCM+, i.v. or 
i.p. ABCB5+ groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
A Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 ABZWCY-HCD Untreated 26.7 ± 9.3 30.6  7.1 39.3  11.3 42.3  6.4 51.4  16.8 60.7  29.9 66.0 ± 11.4 
 t1/2 (min) + ABCB5+ derived CoCM+ 24.0 ± 7.6 24.9 ± 5.6 53.3 ± 28.5 47.2 ± 15.1 52.0 ± 22.7 47.1 ± 25.8 55.0 ± 12.0 
  + i.p. ABCB5+ 25.3 ± 9.8 31.7 ± 13.2 38.6 ± 10.7 43.6 ± 13.1 32.7 ± 8.6 39.0 ± 18.1 41.2 ± 15.5* 
  + i.v. ABCB5+ 23.8 ± 4.4 27.0 ± 9.5 32.5 ± 17.0 45.0 ± 15.3 35.2 ± 13.8 38.8 ± 11.1 43.9 ± 19.1 
 
Appendix 6B Changes of ABZWCY-HCD half-life in PKD/Mhm (Cy/+) groups (n=6). Comparison between ASC derived CM, i.v. or i.p. ASC 
groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
B Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 ABZWCY-HCD Untreated 26.7 ± 9.3 30.6  7.1 39.3  11.3 42.3  6.4 51.4  16.8 60.7  29.9 66.0 ± 11.4 
 t1/2 (min) + ASC derived CM 26.8 ± 7.3 33.4 ± 11.9 38.5 ± 9.6 42.6 ± 9.1 43.0 ± 10.7 51.2 ± 16.8 49.6 ± 15.7 
  + i.p. ASC 34.6 ± 5.7 28.3 ± 5.2 31.1 ± 8.8 40.8 ± 8.2 36.5 ± 9.6 39.3 ± 10.8 38.8 ± 8.1* 
  + i.v. ASC 33.2 ± 7.3 40.28 ± 12.2 31.1 ± 10.1 49.9 ± 23.3 43.0 ± 16.8 54.0 ± 11.2 43.0 ± 19.8 
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Appendix 7A Changes in plasma biochemistry in PCK groups (n=6). Comparison between ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ groups 
and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
A Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.1 0.5 ± 0.1 
 (mg/dl) + ABCB5+ derived CoCM+ 0.2 ± 0.0 0.3  0.0 0.3  0.1 0.4  0.1 0.4  0.1 0.4  0.1 0.5 ± 0.1 
  + i.p. ABCB5+ 0.2 ± 0.0 0.3  0.0 0.4  0.1 0.4  0.1 0.4  0.2 0.4  0.1 0.6 ± 0.2 
  + i.v. ABCB5+ 0.2 ± 0.0 0.3  0.0 0.3  0.1 0.4  0.0 0.4  0.0 0.4  0.0 0.5 ± 0.1 
 Urea Untreated 31.9 ± 2.8 35.0 ± 4.3 32.5 ± 2.9 36.3 ± 6.2 42.1 ± 5.1 44.6 ± 2.3 56.6 ± 3.2 
 (mg/dl) + ABCB5+ derived CoCM+ 32.8 ± 3.1 33.5  2.1 34.6  1.8 37.9  4.7 39.3  5.9 46.5  9.7 50.7 ± 8.9 
  + i.p. ABCB5+ 33.7 ± 5.0 36.1  2.8 40.1  10.0 43.8  14.3 46.0  13.2 50.9  14.1 54.1 ± 16.5 
  + i.v. ABCB5+ 30.9 ± 2.6 33.2  3.3 35.1  3.3 37.1  5.1 40.9  6.3 43.4  8.2 50.3 ± 10.6 
 Na Untreated 139.2 ± 1.2 140.7 ± 2.7 141.0 ± 3.0 139.7 ± 1.2 139.8 ± 1.1 140.6 ± 1.7 143.8 ± 1.8 
 (mmol/l) + ABCB5+ derived CoCM+ 140.3 ± 3.1 138.7  1.4 141.3  1.6 141.7  1.6 138.8  2.4 140.8  2.0 139.3 ± 2.3* 
  + i.p. ABCB5+ 140.9 ± 1.4 139.7  1.7 141.9  2.0 141.7  1.5 140.0  2.2 140.3  1.5 140.3 ± 2.2* 
  + i.v. ABCB5+ 141.0 ± 1.5 139.1  1.6 140.9  1.6 142.7  1.5 141.7  3.2 141.4  1.8 141.0 ± 1.9 
 K Untreated 5.4 ± 0.3 5.0 ± 0.5 5.3 ± 0.3 5.2 ± 0.4 5.4 ± 0.4 5.2 ± 0.4 5.1 ± 0.2 
 (mmol/l) + ABCB5+ derived CoCM+ 5.2 ± 0.4 5.0  0.4 4.7  0.3 4.7  0.2 4.7  0.2 4.7  0.4 5.1 ± 0.5 
  + i.p. ABCB5+ 5.3 ± 0.4 4.7  0.6 4.8  0.5 5.0  0.4 5.3  1.0 4.7  0.4 5.0 ± 0.3 
  + i.v. ABCB5+ 5.1 ± 0.3 4.9  0.6 4.7  0.2 4.7  0.2 4.7  0.4 4.8  0.4 4.7 ± 0.5 
 Ca Untreated 2.7 ± 0.1 2.7 ± 0.1 2.8 ± 0.1 2.7 ± 0.0 2.7 ± 0.1 2.7 ± 0.1 2.8 ± 0.1 
 (mmol/l) + ABCB5+ derived CoCM+ 2.7 ± 0.2 2.7  0.1 2.7  0.1 2.7  0.1 2.7  0.1 2.7  0.1 2.7 ± 0.2 
  + i.p. ABCB5+ 2.7 ± 0.1 2.9  0.4 2.7  0.2 2.7  0.1 2.7  0.1 2.7  0.1 2.7 ± 0.1 
  + i.v. ABCB5+ 2.7 ± 0.1 2.8  0.3 2.7  0.1 2.7  0.1 2.7  0.1 2.7  0.1 2.7 ± 0.1 
 PO4 Untreated 2.3 ± 0.3 2.5 ± 0.3 2.0 ± 0.2 1.6 ± 0.5 2.0 ± 0.4 2.0 ± 0.4 2.2 ± 0.1 
 (mmol/l) + ABCB5+ derived CoCM+ 2.3 ± 0.2 2.4  0.2 2.0  0.2 2.2  0.2 2.2  0.2 2.1  0.2 2.1 ± 0.3 
  + i.p. ABCB5+ 2.2 ± 0.3 2.1  0.2 2.2  0.2 2.2  0.1 2.2  0.1 2.1  0.2 2.2 ± 0.2 
  + i.v. ABCB5+ 2.3 ± 0.5 2.2  0.2 2.2  0.4 2.2  0.1 2.1  0.3 2.1  0.3 2.1 ± 0.2 
 Cholesterol Untreated 140.3 ± 15.6 166.2 ± 16.8 211.5 ± 29.1 237.0 ± 23.7 289.5 ± 36.5 312.6 ± 39.0 301.2 ± 62.1 
 (mg/dl) + ABCB5+ derived CoCM+ 155.3 ± 41.6 175.7  41.5 205.0  55.9 254.3  64.8 273.3  61.0 297.3  79.0 273.5 ± 76.3 
  + i.p. ABCB5+ 143.1 ± 25.5 170.6  29.9 189.3  28.7 223.1  38.9 246.4  48.1 274.3  58.5 294.0 ± 67.9 
  + i.v. ABCB5+ 156.3 ± 37.6 176.1  37.5 185.7  32.2 226.6  45.0 265.0  37.6 280.9  57.3 266.2 ± 44.5 
 Triglycerides Untreated 86.8 ± 15.0 79.3 ± 15.1 93.2 ± 28.3 132.2 ± 36.7 126.7 ± 28.2 137.5 ± 29.5 160.5 ± 46.9 
 (mg/dl) + ABCB5+ derived CoCM+ 85.0 ± 12.3 70.5  12.1 104.8  30.8 111.8  45.7 133.7  39.7 157.5  57.6 143.7 ± 45.0 
  + i.p. ABCB5+ 89.3 ± 15.9 73.1  20.5 103.1  29.4 102.4  27.9 129.9  40.4 129.0  19.0 153.5 ± 47.8 
  + i.v. ABCB5+ 91.5 ± 13.6 83.1  15.3 97.4  28.2 98.3  17.7 113.3  20.0 175.3  56.9 118.2 ± 34.7 
 Glucose Untreated 166.8 ± 10.6 143.7 ± 11.4 149.3 ± 20.0 162.7 ± 32.8 172.8 ± 12.9 143.0 ± 16.4 150.3 ± 24.0 
 (mg/dl) + ABCB5+ derived CoCM+ 165.3 ± 26.4 155.2  25.8 144.5  18.0 151.3  14.6 147.8  21.6 130.3  16.9 147.2 ± 18.2 
  + i.p. ABCB5+ 169.4 ± 24.7 157.1  6.2 142.3  14.2 149.0  16.6 146.9  37.7 139.0  12.1 145.8 ± 23.3 
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  + i.v. ABCB5+ 161.3 ± 18.7 153.9  19.7 139.7  8.5 152.0  13.6 143.7  15.3 136.9  11.5 143.8 ± 11.8 
 Protein Untreated 62.2 ± 1.8 66.0 ± 4.2 82.3 ± 31.3 63.2 ± 4.8 64.0 ± 4.0 66.2 ± 3.1 69.5 ± 2.1 
 (mg/dl) + ABCB5+ derived CoCM+ 64.7 ± 5.3 65.0  4.3 68.7  2.0 67.5  2.9 68.0  1.6 69.5  2.0 69.3 ± 6.4 
  + i.p. ABCB5+ 62.7 ± 4.0 65.6  2.0 69.9  5.9 68.1  4.3 66.7  2.7 68.0  2.5 67.5 ± 3.8 
  + i.v. ABCB5+ 66.1 ± 3.0 69.0  5.3 68.1  3.4 67.7  4.5 67.1  3.8 68.8  2.7 68.3 ± 4.9 
 ALT Untreated 82.5 ± 20.4 69.3  22.1 90.0  21.3 90.3  19.2 77.5  22.6 66.5  34.9 73.3 ± 40.0 
 (U/l) + ABCB5+ derived CoCM+ 68.3 ± 13.1 76.8  15.4 85.3  31.4 78.2  31.0 74.0  26.8 57.3  26.2 61.0 ± 17.8 
  + i.p. ABCB5+ 77.1 ± 6.2 78.0  16.1 93.9  20.5 68.7  28.0 74.0  15.9 60.2  18.6 69.3 ± 16.3 
  + i.v. ABCB5+ 71.9 ± 10.0 81.8  22.1 88.1  14.4 75.7  10.5 70.0  14.2 55.0  14.0 66.1 ± 13.4 
 AST Untreated 134.0 ± 42.1 124.4  40.4 144.5  36.3 134.3  46.1 162.5  84.6 113.8  33.3 135.2 ± 144.9 
 (U/l) + ABCB5+ derived CoCM+ 101.0 ± 22.9 179.0  70.7 134.0  44.0 152.7  78.2 152.0  91.5 129.0  93.2 144.0 ± 67.3 
  + i.p. ABCB5+ 117.0 ± 27.6 135.6  27.5 170.0  54.6 167.1  62.2 166.0  88.5 126.0  106.2 136.8 ± 87.8 
  + i.v. ABCB5+ 119.3 ± 35.4 162.1  33.2 162.7  47.0 150.7  47.9 150.7  47.2 100.7  84.0 119.5 ± 59.1 
 
Appendix 7B Changes in plasma biochemistry in PCK groups (n=6). Comparison between ASC derived CM, i.v. or i.p. ASC groups and untreated. 
Data are shown as mean ± Std.Dev.  
B Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.1 0.5 ± 0.1 
 (mg/dl) + ASC derived CM 0.2 ± 0.1 0.3 ± 0.0 0.3  0.1 0.4  0.0 0.4  0.1 0.5  0.1 0.6 ± 0.1 
  + i.p. ASC 0.3 ± 0.0 0.3 ± 0.0 0.3  0.0 0.3  0.1 0.4  0.0 0.4  0.0 0.5 ± 0.1 
  + i.v. ASC 0.3 ± 0.1 0.3 ± 0.0 0.3  0.0 0.3  0.0 0.4  0.1 0.4  0.1 0.5 ± 0.1 
 Urea Untreated 31.9 ± 2.8 35.0 ± 4.3 32.5 ± 2.9 36.3 ± 6.2 42.1 ± 5.1 44.6 ± 2.3 56.6 ± 3.2 
 (mg/dl) + ASC derived CM 34.4 ± 3.2 37.4   4.7 36.8  6.5 42.1  7.4 47.9  8.9 51.2  7.9 56.7 ± 7.0 
  + i.p. ASC 35.1 ± 0.7 35.4  2.6 34.6  4.5 37.3  4.7 43.4  9.7 46.7  11.5 57.3 ± 10.6 
  + i.v. ASC 35.6 ± 2.6 35.2  6.0 35.8  4.2 38.7  5.0 44.6  6.3 47.1  5.7 56.1 ± 3.5 
 Na Untreated 139.2 ± 1.2 140.7 ± 2.7 141.0 ± 3.0 139.7 ± 1.2 139.8 ± 1.1 140.6 ± 1.7 143.8 ± 1.8 
 (mmol/l) + ASC derived CM 139.9 ± 2.7 140.9  2.0 139.7  3.6 139.1  1.6 141.7  3.7 141.7  1.5 141.7 ± 1.4 
  + i.p. ASC 140.5 ± 2.4 141.2  1.7 140.5 3.3 140.0  1.7 143.8  4.7 142.8  0.8 141.8 ± 1.5 
  + i.v. ASC 140.2 ± 3.1 141.3  2.5 140.7  3.4 139.7  1.5 143.7  4.1 142.5  1.1 142.3 ± 1.4 
 K Untreated 5.4 ± 0.3 5.0 ± 0.5 5.3 ± 0.3 5.2 ± 0.4 5.4 ± 0.4 5.2 ± 0.4 5.1 ± 0.2 
 (mmol/l) + ASC derived CM 5.3 ± 0.4 4.9  0.3 5.1  0.3 5.3  0.4 5.5  0.4 5.7  0.7 5.5 ± 0.5 
  + i.p. ASC 5.2 ± 0.3 4.8  0.3 5.0  0.3 5.5  0.8 5.3  0.4 5.1  0.4 5.3 ± 0.2 
  + i.v. ASC 5.1 ± 0.4 4.8  0.2 5.1  0.5 5.1  0.7 5.5  0.3 5.2  0.4 5.0 ± 0.5 
 Ca Untreated 2.7 ± 0.1 2.7 ± 0.1 2.8 ± 0.1 2.7 ± 0.0 2.7 ± 0.1 2.7 ± 0.1 2.8 ± 0.1 
 (mmol/l) + ASC derived CM 2.7 ± 0.1 2.8  0.1 2.8  0.0 2.7  0.1 2.7  0.1 2.8  0.1 2.8 ± 0.0 
  + i.p. ASC 2.8 ± 0.1 2.8  0.1 2.7  0.1 2.7  0.1 2.8  0.1 2.8  0.1 2.8 ± 0.1 
  + i.v. ASC 2.8 ± 0.1 2.8  0.1 2.7  0.1 2.6  0.2 2.7  0.1 2.8  0.1 2.8 ± 0.1 
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 PO4 Untreated 2.3 ± 0.3 2.5 ± 0.3 2.0 ± 0.2 1.6 ± 0.5 2.0 ± 0.4 2.0 ± 0.4 2.2 ± 0.1 
 (mmol/l) + ASC derived CM 2.3 ± 0.3 2.2  0.2 2.1  0.3 1.7  0.4 2.0  0.2 2.1  0.3 2.0 ± 0.4 
  + i.p. ASC 2.2 ± 0.2 2.4  0.2 2.1  0.2 1.9  0.3 2.0  0.2 2.1  0.3 2.1 ± 0.4 
  + i.v. ASC 2.2 ± 0.2 2.1  0.2 2.1  0.2 2.0  0.3 1.9  0.1 2.0  0.3 1.9 ± 0.3 
 Cholesterol Untreated 140.3 ± 15.6 166.2 ± 16.8 211.5 ± 29.1 237.0 ± 23.7 289.5 ± 36.5 312.6 ± 39.0 301.2 ± 62.1 
 (mg/dl) + ASC derived CM 146.3 ± 17.4 169.6  22.0 200.1  20.2 206.7  56.1 236.0  58.2 238.3  75.9 222.8 ± 64.3 
  + i.p. ASC 161.3 ± 33.3 199.8  38.2 239.5  47.6 264.5  38.5 272.2  48.6 264.7  46.4 257.3 ± 52.1 
  + i.v. ASC 164.5 ± 32.2 186.2  25.6 225.5  32.6 233.0  35.7 208.3  55.4 244.5  28.5 252.8 ± 46.7 
 Triglycerides Untreated 86.8 ± 15.0 79.3 ± 15.1 93.2 ± 28.3 132.2 ± 36.7 126.7 ± 28.2 137.5 ± 29.5 160.5 ± 46.9 
 (mg/dl) + ASC derived CM 82.5 ± 12.6 77.0  16.1 108.9  16.5 118.6  37.1 131.1  31.2 160.4  48.0 148.2 ± 30.2 
  + i.p. ASC 94.0 ± 11.9 92.5  21.6 114.5  25.7 137.8  38.5 126.0  18.5 124.3  22.9 126.5 ± 16.0 
  + i.v. ASC 82.8 ± 12.1 96.0  14.9 124.3  22.0 109.2  21.6 103.3  29.8 118.5  27.5 143.0 ± 30.7 
 Glucose Untreated 166.8 ± 10.6 143.7 ± 11.4 149.3 ± 20.0 162.7 ± 32.8 172.8 ± 12.9 143.0 ± 16.4 150.3 ± 24.0 
 (mg/dl) + ASC derived CM 148.6 ± 13.4 142.7  5.9 146.7  16.2 141.6  17.6 143.7  27.0 131.4  22.1 142.8 ± 23.0 
  + i.p. ASC 157.7 ± 9.9 164.2  13.8 161.0  26.8 161.0  7.0 136.5  8.5 146.3  12.5 141.0 ± 12.0 
  + i.v. ASC 157.8 ± 13.3 144.0  2.8 148.0  14.5 149.5  14.8 145.5  23.1 145.0  12.4 127.0 ± 18.4 
 Protein Untreated 62.2 ± 1.8 66.0 ± 4.2 82.3 ± 31.3 63.2 ± 4.8 64.0 ± 4.0 66.2 ± 3.1 69.5 ± 2.1 
 (mg/dl) + ASC derived CM 65.3 ±3.4 69.3  5.2 69.1  7.1 67.9  6.0 69.4  4.6 72.4  4.7 72.2 ± 4.0 
  + i.p. ASC 63.7 ± 1.9 64.0  1.3 63.7  4.2 63.0  2.7 70.0  4.0 69.8  2.4 69.7 ± 4.1 
  + i.v. ASC 64.2 ± 2.3 65.2  2.6 66.2  4.9 64.5  4.6 68.0  4.2 69.7  3.4 70.5 ± 2.7 
 ALT Untreated 82.5 ± 20.4 69.3  22.1 90.0  21.3 90.3  19.2 77.5  22.6 66.5  34.9 73.3 ± 40.0 
 (U/l) + ASC derived CM 85.0 ± 16.6 89.9  17.3 93.7  10.6 88.0  25.7 99.4  31.2 85.7  27.6 81.3 ± 15.4 
  + i.p. ASC 91.5 ± 21.7 92.5  12.1 72.3  7.3 82.8  25.4 87.7  15.2 81.7  19.3 80.9 ± 20.4 
  + i.v. ASC 87.2 ± 16.2 94.8  13.1 98.2  14.3 90.8  19.0 93.2  21.8 95.0  20.6 83.6 ± 15.5 
 AST Untreated 134.0 ± 42.1 124.4  40.4 144.5  36.3 134.3  46.1 162.5  84.6 113.8  33.3 135.2 ± 144.9 
 (U/l) + ASC derived CM 154.2 ± 54.9 196.4  76.6 245.1  102.7 270.7  120.5 328.4  198.8 368.6  210.1 325.2 ± 146.4 
  + i.p. ASC 147.7 ± 41.4 163.0  44.3 126.0  26.2 115.2  60.6 178.7  86.9 149.8  58.1 155.7 ± 74.9 
  + i.v. ASC 154.7 ± 45.6 171.3  48.8 202.2  86.0 208.7  88.0 255.2  120.6 248.3  111.3 256.0 ± 127.5 
 
Appendix8A Changes in diuresis, food intake and water intake after metabolic cages in PCK groups (n=6). Comparison between ABCB5+ derived 
CoCM+, i.v. or i.p. ABCB5+ groups and untreated. Data are shown as mean ± Std.Dev. 
A Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Diuresis Untreated 16.1  3.1 21.7  4.4 17.6  5.0 18.1  2.7 44.6  21.6 21.4  5.5 25.2  2.7 
 (ml) + ABCB5+ derived CoCM+ 19.5  10.5 15.8  3.6 16.7  2.9 16.1  5.8 19.3  3.0* 20.4  5.8 24.7  8.8 
  + i.p. ABCB5+ 20.6  11.0 19.2  4.0 16.5  4.3 21.6  5.2 55.1  86.2 19.5  5.1 22.4  3.7 
  + i.v. ABCB5+ 20.0  13.2 16.0  4.6 16.5  5.1 17.9  3.7 55.1  5.9 19.5  4.5 18.7  5.9 
 Food intake Untreated 21.8  5.6 17.3  5.0 17.0  3.9 14.6  2.6 14.1  2.7 15.6  0.7 10.8  3.5 
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 (g) + ABCB5+ derived CoCM+ 19.2  5.9 14.0  1.8 13.6  3.1 13.4  4.3 15.0  4.8 12.5  5.1 15.6  5.1 
  + i.p. ABCB5+ 21.9  3.4 17.4  3.2 14.1  2.9 14.3  5.1 12.8  5.6 11.3  3.9 14.5  2.9 
  + i.v. ABCB5+ 19.9  3.8 18.4  3.8 14.9  4.6 14.7  4.3 12.6  3.4 13.4  5.0 15.0  4.3 
 Water intake Untreated 33.8  2.9 37.7  4.5 31.3  3.6 26.2  6.4 32.3  6.4 24.0  11.0 33.2  4.4 
 (g) + ABCB5+ derived CoCM+ 28.4  13.1 23.4  11.7 25.0  3.5 24.3  4.3 29.8  8.6 26.7  13.7 31.8  9.9 
  + i.p. ABCB5+ 32.8  8.3 31.2  4.9 24.0  5.8 29.9  6.9 28.6  11.8 22.2 9.8 30.7  15.9 
  + i.v. ABCB5+ 30.2  12.8 28.7  4.1 24.9  8.2 28.1  4.7 24.4  9.8 26.4  10.0 24.2  13.0 
 
Appendix8B Changes in diuresis, food intake and water intake after metabolic cages in PCK groups (n=6). Comparison between ASC derived CM, 
i.v. or i.p. ASC groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
B Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Diuresis Untreated 16.1  3.1 21.7  4.4 17.6  5.0 18.1  2.7 44.6  21.6 21.4  5.5 25.3  2.7 
 (ml) + ASC derived CM 13.9  2.7 20.1  7.9 19.3  4.8 18.0  3.5 21.2  3.6 26.8  2.3 29.3  12.2 
  + i.p. ASC 21.2  11.7 23.3  10.2 20.7  7.2 20.2  5.5 22.9  4.0 23.8  8.2 25.4  4.3 
  + i.v. ASC 16.2  8.9 21.1  8.0 22.5  3.2 16.8  5.1 17.2  6.5* 25.0  4.3 26.8  6.3 
 Food intake Untreated 21.8  5.6 17.3  5.0 17.0  3.9 14.6  2.6 14.1  2.7 15.6  0.7 10.8  3.5 
 (g) + ASC derived CM 22.8  6.0 15.8  3.5 16.7  4.5 13.9  3.2 16.5  2.8 19.6  3.0 17.4  4.7 
  + i.p. ASC 17.3  5.2 15.7  1.9 16.7  9.4 16.7  2.1 17.5  1.7 14.3  3.9 14.9  3.4 
  + i.v. ASC 17.3  2.7 18.5  3.8 19.2  5.6 15.3  3.5 18.9  8.5 16.3  3.5 14.2  5.8 
 Water intake Untreated 33.8  2.9 37.7  4.5 31.3  3.6 26.2  6.4 32.3  6.4 24.0  11.0 33.2  4.4 
 (g) + ASC derived CM 30.3  5.3 34.5  7.9 32.0  7.7 29.9  3.8 29.9  6.8 36.3  8.8 38.5  17.0 
  + i.p. ASC 36.2  10.0 36.0  10.8 31.6  14.4 32.5  5.1 34.4  5.8 32.8  11.1 38.3  6.8 
  + i.v. ASC 30.3  11.6 41.2  9.7 38.7  7.2 31.4  6.1 30.9  9.6 36.3  1.0 46.4  19.7 
 
Appendix 9A Changes in urine biochemistry in PCK groups (n=6). Comparison between ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ groups 
and untreated. Data are shown as mean ± Std.Dev.  
A) Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 8.1 ± 1.1 11.2 ± 2.0 11.1 ± 2.9 13.3 ± 2.5 13.7 ± 1.3 13.9 ± 2.5 14.8 ± 3.2 
 (mg/16h) + ABCB5+ derived CoCM+ 8.9  1.2 11.8  0.7 12.8  0.9 11.4  2.8 12.3  1.2 12.2  1.4 11.9 ±1.8 
  + i.p. ABCB5+ 9.1  1.5 12.3  0.7 11.6  1.6 12.1  0.9 12.6  1.8 12.3  1.1 12.0 ± 2.4 
  + i.v. ABCB5+ 9.1  1.1 11.7  0.6 12.1  1.0 13.1  1.1 12.2  1.3 12.5  1.3 12.5 ± 1.7 
 Urea Untreated 709.4 ± 120.7 1033.9 ± 689.6 729.7 ± 256.7 701.3 ± 85.4 679.7 ± 65.4 662.2 ± 151.2 681.6 ± 91.3 
 (mg/16h) + ABCB5+ derived CoCM+ 701.7  152.7 717.1  67.1 724.4  101.1 573.4  151.8 627.2  79.0 557.1  107.6 586.1 ± 147.9 
  + i.p. ABCB5+ 749.4  136.8 824.5  204.2 677.2  145.6 662.9  89.6 648.0  91.0 591.3  119.6 610.0 ± 148.5 
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  + i.v. ABCB5+ 709.8  104.6 809.0  128.8 708.5  44.3 735.6  94.8 619.2  135.7 617.6  115.6 571.4 ± 105.2 
 Na Untreated 1.6 ± 0.6 1.4 ± 0.4 1.0 ± 0.5 1.3 ± 0.4 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.2 
 (mmol/16h) + ABCB5+ derived CoCM+ 1.7  0.4 1.2  0.3 1.1  0.2 1.1  0.3 1.3  0.3 1.4  0.2 1.6 ± 0.8 
  + i.p. ABCB5+ 1.9  0.6 1.6  0.5 1.3  0.5 1.6  0.5 1.7  0.9 1.5  0.4 1.5 ± 0.6 
  + i.v. ABCB5+ 1.5  0.4 1.5  0.6 1.3  0.4 1.2  0.3 1.0  0.3 1.6  0.6 1.4 ± 0.9 
 K Untreated 3.9 ± 1.0 4.5 ± 0.9 2.9 ± 1.4 3.5 ± 1.0 4.3 ± 0.4 3.6 ± 1.3 3.5 ± 0.4 
 (mmol/16h) + ABCB5+ derived CoCM+ 4.2  1.1 3.9  0.5 4.0  0.3 3.2  0.7 4.0  0.6 3.7  0.6 4.3 ± 1.5 
  + i.p. ABCB5+ 5.0  1.3 4.8  1.1 4.0  0.8 4.0  0.5 4.4  0.8 3.7  0.7 3.7 ± 0.9 
  + i.v. ABCB5+ 4.2  0.6 4.5  0.9 4.1  0.5 3.9  0.6 3.7  0.5 3.8  0.7 3.6 ± 1.0 
 Ca Untreated 0.06 ± 0.04 0.03 ± 0.01 0.05 ± 0.02 0.07 ± 0.02 0.10 ± 0.02 0.10 ± 0.02 0.08 ± 0.03 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.03  0.02 0.03  0.00 0.04  0.01 0.05  0.02 0.08  0.02 0.09  0.04 0.10 ± 0.03 
  + i.p. ABCB5+ 0.05  0.02 0.05  0.04 0.05  0.07 0.07  0.03 0.08  0.02 0.07  0.03 0.08 ± 0.03 
  + i.v. ABCB5+ 0.03  0.01 0.04  0.02 0.06  0.02 0.06  0.02 0.06  0.03 0.06  0.03 0.06 ± 0.03 
 PO4 Untreated 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
 (mmol/16h) + ABCB5+ derived CoCM+ 0.2  0.2 0.1  0.2 0.1  0.1 0.1  0.1 0.1  0.1 0.2  0.2 0.1 ± 0.1 
  + i.p. ABCB5+ 0.1  0.1 0.2  0.2 0.1  0.1 0.1  0.1 0.1  0.1 0.2  0.1 0.1 ± 0.1 
  + i.v. ABCB5+ 0.1  0.1 0.1  0.1 0.1  0.1 0.2  0.2 0.2  0.1 0.2  0.9 0.3 ± 0.3 
 Glucose Untreated 5.2 ± 1.9 3.5 ± 2.8 2.9 ± 1.2 3.0 ± 1.4 3.5 ± 2.3 3.5 ± 1.2 1.9 ± 1.6 
 (mg/16h) + ABCB5+ derived CoCM+ 3.0  0.6 2.9  0.5 2.4  1.0 1.8  0.8 2.4  0.5 2.0  1.1 2.3 ± 0.6 
  + i.p. ABCB5+ 3.8  0.3 2.9  0.8 2.6  0.7 3.3  0.8 3.1  2.5 2.5  0.7 3.0 ± 0.7 
  + i.v. ABCB5+ 3.0  0.8 3.1  0.5 2.8  1.2 2.6  0.6 2.4  0.4 1.9  0.8 2.4 ± 0.9 
 Protein Untreated 9.6 ± 4.9 31.5 ± 12.5 94.6 ± 44.5 212.4 ± 72.4 353.0 ± 64.1 375.1 ± 85.6 436.8 ± 101.5 
 (mg/16h) + ABCB5+ derived CoCM+ 13.3  10.0 63.3  65.1 117.0  88.3 219.1  59.5 318.2  89.9 328.0  149.7 290.1 ± 114.7 
  + i.p. ABCB5+ 14.1  11.2 66.3  77.4 116.8  66.5 244.0 107.2 313.2  140.7 256.7  116.8 311.9 ± 161.3 
  + i.v. ABCB5+ 19.1  24.1 74.5  83.7 131.2  87.5 200.6  51.1 251.8  40.2 281.8  160.9 288.1 ± 117.3 
 Albumin Untreated 0.7 ± 0.3 13.5 ± 11.1 69.7 ± 34.8 103.3 ± 61.1 178.8 ± 49.8 173.9 ± 71.9 140.6 ± 71.2 
 (mg/16h) + ABCB5+ derived CoCM+ 5.8  9.5 36.4  48.5 78.6  43.6 124.5  70.9 166.4  63.1 201.6  67.4 200.6 ± 68.5 
  + i.p. ABCB5+ 6.8  13.0 36.4  54.4 64.5  27.3 123.7  27.1 181.7  85.9 227.1  141.3 319.8 ± 220.3 
  + i.v. ABCB5+ 6.1  10.9 39.5  56.0 59.5  25.7 136.3  40.8 194.9  56.7 298.3  107.2 200.0 ± 52.9 
 
Appendix 9B Changes in urine biochemistry in PCK groups (n=6). Comparison between ASC derived CM, i.v. or i.p. ASC groups and untreated. 
Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
B) Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 Creatinine Untreated 8.1 ± 1.1 11.2 ± 2.0 11.1 ± 2.9 13.3 ± 2.5 13.7 ± 1.3 13.9 ± 2.5 14.8 ± 3.2 
 (mg/16h) + ASC derived CM 7.8  1.8 11.6  4.0 12.4  2.1 11.6  1.7 12.0  1.8 12.5  3.6 12.3 ± 1.0 
  + i.p. ASC 8.9  2.2 11.7  1.3 13.9  2.3 12.3  1.2 12.3  1.6 11.6  2.3 12.4 ± 1.2 
  + i.v. ASC 8.5  1.8 11.0  1.1 12.9  2.9 10.6  3.2 10.0  1.2 11.4  2.1 12.4 ± 1.7 
 Urea Untreated 709.4 ± 120.7 1033.9 ± 689.6 729.7 ± 256.7 701.3 ± 85.4 679.7 ± 65.4 662.2 ± 151.2 681.6 ± 91.3 
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 (mg/16h) + ASC derived CM 613.1  77.2 609.1  326.3 765.3  219.6 666.6  84.1 617.9  72.3 665.5  125.6 628.7 ± 81.8 
  + i.p. ASC 606.5  48.0 675.1  66.1 823.2  269.7 750.3  118.1 681.4  99.7 575.5  121.2 658.9 ± 111.4 
  + i.v. ASC 610.6  89.6 709.4  116.5 830.4  227.2 620.8  198.5 538.5  118.6 640.9  54.3 659.8 ± 99.6 
 Na Untreated 1.6 ± 0.6 1.4 ± 0.4 1.0 ± 0.5 1.3 ± 0.4 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.2 
 (mmol/16h) + ASC derived CM 1.3  0.3 1.5  0.4 1.3  0.4 1.4  0.3 1.8  0.5 1.9  0.5 1.8 ± 0.6 
  + i.p. ASC 1.4  0.5 1.5  0.4 1.5  0.5 1.5  0.5 1.7  0.5 1.6  0.7 1.3 ± 0.3 
  + i.v. ASC 1.4  0.4 1.6  0.6 1.4  0.6 1.2  0.6 1.3  0.7 1.6  0.3 1.7 ± 0.8 
 K Untreated 3.9 ± 1.0 4.5 ± 0.9 2.9 ± 1.4 3.5 ± 1.0 4.3 ± 0.4 3.6 ± 1.3 3.5 ± 0.4 
 (mmol/16h) + ASC derived CM 3.1  1.3 3.7  0.9 3.7  1.9 3.8  0.8 4.3  0.7 3.6  0.9 4.2 ± 1.4 
  + i.p. ASC 3.4  0.3 3.7  0.5 4.2  1.9 4.6  0.7 3.9  0.3 3.4  1.0 4.0 ± 0.5 
  + i.v. ASC 3.4  0.3 4.0  0.7 4.1  0.9 3.4  1.2 2.9  0.7 4.0  0.6 3.9 ± 0.4 
 Ca Untreated 0.06 ± 0.04 0.03 ± 0.01 0.05 ± 0.02 0.07 ± 0.02 0.10 ± 0.02 0.10 ± 0.02 0.08 ± 0.03 
 (mmol/16h) + ASC derived CM 0.04  0.03 0.04  0.02 0.06  0.02 0.08  0.04 0.07  0.02 0.07  0.03 0.07 ± 0.03 
  + i.p. ASC 0.04  0.02 0.03  0.01 0.07  0.05 0.10  0.04 0.10  0.03 0.08  0.03 0.08 ± 0.02 
  + i.v. ASC 0.03  0.01 0.04  0.02 0.08  0.03 0.08  0.03 0.07  0.03 0.07  0.0.3 0.07 ± 0.01 
 PO4 Untreated 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
 (mmol/16h) + ASC derived CM 0.1  0.1 0.1  0.1 0.2  0.1 0.2  0.1 0.2  0.2 0.2  0.2 0.1 ± 0.1 
  + i.p. ASC 0.1  0.1 0.1  0.1 0.2  0.1 0.1  0.1 0.3  0.1 0.2  0.1 0.1 ± 0.1 
  + i.v. ASC 0.1  0.1 0.0  0.0 0.1  0.1 0.1  0.0 0.2  0.2 0.1  0.1 0.1 ± 0.1 
 Glucose Untreated 5.2 ± 1.9 3.5 ± 2.8 2.9 ± 1.2 3.0 ± 1.4 3.5 ± 2.3 3.5 ± 1.2 1.9 ± 1.5 
 (mg/16h) + ASC derived CM 4.0  1.8 1.5 1.1 3.6  1.7 4.0  2.0 4.1  2.8 4.8  1.4 5.9 ± 4.5 
  + i.p. ASC 2.6  1.5 1.5  1.5 4.6  3.0 5.0  2.1 4.4  1.1 3.3  1.4 4.4 ± 1.6 
  + i.v. ASC 2.6  2.2 1.0  1.1 3.6  1.2 3.5  1.6 4.0  1.3 3.3  2.7 3.7 ± 2.2 
 Protein Untreated 9.6 ± 4.9 31.5 ± 12.5 94.6 ± 44.5 212.4 ± 72.4 353.0 ± 64.1 375.1 ± 85.6 436.8 ± 101.5 
 (mg/16h) + ASC derived CM 18.3  18.6 70.4  40.9 162.2  84.1 186.0  75.9 344.3  65.7 361.9  99.8 398.2 ± 143.4 
  + i.p. ASC 33.8  35.0 107.5  71.5 256.7  122.0 201.6  121.7 341.2  72.3 295.1  102.7 350.4 ± 79.0 
  + i.v. ASC 29.1  23.5 104.3  70.7 219.8  129.4 131.3  80.6 211.7  59.6 284.6  45.3 320.6 ± 63.2 
 Albumin Untreated 0.7 ± 0.3 13.5 ± 11.1 69.7 ± 34.8 103.3 ± 61.1 178.8 ± 49.8 173.9 ± 71.9 140.6 ± 71.2 
 (mg/16h) + ASC derived CM 5.8  8.7 28.1  16.1 82.2  30.7 99.0  34.4 110.4  18.0 137.8  35.0 152.7 ± 66.9 
  + i.p. ASC 17.3  18.4 54.4  38.5 101.1  43.3 209.0  75.7 155.2  38.8 163.1  51.8 197.7 ± 59.3 
  + i.v. ASC 12.0  11.7 50.9  37.6 83.5  24.8 115.1  36.1 86.0  31.9* 158.1  54.3 154.8 ± 28.7 
 
Appendix 10A Changes of ABZWCY-HCD half-life in PCK groups (n=6). Comparison between ABCB5+ derived CoCM+, i.v. or i.p. ABCB5+ 
groups and untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
A) Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 ABZWCY-HCD Untreated 29.7  10.8 34.5  11.7 40.5  16.4 44.0  15.9 53.2  14.4 62.5  10.9 75.5 ± 11.6 
 t1/2 (min) + ABCB5+ derived CoCM+ 24.3  4.6 31.9  4.0 32.3  5.0 31.3  12.5 50.7  21.6 47.4  14.8 66.5 ± 15.1 
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  + i.p. ABCB5+ 23.8  5.2 25.1  14.3 42.7  15.4 33.2  13.4 35.5  7.8 44.6  25.6 45.5 ± 22.7* 
  + i.v. ABCB5+ 20.3  1.4 26.3  4.4 33.0  12.8 32.6  7.5 40.4  20.5 38.6  16.6 50.9 ± 10.1 
 
Appendix 10B Changes of ABZWCY-HCD half-life in PCK groups (n=6). Comparison between ASC derived CM, i.v. or i.p. ASC groups and 
untreated. Data are shown as mean ± Std.Dev. Values significantly different from control are indicated as *p<0.05. 
B) Parameter Animal group Baseline Day25 Day 53 Day 81 Day 109 Day 137 Day 167 
 ABZWCY-HCD Untreated 29.9  10.8 34.5  11.7 40.5  16.4 44.0  15.9 53.2  14.4 62.5  10.9 75.5 ± 11.6 
 t1/2 (min) + ASC derived CM 31.3  11.3 30.9  3.9 42.9  14.6 32.3  11.2 53.0  16.2 72.2  31.5 72.5 ± 24.8 
  + i.p. ASC 26.4  8.1 29.2  6.2 35.4  5.1 36.6  8.1 31.6  10.5 56.4  29.6 52.7 ± 4.9 
  + i.v. ASC 34.4  12.0 35.6  10.8 35.8  10.4 32.0  9.6 54.7  13.8 52.5  4.5 54.5 ± 9.3 
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Abbreviations 
 
ABCB5 ATP-binding cassette member B5 
ABCB5+ Cells expressing ABCB5 
AB-HS Human serum (blood-type AB) 
ADPKD  Autosomal Dominant Polycystic Kidney Disease 
ALT  Alanin-aminotransferase 
ARPKD  Autosomal Recessive Polycystic Kidney Disease  
ASC  Adipose Derived Stromal Cells 
AST  Aspartat-aminotransferase 
BUN  Blood Urea Nitrogen 
BW  Body Weight 
CKD  Chronic kidney disease 
CM  ASC derived conditioned medium 
CoCM+ Co-culture of ABCB5+ cell and THP-1 derived macrophages 
DAPI  4',6-diamidino-2-phenylindole dihydrochloride  
DIRCs  Dermal Immunoregulatory Cells 
ESRD  End-stage renal disease 
GFR   Glomerular Filtration Rate 
GSEA  Gene Set Enrichment Analysis 
H&E  Hematoxylin and eosin 
IF  Immunofluorescence  
INFγ  Interferon γ  
JAK  Janus kinase  
KEGG  Kyoto Encyclopedia of Genes and Genome database  
Kw/BW  Kidney to body weight  
LEDs   Light-Emitting Diodes  
LogFC  Log Fold Changes  
LPS  Lipopolysaccharide  
MCP-1 Monocyte chemoattractant protein-1 
MSC  Mesenchymal Stromal Cells 
NF-B  Nuclear factor-B 
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NIR   Near Infrared  
NPHP  Nephronophthisis 
PKD   Polycystic Kidney Disease 
PKD 1  polycystin 1 
PKD 2  polycystin 2 
PKHD 1 polycystic kidney and hepatic disease 1 
RIN  RNA integrity number  
RT  Room temperature 
SD   Sprague Dawley  
SOCS  Suppressors of cytokine signaling 
Std Dev Standard deviation 
TNF-α  Tumor necrosis factor-α 
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